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ABSTRACT	  
Notch	  Signaling	  Determines	  Lymphatic	  Cell	  Fate	  and	  Regulates	  Sprouting	  Lymphangiogenesis	  	  
Minji	  Kim	  Uh	  
	  
The	  lymphatic	  vascular	  system	  is	  necessary	  for	  physiological	  regulation	  of	  tissue	  fluid	  
homeostasis	  and	  absorption	  of	  dietary	  fat.	  Lymphatics	  also	  function	  in	  the	  inflammatory	  
response	  and	  are	  involved	  in	  pathological	  conditions	  such	  as	  wound	  healing	  and	  cancer.	  We	  
show	  that	  the	  Notch	  signaling	  pathway	  is	  a	  regulator	  of	  both	  developmental	  and	  pathological	  
lymphangiogenesis.	  	  
Notch1	  and	  Notch4	  are	  expressed	  by	  the	  lymphatic	  endothelium,	  and	  Delta-­‐like	  ligand	  4	  
(Dll4)	  is	  the	  predominantly	  expressed	  Notch	  ligand	  in	  the	  developing	  lymphatic	  vessels	  of	  the	  
embryonic	  dermis	  and	  pathological	  lymphatic	  vessels	  of	  the	  wounded	  cornea.	  Dll4	  was	  able	  to	  
induce	  Notch	  activation	  in	  human	  dermal	  lymphatic	  endothelial	  cells	  (HDLECs),	  whereas	  
Jagged1	  (Jag1)	  was	  not.	  In	  HDLECs,	  Notch	  signaling	  is	  activated	  in	  response	  to	  Vascular	  
Endothelial	  Growth	  Factor	  (VEGF)	  or	  Vascular	  Endothelial	  Growth	  Factor-­‐C	  (VEGF-­‐C)	  stimulation.	  
In	  vitro	  assays	  demonstrated	  that	  Notch	  activation	  inhibits	  HDLEC	  proliferation,	  migration,	  and	  
capillary	  network	  formation;	  these	  effects	  were	  coincident	  with	  increased	  levels	  of	  HEY1	  and	  
HEY2,	  biphasic	  regulation	  of	  VEGFR-­‐3,	  and	  decreased	  levels	  of	  VEGFR-­‐2.	  
Using	  genetic	  intervention	  of	  Notch	  signaling,	  we	  demonstrated	  that	  Notch	  regulates	  
developmental	  sprouting	  lymphangiogenesis	  by	  restricting	  growth	  and	  sprouting	  of	  lymphatics	  
in	  the	  murine	  embryonic	  dermis.	  Using	  pharmacological	  intervention	  of	  Notch	  signaling,	  we	  
found	  that	  Notch	  restricted	  pathological	  sprouting	  lymphangiogenesis	  in	  the	  corneal	  suture	  
assay,	  which	  models	  inflammation-­‐induced	  lymphangiogenesis.	  However,	  pharmacological	  
intervention	  of	  Notch	  signaling	  did	  not	  measurably	  affect	  pathological	  sprouting	  
lymphangiogenesis	  in	  an	  orthotopic	  tumor	  model	  of	  human	  breast	  cancer.	  Our	  data	  from	  
analysis	  of	  HDLECs,	  dermis,	  and	  sutured	  cornea	  support	  a	  role	  for	  Dll4-­‐driven	  Notch	  signaling	  in	  
restricting	  sprouting	  lymphangiogenesis.	  	  
Lymphatic	  specification/separation	  requires	  a	  venous	  endothelial	  cell	  to	  become	  a	  
lymphatic	  endothelial	  cell,	  and	  lymphatic	  valve	  formation	  requires	  a	  duct	  endothelial	  cell	  to	  
become	  a	  valve	  endothelial	  cell.	  Through	  analysis	  of	  genes	  regulated	  by	  Notch	  in	  HDLECs,	  we	  
demonstrated	  that	  Notch	  determines	  lymphatic	  endothelial	  cell	  fates.	  Notch	  inhibits	  genes	  
critical	  for	  lymphatic	  specification	  and	  separation	  (PROX1,	  PDPN),	  and	  induces	  genes	  important	  
for	  lymphatic	  valve	  formation	  (FNEIIIA,	  ITGA9,	  CX37).	  
We	  conclude	  that	  Notch	  is	  a	  context-­‐dependent	  regulator	  of	  lymphangiogenesis.	  Notch	  
functions	  in	  the	  tip/stalk,	  venous	  to	  lymphatic,	  and	  duct	  endothelial	  to	  valve	  endothelial	  cell	  
fate	  decisions	  in	  lymphatic	  vasculature.	  Given	  the	  critical	  functions	  of	  the	  lymphatic	  vasculature	  
in	  multiple	  physiological	  and	  pathological	  settings,	  understanding	  Notch	  functions	  in	  the	  
lymphatic	  vasculature	  is	  critical	  to	  design	  treatments	  for	  conditions	  caused	  by	  lymphatic	  
malfunction.	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Development	  of	  the	  lymphatic	  vasculature	  
The	  circulatory	  system,	  which	  is	  composed	  of	  both	  the	  cardiovascular	  and	  lymphatic	  
systems,	  develops	  through	  a	  series	  of	  sequential	  events,	  beginning	  with	  vasculogenesis[1].	  In	  
vasculogenesis,	  multipotent	  hemangioblasts	  of	  mesodermal	  origin	  differentiate	  into	  endothelial	  
progenitor	  cells,	  which	  subsequently	  assemble	  themselves	  to	  form	  a	  primitive	  vascular	  network.	  
The	  next	  step,	  angiogenesis,	  is	  the	  process	  by	  which	  new	  blood	  vessels	  sprout	  from	  pre-­‐existing	  
blood	  vasculature[1].	  This	  allows	  for	  expansion	  and	  remodeling	  of	  the	  primitive	  vasculature	  into	  
a	  hierarchical	  network	  of	  arteries,	  veins,	  and	  intervening	  capillaries.	  Smooth	  muscle	  cells	  are	  
recruited	  to	  stabilize	  larger	  vessels	  while	  pericytes	  are	  recruited	  to	  smaller	  vessels	  and	  
capillaries.	  Once	  the	  vascular	  system	  has	  formed,	  it	  can	  function	  to	  provide	  oxygen	  and	  
nutrients	  while	  removing	  waste	  throughout	  the	  organism.	  	  
The	  venous	  origin	  of	  the	  lymphatic	  system	  (Figure	  1)[2],	  first	  hypothesized	  in	  1902	  by	  
Florence	  Sabin[3],	  has	  been	  confirmed	  through	  lineage	  tracing	  studies[4].	  In	  the	  mouse,	  a	  subset	  
of	  blood	  endothelial	  cells	  in	  the	  anterior	  cardinal	  vein	  becomes	  committed	  to	  the	  lymphatic	  
endothelial	  cell	  (LEC)	  fate	  between	  embryonic	  days	  (E)	  9.5-­‐10.	  The	  lymphatic	  master	  regulator	  
Prox1	  is	  turned	  on	  in	  these	  LEC	  progenitor	  cells	  in	  a	  process	  dependent	  on	  the	  transcription	  
factors	  Coup-­‐TFII	  and	  Sox18[5-­‐7].	  Between	  E11.5-­‐12.5,	  LEC	  progenitor	  cells	  extrude	  through	  a	  
“ballooning”	  mechanism[8]	  and	  migrate	  dorsolaterally	  from	  the	  cardinal	  vein	  to	  form	  the	  
primitive	  lymph	  sacs[2,	  9-­‐12].	  This	  process	  requires	  Vascular	  Endothelial	  Growth	  Factor	  Receptor	  3	  
(VEGFR-­‐3),	  expressed	  by	  the	  lymphatic	  endothelial	  cells,	  and	  the	  VEGFR-­‐3	  ligand	  Vascular	  
Endothelial	  Growth	  Factor-­‐C	  (VEGF-­‐C),	  expressed	  by	  mesenchymal	  cells[13].	  From	  E12.5-­‐14.5,	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lymph	  sacs	  continue	  to	  form	  and	  undergo	  sprouting	  lymphangiogenesis	  to	  form	  the	  initial	  
lymphatic	  plexus[2,	  9-­‐12].	  Further	  remodeling	  and	  maturation	  of	  the	  initial	  lymphatic	  plexus	  forms	  
the	  complete	  lymphatic	  vasculature,	  which	  is	  composed	  of	  smaller	  lymphatic	  capillaries,	  
intermediate	  pre-­‐collecting	  vessels,	  and	  larger	  collecting	  vessels[2,	  9-­‐12].	  Smooth	  muscle	  cells	  are	  
recruited	  to	  stabilize	  collecting	  vessels,	  and	  specialized	  valves	  begin	  to	  develop	  at	  E15.5	  in	  the	  
collecting	  vessels	  to	  allow	  for	  unidirectional	  flow	  of	  lymph[9-­‐12].	  Valves	  are	  of	  particular	  
importance	  in	  the	  lymphatic	  system,	  which	  lacks	  a	  central	  pump	  and	  depends	  on	  skeletal	  
muscle	  movement	  and	  smooth	  muscle	  cell	  contractions	  for	  lymph	  flow.	  	  
Lymphatic	  capillaries,	  pre-­‐collecting	  vessels,	  and	  collecting	  vessels	  have	  unique	  
structural	  characteristics	  that	  differentiate	  them	  from	  each	  other,	  as	  well	  as	  from	  the	  blood	  
vasculature[9-­‐12].	  Lymphatic	  capillaries,	  unlike	  blood	  capillaries,	  are	  blind	  ended	  and	  have	  
discontinuous	  inter-­‐cell	  junctions.	  Lymphatic	  capillaries	  have	  a	  sparse	  basement	  membrane,	  no	  
mural	  cell	  coverage,	  and	  they	  connect	  to	  the	  extracellular	  matrix	  via	  anchoring	  filaments.	  These	  
characteristics	  allow	  for	  effective	  absorption	  of	  fluid	  and	  passage	  of	  cells	  in	  and	  out	  of	  
lymphatic	  capillaries.	  Collecting	  vessels,	  on	  the	  other	  hand,	  have	  continuous	  basement	  
membrane	  and	  smooth	  muscle	  cell	  coverage,	  and	  contain	  valves.	  These	  characteristics	  allow	  for	  
collecting	  vessels	  to	  move	  fluid	  in	  a	  unidirectional	  manner	  for	  return	  to	  the	  venous	  circulation.	  
As	  an	  intermediate	  vessel	  type,	  pre-­‐collecting	  vessels	  possess	  characteristics	  of	  both	  capillaries	  
and	  collecting	  vessels.	  The	  fully	  developed	  lymphatic	  vasculature	  runs	  alongside	  the	  blood	  
vasculature,	  and	  lymphatic	  vessels	  are	  present	  in	  all	  vascularized	  tissues,	  excluding	  the	  bone	  
marrow	  and	  central	  nervous	  system[11,	  12].	  Although	  the	  two	  vascular	  systems	  run	  alongside	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each	  other,	  they	  connect	  only	  in	  defined	  locations	  to	  allow	  for	  lymph	  collected	  by	  the	  lymphatic	  
capillaries	  to	  be	  returned	  to	  the	  blood	  circulation[9-­‐12].	  
	  
Physiological	  and	  pathological	  roles	  of	  the	  lymphatic	  vasculature	  
Proper	  function	  of	  the	  lymphatic	  vasculature	  is	  critical	  for	  life.	  Its	  physiological	  functions	  
include	  regulation	  of	  tissue	  fluid	  homeostasis	  and	  absorption	  of	  lipids	  from	  the	  digestive	  tract[9,	  
11,	  12].	  Fluid	  and	  molecules	  that	  leak	  out	  of	  the	  blood	  vasculature	  are	  taken	  up	  by	  lymphatic	  
capillaries,	  through	  pre-­‐collecting	  vessels	  to	  the	  collecting	  ducts,	  and	  returned	  to	  the	  venous	  
circulation.	  In	  healthy	  humans,	  the	  lymphatic	  system	  collects	  and	  returns	  1-­‐2	  liters	  of	  lymph	  to	  
the	  venous	  circulation	  per	  day[14].	  In	  the	  small	  intestine,	  specialized	  lymphatic	  vessels	  known	  as	  
lacteals	  absorb	  dietary	  lipids,	  which	  are	  subsequently	  taken	  up	  by	  the	  mesenteric	  collecting	  
ducts	  and	  eventually	  enter	  the	  bloodstream	  for	  further	  processing.	  	  
Pathological	  functions	  of	  the	  lymphatic	  vasculature	  include	  resolving	  wounds,	  
responding	  to	  inflammation,	  and	  facilitating	  metastasis	  of	  tumor	  cells[9,	  11,	  12].	  Inflammation	  
induces	  macrophages	  to	  release	  lymphangiogenic	  factors	  such	  as	  VEGF-­‐C	  and	  VEGF-­‐D[15].	  The	  
lymphatic	  endothelium	  can	  attract	  various	  leukocyte	  populations	  by	  releasing	  chemokines	  and	  
adhesion	  molecules[12,	  16].	  Lymphatic	  capillaries	  also	  allow	  for	  transport	  of	  antigens	  and	  antigen-­‐
presenting	  cells	  from	  sites	  of	  inflammation	  to	  the	  lymph	  nodes[9,	  12,	  16].	  Post-­‐inflammation,	  the	  
lymphatics	  function	  to	  clear	  dead	  cells	  and	  fluid[16].	  In	  tumors,	  lymphatics	  can	  act	  as	  a	  conduit	  
for	  metastasis.	  Tumors	  secrete	  a	  multitude	  of	  growth	  factors,	  many	  of	  which	  can	  stimulate	  
lymphangiogenesis	  and/or	  angiogenesis[17,	  18].	  By	  entering	  into	  the	  peritumoral	  lymphatics,	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tumor	  cells	  can	  metastasize	  to	  regional	  lymph	  nodes[17,	  18].	  Thus,	  cancer	  treatment	  often	  
involves	  biopsy	  and	  surgical	  resection	  of	  regional	  lymph	  nodes,	  as	  the	  presence	  of	  metastases	  
in	  lymph	  nodes	  is	  a	  prognostic	  indicator	  of	  poor	  outcome	  in	  multiple	  cancers[12,	  18,	  19].	  Whether	  
regional	  lymph	  node	  metastasis	  is	  a	  bona	  fide	  step	  towards	  distant	  metastasis	  or	  is	  simply	  a	  
characteristic	  of	  more	  aggressive	  cancers	  is	  a	  highly-­‐debated	  topic[20].	  
	   In	  humans,	  malfunction	  of	  the	  lymphatics	  can	  lead	  to	  multiple	  complications[9-­‐12].	  
Lymphedema,	  or	  the	  build-­‐up	  of	  fluid	  in	  tissues,	  results	  when	  lymphatic	  vessels	  are	  lost	  or	  
damaged,	  compromising	  their	  ability	  to	  absorb	  interstitial	  fluid.	  Lymphedema	  most	  often	  
presents	  as	  a	  secondary	  condition,	  resulting	  from	  damage	  to	  lymphatic	  vessels	  or	  removal	  of	  
lymph	  nodes	  during	  surgery	  or	  radiation.	  Malfunctioning	  collecting	  vessels	  can	  lead	  to	  chyle	  
leakage	  into	  the	  peritoneal	  or	  thoracic	  cavities,	  and	  dilation	  of	  the	  lacteals	  in	  the	  small	  intestine,	  
also	  known	  as	  intestinal	  lymphangiectasia,	  can	  compromise	  the	  body’s	  ability	  to	  absorb	  fats	  and	  
protein.	  Unwanted	  lymphangiogenesis	  can	  also	  present	  problems.	  The	  avascularity	  of	  the	  
cornea	  is	  critical	  for	  corneal	  homeostasis,	  but	  in	  pathological	  conditions,	  lymphatic	  and	  blood	  
vessels	  can	  grow	  into	  the	  cornea,	  compromising	  visual	  acuity[21,	  22].	  Furthermore,	  
lymphangiogenesis	  in	  the	  cornea	  can	  exacerbate	  inflammatory	  responses	  in	  the	  cornea	  by	  
facilitating	  immune	  cell	  trafficking	  to	  and	  from	  the	  cornea,	  and	  increase	  risk	  for	  transplant	  






The	  Notch	  signaling	  pathway	  
	   The	  Notch	  signaling	  pathway	  (Figure	  2)[23]	  is	  a	  highly	  conserved	  pathway	  expressed	  in	  
multiple	  cell	  types	  that	  plays	  important	  roles	  in	  determining	  cell	  fate,	  as	  well	  as	  regulating	  
cellular	  proliferation,	  differentiation,	  and	  apoptosis[24-­‐26].	  In	  mammals,	  the	  Notch	  family	  consists	  
of	  4	  receptors	  (Notch1,	  Notch2,	  Notch3,	  and	  Notch4)	  that	  interact	  with	  5	  ligands	  (Delta-­‐like	  
ligands	  1,	  3,	  and	  4,	  and	  Jaggeds	  1	  and	  2).	  Receptor	  and	  ligand	  are	  both	  transmembrane	  proteins,	  
and	  signaling	  occurs	  through	  direct	  contact	  between	  cells.	  Mature	  Notch	  is	  presented	  at	  the	  cell	  
surface	  as	  a	  non-­‐covalently	  bound	  heterodimer[27].	  Upon	  Notch/ligand	  binding,	  a	  
conformational	  change	  in	  Notch	  allows	  for	  cleavage	  in	  the	  extracellular	  region	  by	  ADAM	  family	  
metalloprotease	  TACE	  (S2	  cleavage),	  and	  cleavage	  within	  the	  transmembrane	  region	  by	  
Presenilin/γ-­‐secretase	  (S3	  cleavage).	  This	  releases	  the	  extracellular	  domain	  of	  Notch	  (NECD)	  –	  
which	  bound	  to	  ligand,	  is	  endocytosed	  into	  the	  ligand-­‐presenting	  cell	  –	  from	  the	  intracellular	  
domain	  of	  Notch	  (NICD).	  NICD	  translocates	  to	  the	  nucleus	  where	  it	  binds	  to	  CSL	  (CBF-­‐
1/Su(H)/Lag-­‐1),	  also	  known	  as	  RBP-­‐Jk,	  displacing	  proteins	  that	  make	  CSL	  a	  transcriptional	  
repressor	  and	  recruiting	  other	  co-­‐activator	  proteins,	  including	  Mastermind-­‐like	  proteins[23],	  
switching	  CSL	  into	  a	  transcriptional	  activator.	  This	  complex	  then	  activates	  transcription	  of	  
downstream	  target	  genes,	  including	  the	  HES	  (hairy/enhancer	  of	  split)	  and	  HEY	  (hairy/enhancer-­‐
of-­‐split	  related	  with	  YRPW	  motif)	  transcriptional	  repressors[28].	  This	  allows	  Notch	  to	  both	  





Notch	  signaling	  in	  the	  blood	  vasculature	  
The	  Notch	  family	  plays	  a	  critical	  role	  in	  the	  blood	  vasculature[29],	  as	  evidenced	  by	  the	  
vascular	  phenotypes	  exhibited	  by	  mutants.	  Mice	  nullizygous	  for	  Notch1	  or	  Jag1	  die	  between	  
E9.5-­‐11.5,	  exhibiting	  severe	  vascular	  abnormalities[30,	  31],	  while	  loss	  of	  just	  one	  copy	  of	  Dll4	  is	  
sufficient	  to	  cause	  embryonic	  death[32].	  A	  small	  number	  of	  Dll4+/-­‐	  mice	  outbred	  to	  the	  CD1	  
background	  survive	  to	  birth,	  and	  these	  mice	  display	  severe	  hypersprouting	  of	  blood	  vasculature	  
with	  increased	  sprouts,	  branch	  points,	  and	  vessel	  density[33].	  Interestingly,	  mice	  with	  
endothelial-­‐specific	  loss	  of	  Jag1	  exhibit	  hyposprouting	  of	  blood	  vasculature	  with	  reduced	  
sprouts,	  branch	  points,	  and	  vessel	  density[34].	  Mice	  nullizygous	  for	  Notch4	  are	  viable	  and	  fertile,	  
but	  Notch1-­‐/-­‐;Notch4-­‐/-­‐	  mice	  die	  embryonically	  with	  more	  severe	  vascular	  phenotypes	  than	  mice	  
nullizygous	  for	  Notch1	  alone[30].	  Mice	  nullizygous	  for	  Dll1	  die	  shortly	  after	  birth	  with	  vascular	  
defects[35].	  	  
The	  tip/stalk	  model	  has	  been	  developed	  to	  explain	  how	  Notch	  signaling	  functions	  in	  the	  
context	  of	  sprouting	  angiogenesis[36]	  (Figure	  3),	  and	  explains	  the	  severe	  hypersprouting	  
phenotype	  seen	  in	  Dll4+/-­‐	  mice[33].	  The	  endothelial	  cell	  leading	  the	  way	  at	  the	  front	  of	  the	  sprout,	  
also	  known	  as	  the	  “tip	  cell”,	  extends	  filopodia	  to	  sense	  its	  surroundings	  and	  is	  highly	  responsive	  
to	  Vascular	  Endothelial	  Growth	  Factor	  (VEGF)[37].	  When	  VEGF	  binds	  VEGF	  receptor-­‐2	  (VEGFR-­‐2)	  
in	  the	  tip	  cell,	  a	  signaling	  cascade	  is	  initiated,	  in	  which	  Dll4	  expression	  is	  induced	  in	  the	  tip	  cell[33,	  
38,	  39],	  which	  activates	  Notch	  in	  the	  neighboring	  “stalk	  cell”.	  NICD	  then	  translocates	  to	  the	  
nucleus	  of	  the	  stalk	  cell	  and,	  through	  its	  transcriptional	  effectors,	  represses	  VEGFR-­‐2.	  This	  
ensures	  that	  the	  tip	  cell,	  but	  not	  the	  stalk	  cell,	  is	  highly	  responsive	  to	  VEGF	  stimulation,	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preventing	  hypersprouting.	  However,	  tip	  and	  stalk	  cell	  identities	  are	  not	  static.	  Competition	  
between	  cells	  to	  adopt	  the	  tip	  or	  stalk	  cell	  positions	  is	  a	  highly	  dynamic	  process,	  and	  cells	  are	  
constantly	  shifting	  between	  the	  two	  cell	  types[40].	  	  
	  
Notch	  signaling	  in	  lymphatic	  vasculature	  
The	  field	  of	  lymphatic	  vascular	  biology	  has	  benefited	  in	  the	  past	  fifteen	  to	  twenty	  years	  
from	  the	  identification	  of	  markers	  that	  are	  specific	  to	  or	  highly	  expressed	  by	  LECs,	  and	  the	  
phenotypes	  of	  mice	  lacking	  these	  genes	  have	  been	  identified[10,	  11,	  41].	  A	  list	  of	  genes	  required	  
for	  lymphatic	  vascular	  development	  and	  function	  is	  provided	  in	  Table	  1.	  	  
Given	  that	  lymphatics	  have	  a	  venous	  origin	  and	  that	  Notch	  plays	  important	  roles	  in	  the	  
blood	  vasculature,	  interest	  has	  recently	  shifted	  to	  understanding	  Notch	  signaling	  in	  the	  
lymphatic	  vasculature.	  Studying	  the	  effects	  of	  genetic	  ablation	  of	  Notch	  pathway	  components	  
in	  the	  context	  of	  the	  lymphatic	  endothelium	  has	  become	  possible	  through	  the	  development	  of	  
the	  Prox1-­‐CreERT2	  lymphatic-­‐specific	  driver	  line[4],	  as	  global	  Notch	  knockouts	  die	  due	  to	  vascular	  
defects	  before	  lymphatic	  phenotypes	  can	  manifest	  themselves.	  	  
We	  sought	  to	  understand	  the	  role	  of	  Notch	  signaling	  in	  developmental	  and	  pathological	  
lymphangiogenesis.	  We	  hypothesized	  that	  Notch	  regulates	  sprouting	  lymphangiogenesis	  
through	  regulation	  of	  genes	  important	  in	  this	  process,	  namely	  VEGFR-­‐3.	  Through	  analysis	  of	  
cultured	  LECs,	  we	  show	  that	  Notch	  transcriptionally	  regulates	  VEGFR-­‐3,	  a	  critical	  player	  in	  
sprouting	  lymphangiogenesis.	  We	  report	  that	  Notch	  is	  a	  negative	  regulator	  of	  HDLEC	  
proliferation,	  migration,	  and	  network	  formation	  in	  in	  vitro	  assays	  designed	  to	  mimic	  the	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different	  steps	  of	  lymphangiogenesis.	  We	  also	  show	  that	  Notch	  signaling	  is	  responsive	  to	  VEGF	  
or	  VEGF-­‐C	  stimulation.	  Using	  pharmacological	  and	  genetic	  tools	  in	  in	  vivo	  models,	  we	  
demonstrate	  that	  Notch	  regulates	  sprouting	  lymphangiogenesis	  in	  both	  developmental	  and	  
pathological	  settings	  by	  limiting	  lymphatic	  sprouting.	  Furthermore,	  we	  show	  that	  Notch	  plays	  
important	  roles	  in	  lymphatic	  cell	  fate	  decisions.	  We	  report	  that	  Notch	  transcriptionally	  
regulates	  genes	  required	  for	  lymphatic	  specification/separation	  and	  lymphatic	  valve	  formation,	  
two	  settings	  in	  which	  lymphatic	  endothelial	  cells	  must	  make	  cell-­‐fate	  decisions.	  We	  conclude	  






























Figure 1. Venous origin of the lymphatic vasculature. In the mouse, lymphatic specification from the 
venous vasculature begins at E9.75 with the polarized expression of Prox1 in the anterior cardinal 
vein. From E11.5-12.5, Prox1+ cells form primitive lymph sacs. From E12.5, lymph sacs undergo 
further sprouting, differentiation, and maturation to form the lymphatic plexus. Adapted from Oliver, 
G. and R.S. Srinivasan, Endothelial cell plasticity: how to become and remain a lymphatic endothelial 
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Figure 2. The Notch signaling pathway. The Notch signaling pathway is initiated when two neighbor-
ing cells interact via receptors (Notch1-Notch4) and ligands (Delta-like ligand 1,3,4 and Jagged 1,2). 
Notch is presented at the cell surface as a non-covalently bound heterodimer. Upon receptor/ligand 
binding, a conformational change in the receptor allows for two cleavages in the extracellular and 
transmembrane regions, releasing the intracellular domain of the receptor (ICN). ICN translocates to 
the nucleus, where it binds to CSL/RBP-Jk and recruits Mastermind-like (MAML) and other 
co-activators (Co-A), displacing co-repressors (Co-R). This switches CSL/RBP-Jk from a transcriptional 
repressor to a transcriptional activator. Adapted from McElhinny, A.S., J.L. Li, and L. Wu, Mastermind-
like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling 








Figure 3. The tip/stalk model of sprouting angiogenesis. An angiogenic sprout is composed of the tip 
cell, a cell at the front of the sprout that expresses high levels of VEGFR-2, extends multiple filopodia 
to sense its surroundings, and migrates toward VEGF; and stalk cells, which follow behind the tip cell. 
When VEGF binds VEGFR-2 in the tip cell, the Notch ligand Dll4 is induced. Dll4 signals to Notch in the 
neighboring stalk cell, and Notch transriptionally represses VEGFR-2 in the stalk cell. This results in a 
highly VEGF-responsive tip cell and poorly-responsive stalk cells, allowing for tightly controlled 
sprouting. Adapted from Thurston, G. and J. Kitajewski, VEGF and Delta-Notch: interacting signalling 































Table	  1.	  List	  of	  genes	  important	  in	  lymphatic	  vasculature	  
Gene	   Expression	  Pattern	   Mutant	  Phenotypes	  
Prox1	  
LEC	  progenitor	  cells	  in	  the	  
cardinal	  vein	  early	  on	  (E9.5),	  
then	  by	  all	  LECs;	  hepatocytes,	  




Prox1-­‐/-­‐	  is	  embryonic	  lethal	  at	  
E14.5-­‐15	  due	  to	  complete	  lack	  of	  
LECs[7];	  surviving	  Prox1+/-­‐	  mice	  
display	  edema	  and	  chylous	  
ascites[7]	  
Sox18	  
LEC	  progenitor	  cells	  in	  the	  
cardinal	  vein	  early	  on;	  then	  by	  all	  
LECs	  until	  E14.5,	  arterial	  and	  
venous	  BECs,	  hair	  follicle	  cells	  
Sox18-­‐/-­‐	  is	  embryonic	  lethal	  at	  
E14.5	  in	  C57BL/6	  background	  
due	  to	  complete	  lack	  of	  LECs[5];	  
Sox18+/-­‐	  display	  mild	  edema	  and	  
lymphatic	  vessel	  patterning	  
defects[5]	  
Coup-­‐TFII	  
LEC	  progenitor	  cells	  in	  the	  
cardinal	  vein	  early	  on,	  then	  by	  all	  
LECs;	  venous	  BECs,	  vascular	  
smooth	  muscle	  cells	  
Coup-­‐TFII-­‐/-­‐	  is	  embryonic	  lethal	  
at	  E10	  with	  abnormal	  venous	  
development[42];	  deletion	  of	  
Coup-­‐TFII	  in	  vasculature	  (Tie2-­‐
Cre;	  Coup-­‐TFIIfl/fl)	  results	  in	  80%	  




LECs	  (E11),	  keratinocytes,	  
podocytes,	  alveolar	  cells,	  
osteoblasts	  
Pdpn-­‐/-­‐	  is	  perinatally	  lethal	  in	  
129/SvEv	  background	  due	  to	  
respiratory	  failure[43];	  a	  fraction	  
of	  Pdpn-­‐/-­‐	  mice	  survive	  in	  
C57BL/6	  background	  and	  display	  
blood	  in	  lymphatics	  due	  to	  
defective	  platelet	  activation[44]	  
Lyve1	  	  
LEC	  progenitor	  cells	  in	  the	  
cardinal	  vein	  early	  on	  (E9),	  then	  
by	  all	  LECs;	  macrophages,	  
liver/spleen/lymph	  node	  
sinusoidal	  BECs	  




LECs	  (E13.5),	  progressively	  
becomes	  restricted	  to	  lymphatic	  
valve	  ECs	  postnatally	  (P3-­‐P7)	  
Cx37-­‐/-­‐	  mice	  are	  viable[46]	  but	  
display	  enlarged	  jugular	  lymph	  
sacs	  and	  reduced	  number	  of	  
valves	  in	  collecting	  ducts[47]	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Lymphatic	  valve	  ECs,	  fibroblasts,	  
epithelial	  cells,	  etc	  
FnEIIIA-­‐/-­‐	  mice	  are	  viable	  and	  
fertile	  but	  display	  normal	  skin	  
wound	  healing	  and	  shortened	  
life	  span[48],	  as	  well	  as	  reduced	  




LECs,	  with	  highest	  expression	  in	  
lymphatic	  valve	  ECs,	  vascular	  
smooth	  muscle	  cells	  
Itga9-­‐/-­‐	  is	  perinatally	  lethal	  with	  
respiratory	  failure	  caused	  by	  
chylothorax[50]	  due	  to	  reduced	  
and	  abnormal	  lymphatic	  valves	  
in	  collecting	  vessels[49]	  
Lama5	  
(Lamininα5)	  
Cells	  of	  the	  kidney,	  lung,	  skin,	  
intestine,	  skeletal	  muscle	  cells,	  
etc	  
Lama5-­‐/-­‐	  is	  lethal	  by	  E16.5	  
displaying	  defects	  in	  anterior	  
neural	  tube	  closure	  and	  digit	  
septation,	  as	  well	  as	  reduced	  
placental	  labyrinth	  and	  defective	  
placental	  vasculature[51]	  
Vegfr3	   LECs,	  BECs	  early	  in	  development	  but	  becomes	  reduced	  later	  on	  
Vegfr3-­‐/-­‐	  is	  embryonic	  lethal	  
beginning	  at	  E9.5	  due	  to	  defects	  
in	  blood	  vessel	  remodeling	  
resulting	  in	  cardiovascular	  
failure[52];	  mice	  mutant	  for	  the	  
ligand	  binding	  domain	  
(Vegfr3ΔLBD/ΔLBD)	  or	  tyrosine	  
kinase	  domain	  (Vegfr3TKmut/Tkmut)	  
have	  normal	  blood	  vasculature	  
but	  display	  defects	  in	  
development	  of	  lymphatic	  
vasculature,	  leading	  to	  edema[53]	  
Efnb2	  (EphrinB2)	  
LECs,	  with	  highest	  expression	  in	  
lymphatic	  valve	  ECs;	  arterial	  
BECs,	  vascular	  smooth	  muscle	  
cells	  
Efnb2-­‐/-­‐	  is	  embryonic	  lethal	  
before	  E11.5	  due	  to	  defects	  in	  
embryonic	  vasculature[54];	  mice	  
with	  mutated	  PDZ	  binding	  sites	  
(Efnb2ΔV/ΔV)	  have	  normal	  blood	  
vasculature	  but	  display	  defects	  
in	  development	  of	  lymphatic	  
vasculature	  and	  lack	  of	  





















Isolation	  of	  Human	  Dermal	  Lymphatic	  Endothelial	  Cells	  (HDLECs)	  
Human	  neonatal	  foreskins	  were	  minced,	  rinsed	  in	  phosphate-­‐buffered	  saline	  (PBS,	  
Gibco)	  to	  remove	  blood,	  then	  digested	  in	  DMEM	  low	  glucose	  medium	  (Gibco)	  supplemented	  
with	  Ca2+/Mg2+,	  2%	  fetal	  bovine	  serum	  (FBS),	  1X	  pen/strep	  (100U	  penicillin/100U	  streptomycin,	  
Invitrogen),	  and	  1mg/mL	  collagenase	  A	  (Roche)	  for	  30min	  at	  37°C	  in	  a	  rotating	  incubator.	  An	  
equal	  volume	  of	  “Buffer	  A”	  (PBS	  supplemented	  with	  5mg/mL	  bovine	  serum	  albumin	  [BSA]	  and	  
0.6%	  Acid	  Citrate	  Dextrose	  Solution	  A)	  was	  added	  and	  tissue	  was	  crushed	  with	  a	  cell	  scraper	  to	  
release	  cells	  (3X).	  Solution	  was	  filtered	  through	  a	  100μm	  cell	  strainer,	  centrifuged	  at	  1500rpm	  
for	  5min	  at	  4°C,	  and	  resuspended	  in	  Buffer	  A.	  CD31+	  cells	  were	  isolated	  using	  the	  Dynabead®	  
magnetic	  bead	  system	  (Invitrogen)	  as	  per	  manufacturer’s	  instructions.	  CD31+	  cells	  were	  
expanded,	  then	  further	  purified	  by	  fluorescence	  activated	  cell	  sorting	  (FACS)	  using	  the	  BD	  
FACSAriaTM	  flow	  cytometer	  to	  obtain	  CD31+;	  podoplanin+;	  CD34-­‐	  HDLECs	  (Figure	  1,	  Table	  1).	  	  
	  
Cell	  Lines	  
	   All	  cells	  were	  maintained	  at	  37°C	  in	  a	  mixture	  of	  5%	  CO2	  and	  95%	  humidified	  air.	  HDLECs	  
were	  maintained	  on	  fibronectin-­‐coated	  plates	  in	  EGMTM-­‐2	  MV	  Endothelial	  Cell	  Growth	  Media	  
(Lonza)	  supplemented	  with	  FBS	  (final	  concentration	  of	  5%)	  and	  10ng/mL	  VEGF-­‐C	  (R&D),	  and	  
used	  before	  passage	  7.	  The	  MDA-­‐MB-­‐231	  human	  mammary	  tumor	  cell	  line	  (ATCC)	  was	  
maintained	  in	  Eagle’s	  Minimum	  Essential	  Medium	  (EMEM,	  ATCC)	  supplemented	  with	  10%	  FBS	  
and	  1X	  pen/strep.	  The	  luciferase	  expressing	  subline	  MDA-­‐MB-­‐231-­‐luc-­‐D3H2LN®	  (Perkin	  Elmer)	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   HDLECs	  plated	  to	  90%	  confluency	  on	  fibronectin-­‐coated	  glass	  coverslips	  were	  fixed	  with	  
4%	  paraformaldehyde	  (PFA)	  for	  15min	  at	  RT,	  then	  blocked/permeabilized	  with	  PBS	  containing	  
0.1%	  Triton	  X-­‐100	  and	  5%	  serum	  for	  30min	  at	  RT.	  Cells	  were	  incubated	  in	  PBS	  with	  5%	  
appropriate	  serum	  and	  appropriate	  primary	  antibodies	  (Table	  1)	  for	  2hrs	  at	  RT,	  then	  in	  PBS	  with	  
5%	  serum	  and	  appropriate	  Alexa	  Fluor®	  secondary	  antibodies	  at	  1:500	  for	  2hrs	  at	  RT.	  Coverslips	  
were	  mounted	  on	  slides	  using	  VECTASHIELD®	  mounting	  medium	  containing	  DAPI	  (Vector	  
Laboratories).	  	  
	  
Lentivirus-­‐Mediated	  Stable	  Transduction	  of	  HDLECs	  
1.5x106	  293T	  packaging	  cells	  were	  calcium	  phosphate-­‐transfected	  as	  previously	  
described[57]	  with	  the	  following	  plasmids:	  3μg	  of	  pVSVG,	  5μg	  of	  pRRE,	  2.5μg	  of	  pRSV-­‐Rev,	  and	  
10ug	  of	  pCCL	  lentiviral	  plasmids	  encoding	  genes	  of	  interest.	  We	  activated	  Notch	  using	  pCCL	  
lentiviral	  vectors	  encoding	  N1IC	  (Figure	  2),	  N4/int3	  (Figure	  2),	  or	  GFP	  (ctrl).	  N1IC	  comprises	  the	  
Notch1	  intracellular	  domain,	  and	  N4/int3	  comprises	  the	  Notch4	  transmembrane	  and	  
intracellular	  domains.	  We	  inhibited	  Notch	  using	  a	  pCCL	  lentiviral	  vector	  encoding	  N1ECDFc1-­‐36	  
(Figure	  3)	  or	  hFc	  (ctrl).	  N1ECDFc1-­‐36	  comprises	  EGF-­‐like	  repeats	  1-­‐36	  in	  the	  extracellular	  domain	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of	  human	  Notch1	  fused	  to	  human	  Fc.	  48hrs	  after	  transfection,	  supernatant	  containing	  lentiviral	  
particles	  shed	  by	  the	  293T	  cells	  was	  collected,	  passed	  through	  a	  0.45μm	  filter,	  and	  used	  to	  
replace	  normal	  cell	  growth	  medium	  on	  HDLECs.	  24hrs	  after	  infection,	  medium	  was	  replaced	  
with	  normal	  cell	  growth	  medium.	  48hrs	  after	  infection	  (24hrs	  after	  medium	  was	  replaced),	  cells	  
were	  collected	  for	  RNA	  or	  protein	  isolation.	  
	  
Adenovirus-­‐Mediated	  Infection	  of	  HDLECs	  
1x106	  HDLECs	  were	  infected	  in	  suspension	  with	  adenovirus	  at	  a	  multiplicity	  of	  infection	  
(MOI)	  of	  20,	  in	  low	  serum	  (2%)	  media,	  for	  1hr	  at	  37°C.	  48hrs	  after	  infection,	  cells	  were	  collected	  
for	  RNA	  or	  protein	  isolation.	  	  
	  
Proliferation	  Assay	  
	   1x104	  HDLECs	  were	  plated	  in	  triplicate	  in	  24	  well	  plates,	  using	  normal	  growth	  medium.	  
2hrs	  later	  (“0hr”	  time	  point)	  and	  72hrs	  later,	  cell	  number	  was	  quantified	  using	  the	  Cell	  Counting	  
Kit-­‐8	  (Dojindo)	  and	  VersaMAX	  microplate	  reader	  (Molecular	  Devices),	  as	  per	  manufacturers’	  







	   HDLECs	  were	  plated	  O/N	  to	  confluence	  (7x104)	  in	  triplicate	  in	  12	  well	  plates,	  using	  
normal	  growth	  medium.	  The	  next	  day	  (“0hr”	  time	  point),	  a	  scratch	  was	  made	  across	  the	  
diameter	  of	  each	  well	  using	  a	  p200	  pipet	  tip,	  and	  medium	  was	  changed	  to	  serum-­‐free	  medium	  
(SFM)	  containing	  100ng/mL	  VEGF-­‐C	  (R&D).	  Pictures	  were	  taken	  every	  4hrs	  up	  to	  the	  25hr	  time	  
point.	  Cell	  migration	  rate	  was	  calculated	  using	  TScratch	  software.	  This	  assay	  was	  performed	  a	  
minimum	  of	  3	  times.	  
	  
Network	  Formation	  Assay	  
	   4x104	  HDLECs	  were	  seeded	  in	  triplicate	  between	  two	  collagen	  gels	  (Wako)	  overlaid	  with	  
SFM	  containing	  100ng/mL	  VEGF-­‐C	  (R&D),	  in	  24	  well	  plates.	  Pictures	  were	  taken	  of	  cell	  network	  
formation	  after	  72hrs.	  This	  assay	  was	  performed	  a	  minimum	  of	  3	  times.	  
	  
Co-­‐Culture	  Notch	  Reporter	  Assay	  
	   Cells	  were	  plated	  to	  90%	  confluency,	  then	  lipofected	  using	  Opti-­‐MEM®	  medium	  
(Invitrogen)	  and	  Lipofectamine®	  2000	  reagent	  (Invitrogen)	  as	  per	  manufacturer’s	  instructions.	  
HDLECs	  were	  lipofected	  with	  the	  Notch	  reporter	  plasmid	  pGL3.11CSL-­‐luc	  (containing	  11	  repeats	  
of	  a	  CSL-­‐responsive	  element)	  and	  pGL3.Renilla-­‐luc	  housekeeping	  plasmid.	  HeLa	  cells	  were	  
lipofected	  with	  pCR3	  plasmids	  expressing	  Dll4-­‐FLAG,	  Jag1-­‐FLAG,	  or	  ctrl.	  4hrs	  after	  lipofection,	  
medium	  was	  replaced	  with	  normal	  cell	  growth	  medium.	  24hrs	  after	  lipofection,	  HeLa	  and	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HDLECs	  were	  co-­‐cultured	  together	  at	  a	  1:1	  ratio	  in	  fibronectin-­‐coated	  plates	  and	  HDLEC	  
medium.	  24hrs	  after	  co-­‐culture,	  a	  luciferase	  reporter	  assay	  was	  performed	  using	  the	  Dual-­‐
Luciferase®	  Reporter	  Assay	  System	  (Promega)	  and	  a	  TD-­‐20/20	  luminometer	  (Turner	  Designs),	  as	  
per	  manufacturers’	  instructions.	  Each	  condition	  was	  performed	  in	  triplicate;	  due	  to	  time	  
constraints	  this	  assay	  was	  performed	  only	  twice.	  	  
	  
Activation	  of	  Endogenous	  Notch	  with	  EDTA	  
	   HDLECs	  plated	  to	  confluency	  were	  treated	  with	  a	  γ-­‐secretase	  inhibitor	  (compound	  E)	  at	  
200nM	  O/N	  at	  37°C	  to	  suppress	  endogenous	  Notch	  signaling.	  The	  next	  day,	  compound	  E	  was	  
removed	  by	  washing	  cells	  with	  PBS,	  and	  endogenous	  Notch	  signaling	  was	  activated	  by	  treating	  
HDLECs	  for	  15min	  at	  37°C	  with	  10mM	  EDTA.	  Cells	  were	  collected	  for	  RNA	  isolation	  at	  multiple	  
time	  points.	  
	  
Gene	  Expression	  Analysis	  
	   RNA	  was	  isolated	  from	  cultured	  cells	  using	  the	  RNEasy®	  Mini	  Kit	  (Qiagen),	  as	  per	  
manufacturer’s	  instructions.	  RNA	  was	  reverse	  transcribed	  to	  cDNA	  using	  the	  VersoTM	  cDNA	  
Synthesis	  Kit	  (Thermo	  Fisher)	  as	  per	  manufacturer’s	  instructions.	  Semi-­‐quantitative	  PCR	  was	  
performed	  using	  1μL	  of	  cDNA,	  primers	  specific	  to	  genes	  of	  interest	  (Table	  2),	  and	  Platinum®	  Taq	  
DNA	  Polymerase	  (Invitrogen).	  Quantitative	  Real	  Time	  PCR	  (qRT-­‐PCR)	  was	  performed	  in	  triplicate	  
for	  each	  condition,	  using	  ABsoluteTM	  Blue	  QPCR	  SYBR	  Green	  Master	  Mix	  (Thermo	  Fisher)	  and	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the	  Applied	  Biosystems	  7300	  Real-­‐Time	  PCR	  System	  (Applied	  Biosystems),	  as	  per	  manufacturers’	  
instructions.	  Primers	  specific	  to	  genes	  of	  interest	  (Table	  2)	  and	  qRT-­‐PCR	  standards	  specific	  to	  
genes	  of	  interest	  were	  used.	  Data	  was	  analyzed	  with	  Microsoft	  Excel.	  Gene	  expression	  analysis	  
was	  performed	  a	  minimum	  of	  3	  times.	  	  
	  
Protein	  Expression	  Analysis	  
	   Cell	  lysates	  were	  isolated	  from	  cultured	  cells	  in	  TENT	  lysis	  buffer	  supplemented	  with	  
HaltTM	  Protease	  Inhibitor	  Cocktail	  (Pierce).	  20μg	  -­‐	  40μg	  of	  total	  cell	  lysates	  were	  resolved	  by	  
SDS-­‐PAGE	  and	  transferred	  onto	  nitrocellulose	  membranes.	  Membranes	  were	  blocked	  for	  30min	  
in	  PBS	  with	  0.1%	  Tween,	  2%	  milk,	  and	  2%	  BSA	  at	  RT,	  incubated	  with	  the	  appropriate	  primary	  
antibodies	  in	  blocking	  buffer	  O/N	  at	  4°C	  (Table	  1),	  then	  incubated	  with	  the	  appropriate	  HRP-­‐
conjugated	  secondary	  antibodies	  in	  blocking	  buffer	  at	  1:5000	  for	  30min	  at	  RT.	  Bands	  were	  
detected	  using	  Amersham	  ECL	  Western	  Blotting	  Detection	  Reagents	  (GE	  Healthcare	  Life	  
Sciences).	  Protein	  expression	  analysis	  was	  performed	  a	  minimum	  of	  3	  times.	  	  
	  
VEGF	  and	  VEGF-­‐C	  Treatment	  of	  HDLECs	  
	   Confluent	  cultures	  were	  serum-­‐starved	  O/N	  in	  EBM-­‐2	  basal	  medium	  with	  0.1%	  BSA,	  1%	  
FBS	  and	  subsequently	  for	  5hrs	  in	  EBM-­‐2	  basal	  medium	  with	  0.1%	  BSA,	  no	  FBS.	  Starvation	  
medium	  was	  replaced	  with	  EBM-­‐2/0.1%	  BSA	  with	  VEGF	  (100ng/mL)	  or	  VEGF-­‐C	  (100ng/mL)	  for	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1hr.	  Cells	  were	  then	  collected	  for	  RNA	  isolation.	  Due	  to	  time	  constraints	  this	  assay	  was	  
performed	  only	  once.	  
	  
Flow	  Cytometry	  
	   HDLECs	  were	  incubated	  with	  appropriate	  primary	  antibodies	  in	  PCN	  buffer	  for	  30min	  at	  
4°C	  (Table	  1),	  then	  incubated	  with	  appropriate	  fluorescent	  secondary	  antibodies	  in	  PCN	  buffer	  
at	  1:200	  for	  20min	  at	  4°C.	  Cells	  were	  passed	  through	  polystyrene	  tubes	  with	  filter	  tops,	  then	  
analyzed	  with	  the	  BD	  FACSCaliburTM	  flow	  cytometer.	  Flow	  cytometry	  analysis	  was	  performed	  a	  
minimum	  of	  3	  times.	  
	  
Mouse	  Lines	  
	   Prox1CreERT2[4]	  and	  DNMAMLfl/fl[58]	  mice	  used	  in	  embryonic	  dorsal	  skin	  studies	  have	  
been	  previously	  described.	  12	  week	  old,	  wild-­‐type	  female	  C57BL/6J	  mice	  used	  in	  corneal	  suture	  
studies	  were	  obtained	  from	  Jackson	  Laboratories.	  6-­‐8	  week	  old,	  athymic	  nude	  female	  mice	  
used	  in	  tumor	  studies	  were	  obtained	  from	  Harlan.	  All	  experiments	  using	  mice	  followed	  
guidelines	  and	  protocols	  approved	  by	  Columbia	  University’s	  Institutional	  Animal	  Care	  and	  Use	  
Committee.	  Corneal	  suture	  assays	  adhered	  to	  the	  Association	  for	  Research	  in	  Vision	  and	  




Embryonic	  Dorsal	  Skin	  Studies	  and	  Whole-­‐Mount	  Immunohistochemistry	  
	   20mg/mL	  tamoxifen	  dissolved	  in	  corn	  oil	  was	  administered	  by	  oral	  gavage	  to	  pregnant	  
dams	  at	  10mg/40g	  of	  body	  weight	  on	  E12.5.	  At	  E14.5,	  dorsal	  skin	  was	  microdissected	  from	  each	  
embryo,	  fixed	  for	  2hrs	  in	  4%	  PFA,	  then	  blocked/permeabilized	  for	  2hrs	  at	  RT	  in	  PBS	  containing	  
10%	  appropriate	  serum	  and	  0.3%	  Triton	  X-­‐100.	  Skins	  were	  incubated	  with	  the	  appropriate	  
primary	  antibodies	  in	  blocking	  buffer	  O/N	  at	  4°C	  (Table	  1),	  then	  incubated	  with	  the	  appropriate	  
fluorescent	  secondary	  antibodies	  in	  blocking	  buffer	  at	  1:500	  O/N	  at	  4°C.	  Skins	  were	  mounted	  
on	  slides	  using	  VECTASHIELD®	  mounting	  medium	  containing	  DAPI	  (Vector	  Laboratories).	  3-­‐6	  
embryos	  were	  analyzed	  per	  genotype.	  1	  litter	  has	  been	  analyzed	  to	  date.	  
	  
Corneal	  Suture	  Studies	  and	  Whole-­‐Mount	  Immunohistochemistry	  
	   11-­‐0	  nylon	  sutures	  (Covidien)	  were	  placed	  in	  both	  corneas	  of	  mice.	  In	  the	  first	  
experiment,	  adenoviruses	  expressing	  N1ECDFc1-­‐24	  (Figure	  3)	  or	  hFc	  (ctrl)	  were	  administered	  by	  
retro-­‐orbital	  injection	  (5x108	  ffu/mouse)	  on	  day	  0,	  a	  single	  continuous	  suture	  covering	  at	  least	  a	  
180°	  circumference	  was	  placed	  on	  day	  4,	  and	  eyes	  were	  collected	  on	  day	  16.	  In	  all	  other	  
experiments,	  3	  sutures	  were	  placed	  as	  knots	  on	  the	  nasal/superior/inferior	  positions	  on	  day	  0,	  
adenoviruses	  expressing	  Notch1	  decoys	  (N1ECDFc’s,	  Figure	  3)	  or	  hFc	  (ctrl)	  were	  administered	  
by	  retro-­‐orbital	  injection	  (5x108	  ffu/mouse)	  on	  day	  4,	  and	  eyes	  were	  collected	  on	  day	  7	  or	  10.	  
Both	  suture	  methods	  yielded	  the	  same	  results.	  Serum	  was	  collected	  regularly	  from	  mice	  to	  
monitor	  circulating	  levels	  of	  Notch1	  decoys	  by	  Western	  blot.	  3-­‐4	  mice	  were	  analyzed	  per	  group	  
per	  experiment.	  N1ECDFc1-­‐24	  treatment	  was	  analyzed	  in	  3	  separate	  experiments,	  N1ECDFc1-­‐13	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treatment	  was	  analyzed	  in	  2	  separate	  experiments,	  and	  N1ECDFc10-­‐24	  treatment	  was	  analyzed	  in	  
1	  experiment.	  
	   Corneas	  were	  microdissected	  from	  each	  eye,	  digested	  with	  Proteinase	  K	  (20μg/mL)	  for	  
5min	  at	  RT,	  permeabilized	  with	  100%	  methanol	  for	  30min	  at	  RT,	  then	  blocked/permeabilized	  
O/N	  at	  4°C	  in	  PBS	  with	  2.5%	  BSA,	  0.5%	  Triton	  X-­‐100.	  Corneas	  were	  incubated	  with	  the	  
appropriate	  primary	  antibodies	  in	  blocking	  buffer	  O/N	  at	  4°C	  (Table	  1),	  then	  incubated	  with	  the	  
appropriate	  fluorescent	  secondary	  antibodies	  in	  blocking	  buffer	  at	  1:500	  O/N	  at	  4°C.	  Corneas	  
were	  flat-­‐mounted	  on	  slides	  using	  VECTASHIELD®	  mounting	  medium	  containing	  DAPI	  (Vector	  
Laboratories).	  	  
	  
Tumor	  Studies	  and	  Immunohistochemistry	  
	   5x105	  to	  1.5x106	  cells	  were	  suspended	  in	  a	  solution	  containing	  50%	  PBS,	  50%	  MatrigelTM	  
(BD),	  and	  orthotopically	  implanted	  into	  the	  4th	  mammary	  fat	  pad	  of	  mice.	  Adenoviruses	  
expressing	  Notch1	  decoys	  (N1ECDFc’s,	  Figure	  3)	  or	  hFc	  (ctrl)	  were	  administered	  by	  retro-­‐orbital	  
injection	  (5x108	  ffu/mouse)	  at	  the	  beginning	  and	  mid-­‐point	  of	  the	  tumor	  study.	  Serum	  was	  
collected	  regularly	  from	  mice	  to	  monitor	  circulating	  levels	  of	  Notch1	  decoys	  by	  Western	  blot.	  
Tumor	  progression	  was	  monitored	  with	  weekly	  caliper	  measurements	  and	  luciferase	  imaging	  
using	  the	  IVIS®	  Imaging	  System	  and	  Living	  Image	  Software	  (Caliper	  Life	  Sciences),	  10min	  after	  
intraperitoneal	  injection	  of	  30mg/mL	  D-­‐luciferin	  (Caliper	  Life	  Sciences)	  at	  150mg/kg	  of	  body	  
weight.	  In	  vivo	  monitoring	  for	  metastases	  was	  performed	  weekly	  throughout	  the	  experiment	  
and	  ex	  vivo	  post-­‐sacrifice	  with	  the	  IVIS®	  Imaging	  System	  and	  Living	  Image	  Software.	  4-­‐10	  mice	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were	  analyzed	  per	  group	  per	  experiment.	  N1ECDFc1-­‐24	  treatment	  was	  analyzed	  in	  3	  separate	  
experiments,	  while	  N1ECDFc1-­‐13	  and	  N1ECDFc10-­‐24	  treatments	  were	  analyzed	  in	  1	  experiment.	  	  
At	  end	  points,	  mice	  were	  sacrificed	  and	  tumors,	  lungs,	  and	  axillary	  lymph	  nodes	  were	  
collected.	  Tumors	  were	  fresh	  frozen	  in	  Tissue-­‐Tek®	  OCT	  compound	  (Sakura	  Finetek),	  while	  lungs	  
and	  axillary	  lymph	  nodes	  were	  frozen	  after	  O/N	  fixation	  in	  4%	  PFA	  at	  4°C.	  7μm	  sections	  were	  
post-­‐fixed	  in	  ice-­‐cold	  acetone	  for	  3min	  and	  blocked	  for	  1hr	  at	  RT	  in	  PBS	  with	  3%	  BSA	  and	  2%	  
appropriate	  serum.	  Tissues	  were	  incubated	  with	  the	  appropriate	  primary	  antibodies	  in	  blocking	  
buffer	  O/N	  at	  4°C	  (Table	  1),	  then	  incubated	  with	  the	  appropriate	  Alexa	  Fluor®	  secondary	  
antibodies	  in	  blocking	  buffer	  at	  1:750	  for	  30min	  at	  RT.	  Tissues	  were	  mounted	  on	  slides	  using	  
VECTASHIELD®	  mounting	  medium	  containing	  DAPI	  (Vector	  Laboratories).	  
	  
Image	  Acquisition,	  Quantification,	  and	  Statistical	  Analysis	  
	   Images	  of	  in	  vitro	  assays	  using	  cultured	  cells	  were	  acquired	  with	  a	  Zeiss	  Axiovert	  40	  CSL	  
inverted	  microscope.	  Images	  of	  immunocytochemistry	  and	  immunohistochemistry	  of	  tumors	  
were	  acquired	  with	  a	  Nikon	  Eclipse	  E800	  and	  analyzed	  with	  Adobe	  Photoshop.	  Vessel	  or	  
macrophage	  density	  was	  calculated	  by	  dividing	  positive	  pixels	  of	  a	  defined	  color	  threshold	  
within	  a	  set	  field	  by	  total	  number	  of	  pixels	  in	  the	  field.	  Images	  of	  whole-­‐mount	  embryonic	  
dorsal	  skin	  and	  corneas	  were	  acquired	  with	  a	  Zeiss	  LSM	  510	  Meta	  confocal	  microscope	  or	  Nikon	  
A1	  confocal	  microscope	  and	  analyzed	  with	  ImageJ	  or	  Adobe	  Photoshop.	  Vascular	  coverage	  was	  
calculated	  by	  quantifying	  area	  covered	  by	  vasculature	  and	  dividing	  by	  total	  area	  of	  the	  
specimen.	  Macrophage	  density	  was	  calculated	  by	  dividing	  positive	  pixels	  of	  a	  defined	  color	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threshold	  within	  a	  set	  field	  by	  total	  number	  of	  pixels	  in	  the	  field.	  Lymphatic	  sprouts	  and	  branch	  
points	  were	  counted	  per	  field.	  Two-­‐tailed	  student’s	  t-­‐test	  was	  used	  for	  statistical	  analysis	  and	  


































Figure 1. HDLEC cell surface marker profile. HDLECs isolated from human neonatal foreskins are 
CD31+ and podoplanin+. Human umbilical venous endothelial cells (HUVEC) which are blood endo-
thelial cells (BEC), and human dermal microvascular endothelial cells (HDMEC) which are a mix of 









Figure 2. Structures of Notches, ligands, and Notch activation constructs. The structures of 
full-length Notch1, Notch4, Dll4, and Jag1 are shown above. N1IC consists of the intracellular domain 
of Notch1 and N4/int3 consists of the transmembrane and intracellular domains of Notch4. EGF = 
Epidermal growth factor; LNR = LIN-12/Notch repeats; RAM = Rbp-associated molecule domain; NLS 
= Nuclear localization signal; TAD = Transactivation domain; PEST = Proline (P), glutamic acid (E), 

















Figure 3. Structures of Notch inhibition constructs. The structure of full-length Notch1 is shown 
above. Notch1 decoys, also known as N1ECDFCs, function as inhibitors of Notch signaling.   
N1ECDFc1-36 consists of all 36 EGF-like repeats in the extracellular domain of Notch1 fused to human 
Fc. It can bind and inhibit both Dll and Jag ligand-induced signaling. N1ECDFc1-24 consists of EGF-like 
repeats 1-24 in the extracellular domain of Notch1 fused to human Fc. It can bind and inhibit both Dll 
and Jag ligand-induced signaling. N1ECDFc1-13 consists of EGF-like repeats 1-13 in the extracellular 
domain of Notch1 fused to human Fc. It can bind and inhibit Dll ligand-induced signaling. N1ECDFc10-24 
consists of EGF-like repeats 10-24 in the extracellular domain of Notch1 fused to human Fc. It can 
bind and inhibit Jag ligand-induced signaling.
N1ECDFc1-36































Table	  1.	  List	  of	  antibodies	  
Antibody	  (host)	   Use	   Vendor	   Catalog	  Number	   Dilution	  
CD31	  (mouse)	   FACS	   Dako	   M0823	   1:100	  
CD31	  (rat)	   IHC	   BD	  Pharmingen	   553370	   1:200	  
CD34-­‐PE	  (mouse)	   FACS	   BD	  Pharmingen	   5550619	   1:100	  
Cx37	  (rabbit)	   WB	   ADI	   CX37A11-­‐A	   1:200	  
Dll4	  (goat)	   ICC	   R&D	   AF1389	   1:50	  
Dll4	  (goat)	   IHC	   R&D	   AF1389	   1:100	  
F4/80	  (rat)	   IHC	   eBioscience	   14-­‐4801-­‐82	   1:250	  
Fc-­‐HRP	  (rabbit)	   WB	   Sigma	   A0170	   1:5000	  
FN	  (rabbit)	   WB	   Abcam	   ab23750	   1:2000	  
FN-­‐EIIIA	  (mouse)	   WB	   Abcam	   ab6328	   1:1000	  
Integrinα9	  (mouse)	   FACS	   Millipore	   MAB2078Z	   1:100	  
Jag1	  (rabbit)	   ICC	   Santa	  Cruz	   sc-­‐8303	   1:50	  
Jag1	  (goat)	   IHC	   R&D	   AF599	   1:100	  
LYVE1	  (rabbit)	   IHC	   Abcam	   ab14917	   1:500	  
Notch1	  (goat)	   ICC	   Santa	  Cruz	   sc-­‐6014	   1:50	  
Notch1	  (goat)	   IHC	   R&D	   AF1057	   1:200	  
Notch4	  (rabbit)	   ICC	   Santa	  Cruz	   sc-­‐5594	   1:50	  
Notch4	  (rabbit)	   IHC	   Santa	  Cruz	   sc-­‐5594	   1:100	  
Podoplanin	  (mouse)	   FACS	   AngioBio	   11-­‐003	   1:200	  
α-­‐tubulin	  (mouse)	   WB	   Sigma	   T6074	   1:5000	  
VEGFR-­‐3	  (goat)	   IHC	   R&D	   AF743	   1:100	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Table	  2.	  List	  of	  PCR	  primers	  
Gene	   Forward	  Primer	  Sequence	  	  	  	  	  	  	  	  	  	  	  	  (5'	  →	  3')	  
Reverse	  Primer	  Sequence	  	  	  	  	  	  	  	  	  	  	  	  
(5'	  →	  3')	  
BETA	  ACTIN	   CGAGGCCCAGAGCAAGAGAG	   CTCGTAGATGGGCACAGTGTG	  
CONNEXIN37	   GGTGGGTAAGATCTGGCTGA	   GGCCGTGTTACACTCGAAAT	  
DELTA	  LIKE	  LIGAND	  
1	   CTACACGGGCAGGAACTGCAG	   CGCCTTCTTGTTGGTGTTCTTG	  
DELTA	  LIKE	  LIGAND	  
3	   CTCTTCTTCAGAGTCTGCCTGAAG	   TCCTAACTCCTCTCTCCAGGTTTC	  
DELTA	  LIKE	  LIGAND	  
4	   CGGGTCATCTGCAGTGACAAC	  
AGTTGAGATCTTGGTCACAAAACA
G	  
FIBRONECTIN	  EIIIA+	   TTGATCGCCCTAAAGGACTG	   ACCATCAGGTGCAGGGAATA	  
FIBRONECTIN	  EIIIA-­‐	   GGTAACCACCATTCCTGCAC	   CCTGATACAACCACGGATGA	  
HES1	   CCCAACGCAGTGTCACCTTC	   TACAAAGGCGCAATCCAATATG	  
HEY1	   ACGAGAATGGAAACTTGAGTTC	   AACTCCGATAGTCCATAGCAAG	  
HEY2	   ATGAGCATAGGATTCCGAGAGTG	   GGCAGGAGGCACTTCTGAAG	  
INTEGRINA9	   CGGAATCATGTCTCCAACCT	   TCTCTGCACCACCAGATGAG	  
JAGGED1	   GCTTGGATCTGTTGCTTGGTGAC	   ACTTTCCAAGTCTCTGTTGTCCTG	  
JAGGED2	   GCTATTTCGAGCTGCAGCTGAG	   GCGGCAGGTAGAAGGAGTTG	  
NOTCH1	   CTCACCTGGTGCAGACCCAG	   GCACCTGTAGCTGGTGGCTG	  
NOTCH2	   CAGTGTGCCACAGGTTTCACTG	   GCATATACAGCGGAAACCATTCAC	  
NOTCH3	   CGCCTGAGAATGATCACTGCTTC	   TCACCCTTGGCCATGTTCTTC	  
NOTCH4	   GGTGACACCCCTGATGTCAG	   AGCCTGGCAGCCAGCATC	  
PODOPLANIN	   CCCAGGAGAGCAACAACTCAAC	   CTCGATGCGAATGCCTGTTAC	  
PROX1	   ACGTAAAGTTCAACAGATGCATTAC	   CCAGCTTGCAGATGACCTTG	  
VEGFR2	   GGACTGGCTTTGGCCCA	  T	   CTTGCTGTCCCAGGAAATTCTG	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Sprouting	  lymphangiogenesis	  is	  the	  growth	  of	  new	  lymphatic	  vessels	  from	  pre-­‐existing	  
lymphatic	  vessels.	  This	  process	  first	  begins	  in	  mouse	  development	  at	  embryonic	  day	  (E)12.5,	  
when	  the	  primitive	  lymph	  sacs	  that	  have	  migrated	  off	  of	  the	  cardinal	  vein	  continue	  on	  to	  form	  
the	  lymphatic	  plexus[9-­‐12].	  After	  development,	  sprouting	  lymphangiogenesis	  occurs	  more	  
sparingly,	  with	  the	  majority	  occurring	  in	  pathological	  conditions,	  such	  as	  in	  response	  to	  
inflammation	  and	  tumors	  (Chapters	  4	  and	  5,	  respectively).	  Lymphangiogenesis	  is	  a	  multi-­‐step	  
process	  that	  requires	  capillary	  lymphatic	  endothelial	  cells	  (LECs)	  to	  proliferate,	  directionally	  
migrate,	  and	  coalesce	  to	  form	  connected	  networks.	  One	  could	  imagine	  that	  lymphangiogenesis,	  
like	  angiogenesis,	  also	  requires	  determination	  of	  the	  tip	  cell,	  the	  cell	  leading	  the	  way	  of	  a	  
sprout;	  and	  stalk	  cell,	  the	  cell	  following	  behind	  the	  tip	  cell.	  This	  would	  ensure	  that	  sprouting	  is	  
regulated	  and	  proper	  lymphatic	  patterning	  is	  achieved.	  Disruption	  of	  any	  step	  in	  
lymphangiogenesis	  can	  result	  in	  hypersprouting	  of	  lymphatic	  capillaries	  or	  lymphatic	  
hyperplasia[9-­‐12].	  Hypersprouting	  is	  defined	  by	  an	  increase	  in	  sprouts	  and	  branch	  points.	  
Hyperplasia	  is	  a	  result	  of	  increased	  LEC	  proliferation,	  increased	  LEC	  migration,	  and/or	  dilation	  of	  
lymphatic	  vessels.	  Alternatively,	  disruption	  of	  lymphangiogenesis	  can	  result	  in	  hyposprouting,	  
which	  is	  a	  reduction	  in	  sprouts	  and	  branch	  points;	  or	  hypoplasia,	  which	  can	  result	  from	  
decreased	  LEC	  proliferation	  and	  migration[9-­‐12].	  Any	  of	  these	  disruptions	  can	  compromise	  
lymphangiogenesis	  and	  lymphatic	  function.	  
VEGFR-­‐3	  and	  VEGFR-­‐2	  are	  the	  primary	  mediators	  of	  sprouting	  lymphangiogenesis	  and	  
sprouting	  angiogenesis[59,	  60].	  Expression	  of	  both	  receptors	  has	  been	  observed	  in	  lymphatic	  and	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blood	  vascular	  systems[59,	  60].	  VEGFR-­‐3	  is	  expressed	  by	  the	  blood	  vasculature	  prior	  to	  the	  
development	  of	  the	  lymphatic	  vasculature[52],	  but	  its	  expression	  is	  gradually	  downregulated	  as	  
it	  becomes	  largely	  restricted	  to	  the	  lymphatic	  vasculature[59,	  60].	  There	  are	  several	  exceptions	  to	  
this	  expression	  pattern	  for	  VEGFR-­‐3	  at	  later	  time	  points	  during	  development	  and	  in	  disease.	  For	  
instance,	  VEGFR-­‐3	  is	  highly	  expressed	  at	  sites	  of	  active	  sprouting	  angiogenesis[59,	  60].	  VEGFR-­‐3	  is	  
strongly	  expressed	  by	  angiogenic	  tip	  cells	  in	  the	  postnatal	  retina,	  as	  well	  as	  by	  tumor	  blood	  
vasculature[61].	  VEGFR-­‐2	  is	  also	  strongly	  expressed	  by	  angiogenic	  tip	  cells,	  as	  well	  as	  angiogenic	  
stalk	  cells[59].	  VEGFR-­‐2	  is	  also	  expressed	  by	  the	  lymphatic	  vasculature,	  but	  at	  lower	  levels	  than	  in	  
the	  blood	  vasculature[59].	  VEGF-­‐A	  (VEGF)	  is	  the	  primary	  ligand	  for	  VEGFR-­‐2	  and	  VEGF-­‐C	  the	  
primary	  ligand	  for	  VEGFR-­‐3,	  but	  VEGF-­‐C	  can	  acquire	  VEGFR-­‐2	  activating	  properties	  through	  
proteolytic	  processing[62-­‐64].	  Both	  VEGF	  and	  VEGF-­‐C	  induce	  formation	  of	  VEGFR-­‐2/VEGFR-­‐3	  
heterodimers	  in	  angiogenic	  sprouts[65],	  further	  intertwining	  the	  two	  pathways.	  As	  lymphatic	  
vessels	  express	  both	  VEGFR-­‐3	  and	  VEGFR-­‐2,	  one	  could	  speculate	  that	  heterodimers	  may	  play	  a	  
role	  in	  lymphangiogenesis.	  Thus	  the	  functions	  of	  these	  two	  receptors	  and	  their	  ligands	  are	  
intimately	  linked	  and	  can	  influence	  each	  other.	  	  
VEGFR-­‐2	  and	  Notch	  are	  the	  two	  key	  players	  in	  a	  feedback	  loop	  that	  has	  been	  studied	  
extensively	  and	  underlies	  the	  process	  of	  sprouting	  angiogenesis[33,	  38,	  39,	  59,	  60].	  Angiogenic	  tip	  
cells	  at	  the	  front	  of	  a	  sprouting	  blood	  capillary	  highly	  express	  VEGFR-­‐2,	  and	  upon	  activation	  by	  
VEGF,	  induce	  Dll4	  in	  the	  tip	  cell[59,	  60].	  Tip	  cell	  Dll4	  then	  activates	  Notch	  signaling	  in	  the	  stalk	  cell,	  
resulting	  in	  inhibition	  of	  VEGFR-­‐2	  expression	  in	  the	  stalk	  cell[59,	  60].	  Evidence	  suggests	  that	  
VEGFR-­‐3	  can	  regulate	  Notch	  signaling	  as	  well	  –	  deletion	  of	  VEGFR-­‐3	  in	  blood	  endothelial	  cells	  
(BECs)	  causes	  hypersprouting	  in	  the	  retina	  concurrent	  with	  decreased	  levels	  of	  Dll4,	  suggesting	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that	  loss	  of	  VEGFR-­‐3	  reduces	  Dll4/Notch	  signaling	  and	  inhibits	  angiogenic	  tip/stalk	  cell	  
selection[66].	  
Notch	  regulation	  of	  VEGFR-­‐3	  has	  been	  extensively	  studied	  in	  both	  the	  lymphatic	  and	  
blood	  vasculature,	  but	  a	  uniform	  model	  has	  yet	  to	  emerge[59,	  60].	  In	  the	  blood	  vasculature,	  Notch	  
is	  reported	  to	  suppress	  VEGFR-­‐3	  expression	  in	  zebrafish	  and	  mouse	  models[61,	  67-­‐69].	  Other	  
reports,	  including	  work	  from	  our	  group,	  demonstrate	  that	  Notch	  induces	  VEGFR-­‐3	  expression	  in	  
cultured	  blood	  endothelial	  cells	  (BECs)[70,	  71]	  and	  in	  the	  intersomitic	  blood	  vessels	  of	  the	  murine	  
embryo[71].	  Reporter	  assays	  and	  chromatin	  immunoprecipitation	  performed	  by	  our	  group	  show	  
direct	  binding	  and	  activation	  of	  the	  VEGFR-­‐3	  promoter	  by	  the	  Notch	  intracellular	  domain	  
(NICD)/CSL	  complex	  in	  BECs[71].	  In	  cultured	  human	  dermal	  lymphatic	  endothelial	  cells	  (HDLECs),	  
Notch	  effectors	  HEY1	  and	  HEY2	  repress	  VEGFR-­‐3	  expression[72].	  Still	  other	  reports	  demonstrate	  
no	  changes	  in	  VEGFR-­‐3	  expression	  with	  Notch	  activation	  or	  inactivation[73,	  74].	  Given	  the	  
importance	  of	  Notch	  and	  VEGFR-­‐3	  in	  both	  lymphatic	  and	  blood	  vasculature,	  determining	  how	  
the	  two	  regulate	  each	  other	  is	  a	  priority.	  	  
To	  date,	  information	  on	  how	  Notch	  functions	  in	  lymphangiogenesis	  is	  limited	  and	  lacks	  
consensus.	  We	  discuss	  the	  results	  from	  the	  three	  main	  reports	  implicating	  Notch	  in	  sprouting	  
lymphangiogenesis	  below.	  	  
In	  a	  zebrafish	  model,	  Geudens	  et	  al.	  found	  that	  silencing	  Dll4	  increased	  the	  fraction	  of	  
venous	  intersomitic	  vessels	  (vISVs),	  decreased	  the	  number	  of	  arterial	  intersomitic	  vessels	  
(aISVs),	  and	  stalled	  sprouting	  of	  lymphatic	  intersomitic	  vessels	  (LISVs)[70].	  Sprouted	  LISVs	  were	  
often	  misrouted	  along	  vISVs,	  instead	  of	  developing	  along	  aISVs	  as	  expected[70].	  The	  authors	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proposed	  several	  potential	  models	  that	  could	  explain	  these	  phenotypes:	  1)	  Dll4/Notch	  silencing	  
had	  primary	  effects	  on	  blood	  vessels,	  leading	  to	  secondary	  effects	  on	  lymphatic	  vessels;	  2)	  
Dll4/Notch	  silencing	  disabled	  the	  arterial	  endothelium	  from	  releasing	  lymphangiogenic	  factors;	  
and/or	  3)	  Dll4	  expressed	  by	  arterial	  endothelial	  cells	  signals	  in	  trans	  to	  Notch	  lymphatic	  
endothelial	  cells	  to	  guide	  their	  sprouting.	  The	  authors	  concluded	  that	  in	  the	  zebrafish,	  
Dll4/Notch	  signaling	  is	  necessary	  for	  guided	  sprouting	  lymphangiogenesis	  alongside	  arterial	  
intersomitic	  templates[70].	  
Niessen	  et	  al.	  targeted	  murine	  sprouting	  lymphangiogenesis	  with	  neutralizing	  antibodies	  
against	  Notch1	  (αNotch1)	  or	  Dll4	  (αDll4).	  They	  reported	  that	  Notch	  inhibition	  reduced	  LYVE1+	  
lymphatic	  vessel	  density	  (LVD)	  in	  physiological	  sprouting	  lymphangiogenesis	  of	  the	  postnatal	  
mouse	  ear	  and	  tail	  dermis[74].	  αDll4	  treatment	  also	  decreased	  LYVE1+	  LVD	  in	  a	  model	  of	  
pathological	  lymphangiogenesis	  (discussed	  in	  Chapter	  4)[74].	  To	  determine	  the	  molecular	  
mechanism	  by	  which	  Notch	  suppressed	  sprouting	  lymphangiogenesis,	  the	  authors	  quantified	  
expression	  of	  VEGFR-­‐3	  and	  ephrinB2,	  a	  necessary	  component	  of	  VEGFR	  signaling[75,	  76],	  after	  
Notch	  inhibition[74].	  In	  tail	  dermal	  lymphatics,	  αDll4	  treatment	  did	  not	  alter	  VEGFR-­‐3	  expression,	  
but	  reduced	  ephrinB2	  expression[74].	  Thus	  the	  authors	  postulated	  that	  Notch	  promotes	  
sprouting	  lymphangiogenesis	  through	  indirect	  regulation	  of	  VEGFR-­‐3	  signaling[74].	  However,	  
Niessen	  et	  al.‘s	  method	  for	  quantifying	  LVD	  may	  not	  be	  adequate,	  as	  they	  also	  reported	  that	  
knockdown	  of	  Notch1	  or	  Dll4	  in	  cultured	  HDLECs	  resulted	  in	  significant	  downregulation	  of	  
LYVE1	  expression[74].	  Thus	  their	  phenotype	  may	  be	  a	  result	  of	  reduced	  expression	  of	  LYVE1	  and	  
not	  reduced	  LVD[74].	  The	  authors	  did	  not	  address	  this	  possibility	  or	  stain	  with	  another	  lymphatic	  
vessel	  marker	  to	  confirm	  their	  findings.	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Zheng	  et	  al.	  engineered	  a	  Dll4	  decoy	  composed	  of	  the	  Dll4	  extracellular	  domain	  fused	  to	  
Fc	  (Dll4-­‐Fc)	  to	  inhibit	  Notch	  signaling[73].	  Notch	  inhibition	  with	  Dll4-­‐Fc	  stimulated	  sprouting	  
physiological	  lymphangiogenesis	  in	  the	  postnatal	  mouse	  ear[73].	  Blockade	  of	  VEGF	  signaling	  
inhibited	  sprouting	  lymphangiogenesis	  stimulated	  by	  Dll4-­‐Fc,	  demonstrating	  that	  sprouting	  
lymphangiogenesis	  after	  Notch	  inhibition	  is	  at	  least	  partially	  achieved	  through	  increased	  
VEGF/VEGFR-­‐2	  signaling[73].	  Furthermore,	  Notch	  signaling	  was	  activated	  in	  HDLECs	  treated	  with	  
VEGF,	  placing	  Notch	  both	  upstream	  and	  downstream	  of	  VEGF	  signaling[73].	  The	  authors	  
postulated	  that	  in	  lymphatics,	  Notch	  strongly	  regulates	  the	  VEGF/VEGFR-­‐2	  signaling	  axis	  but	  not	  
the	  VEGF-­‐C/VEGFR-­‐3	  signaling	  axis.	  To	  determine	  the	  molecular	  mechanism,	  VEGFR-­‐2	  and	  
VEGFR-­‐3	  expression	  was	  analyzed	  in	  HDLECs	  treated	  with	  Dll4-­‐Fc.	  Notch	  inhibition	  did	  not	  alter	  
VEGFR-­‐2	  nor	  VEGFR-­‐3	  levels	  in	  vitro,	  and	  no	  expression	  analysis	  was	  performed	  in	  the	  mouse	  
model[73].	  However,	  the	  authors	  observed	  reduced	  expression	  of	  ephrinB2	  in	  cultured	  HDLECs	  
treated	  with	  Dll4-­‐Fc[73].	  The	  authors	  postulated	  that	  Notch	  suppresses	  lymphangiogenesis	  by	  
indirectly	  inhibiting	  VEGF/VEGFR	  signaling.	  Thus,	  Zheng	  et	  al.	  and	  Niessen	  et	  al.	  both	  implicated	  
Notch	  regulation	  of	  ephrinB2,	  as	  a	  regulator	  of	  lymphangiogenesis,	  but	  posed	  opposing	  
mechanisms[73,	  74].	  However,	  treatment	  of	  HDLECs	  with	  ephrinB2-­‐blocking	  antibodies	  did	  not	  
recapitulate	  the	  enhanced	  sprouting	  lymphangiogenesis	  seen	  with	  Dll4-­‐Fc[73].	  Thus	  the	  authors	  
identified	  interaction	  between	  Notch	  and	  VEGF	  signaling	  in	  physiological	  sprouting	  
lymphangiogenesis,	  but	  were	  unable	  to	  identify	  the	  molecular	  mechanism	  by	  which	  this	  occurs.	  	  
In	  summary,	  Geudens	  et	  al.	  and	  Niessen	  et	  al.	  concluded	  that	  Notch	  signaling	  induces	  
sprouting	  lymphangiogenesis	  during	  development[70,	  74]	  and	  wound-­‐healing[74],	  while	  Zheng	  et	  al.	  
concluded	  that	  Notch	  signaling	  suppresses	  sprouting	  lymphangiogenesis	  during	  development[73].	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Thus,	  the	  interplay	  between	  Notch	  and	  VEGF	  receptors	  and	  how	  they	  regulate	  sprouting	  
lymphangiogenesis	  is	  yet	  to	  be	  fully	  defined.	  Furthermore,	  a	  shared	  limitation	  of	  these	  studies	  
is	  that	  none	  have	  focused	  on	  cell-­‐autonomous	  functions	  of	  Notch	  in	  lymphatic	  endothelial	  cells.	  
These	  opposing	  results	  and	  the	  lack	  of	  a	  molecular	  mechanism	  called	  for	  further	  investigation.	  
We	  considered	  that	  Notch	  plays	  important	  roles	  in	  cell-­‐fate	  determination[24-­‐26]	  and	  sprouting	  
angiogenesis[33,	  59,	  60].	  Given	  the	  importance	  of	  cell-­‐fate	  determination	  in	  sprouting	  
lymphangiogenesis,	  and	  given	  the	  parallels	  between	  the	  lymphatic	  and	  blood	  vasculature,	  we	  
set	  out	  to	  investigate	  how	  Notch	  signaling	  in	  lymphatic	  endothelial	  cells	  regulates	  sprouting	  
lymphangiogenesis.	  Previous	  work	  on	  Notch	  in	  lymphatic	  and	  blood	  vasculature	  led	  us	  to	  
hypothesize	  that	  Notch	  signaling	  regulates	  lymphangiogenesis	  through	  regulation	  of	  VEGFR-­‐3	  
and	  VEGFR-­‐2.	  	  
	  
RESULTS	  
Cultured	  lymphatic	  endothelial	  cells	  express	  Notch	  proteins	  and	  Notch	  ligands	  
We	  performed	  a	  survey	  of	  the	  expression	  of	  Notch	  proteins	  and	  Notch	  ligands	  in	  
lymphatic	  endothelial	  cells	  that	  we	  isolated	  from	  neonatal	  human	  dermis.	  These	  cells	  are	  
referred	  to	  as	  human	  dermal	  lymphatic	  endothelial	  cells	  (HDLECs).	  HDLECs	  are	  
CD31+/podoplanin+/CD34-­‐	  (Chapter	  2,	  Figure	  1),	  and,	  as	  their	  name	  suggests,	  of	  dermal	  
lymphatic	  capillary	  origin.	  Thus	  these	  cells	  are	  ideal	  for	  the	  study	  of	  sprouting	  
lymphangiogenesis.	  We	  detected	  Notch1,	  Notch4,	  Dll4,	  and	  Jag1	  transcripts	  (data	  not	  shown)	  
and	  protein	  (Figure	  1)	  in	  HDLECs.	  These	  are	  the	  same	  receptors	  and	  ligands	  in	  the	  Notch	  family	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that	  are	  expressed	  in	  cultured	  human	  umbilical	  venous	  endothelial	  cells	  (HUVECs,	  data	  not	  
shown).	  	  
	  
Murine	  lymphatic	  vasculature	  expresses	  Notch	  components	  
In	  order	  to	  confirm	  our	  expression	  analysis	  in	  cultured	  HDLECs,	  we	  performed	  
expression	  analysis	  in	  murine	  sprouting	  lymphatics	  during	  development.	  In	  the	  mouse	  
embryonic	  dermis,	  the	  lymphatic	  vasculature	  develops	  in	  a	  highly	  consistent	  pattern.	  We	  
whole-­‐mount	  stained	  embryonic	  dermises	  for	  LYVE1,	  a	  lymphatic	  endothelial	  marker,	  and	  CD31,	  
a	  pan-­‐endothelial	  marker	  that	  is	  expressed	  strongly	  by	  blood	  vasculature	  and	  weakly	  by	  
lymphatic	  vasculature	  (Figure	  2).	  At	  E14.5	  in	  the	  dorsal	  region,	  two	  lymphangiogenic	  capillary	  
fronts	  were	  observed	  approaching	  the	  midline	  in	  a	  lateral	  to	  medial	  direction	  from	  either	  side	  
(Figure	  2).	  At	  this	  time	  point,	  the	  two	  angiogenic	  fronts	  had	  already	  reached	  the	  midline	  and	  
fused	  to	  form	  a	  dense	  blood	  capillary	  network	  (Figure	  2),	  indicating	  that	  lymphangiogenesis	  in	  
the	  dorsal	  dermis	  continues	  after	  angiogenesis	  is	  complete.	  We	  concluded	  that	  the	  murine	  
embryonic	  dermis	  would	  be	  an	  ideal	  model	  for	  the	  study	  of	  physiological	  sprouting	  
lymphangiogenesis.	  	  
Our	  group	  has	  previously	  shown	  expression	  of	  Notch1	  and	  Notch4	  in	  dermal	  lymphatic	  
capillaries[71],	  using	  immunohistochemical	  analysis	  of	  postnatal	  day	  4	  (P4)	  murine	  dermal	  
sections.	  To	  build	  upon	  these	  findings	  we	  analyzed	  ligand	  expression.	  Whole-­‐mount	  
immunohistochemical	  analysis	  revealed	  Dll4	  expression	  in	  the	  developing	  lymphatics	  and	  in	  the	  
neighboring	  blood	  vessels	  in	  the	  embryonic	  dermis	  (Figure	  3A).	  Jag1	  was	  not	  detected	  in	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developing	  lymphatics,	  though	  it	  was	  expressed	  by	  the	  neighboring	  blood	  vessels	  (Figure	  3B).	  
Consistent	  with	  previous	  publications[77-­‐79],	  strong	  Dll4	  expression	  was	  observed	  in	  the	  arterial	  
endothelium	  (Figure	  3A)	  and	  strong	  Jag1	  expression	  was	  observed	  in	  arterial	  endothelium	  and	  
vascular	  smooth	  muscle	  cells	  (Figure	  3B).	  Expression	  of	  Dll4	  in	  the	  lymphatic	  vasculature	  was	  
lower	  than	  in	  blood	  vasculature	  (Figure	  3A).	  We	  conclude	  that	  Notch1,	  Notch4,	  and	  Dll4	  are	  
expressed	  by	  dermal	  lymphatics.	  Based	  upon	  the	  lack	  of	  Jag1	  expression	  in	  this	  setting,	  we	  
hypothesize	  that	  Jag1	  becomes	  upregulated	  upon	  culturing	  of	  HDLECs	  from	  dermis.	  
HDLECs	  overexpressing	  Dll4	  preferentially	  assume	  the	  tip	  cell	  position	  in	  vitro[73].	  We	  
investigated	  whether	  Dll4	  was	  a	  lymphatic	  tip	  cell	  marker	  in	  the	  murine	  lymphatic	  vasculature.	  
Indeed,	  upon	  closer	  examination	  of	  developmental	  dermal	  lymphatics,	  we	  found	  enriched	  Dll4	  
expression	  (Figure	  3C’)	  at	  the	  leading	  edge	  of	  lymphangiogenic	  sprouts	  (Figure	  3C)	  in	  a	  pattern	  
reminiscent	  of	  Dll4	  expression	  in	  angiogenic	  sprouts.	  Closer	  examination	  confirmed	  that	  Jag1	  
(Figure	  3D’)	  was	  not	  expressed	  in	  lymphangiogenic	  sprouts	  (Figure	  3D).	  Thus,	  we	  provide	  the	  
first	  documentation	  of	  Dll4	  as	  a	  lymphatic	  tip	  cell	  marker	  in	  the	  physiological	  lymphatic	  
vasculature,	  suggesting	  that	  Dll4	  plays	  an	  important	  role	  in	  sprouting	  lymphangiogenesis.	  
	  
Notch	  activation	  in	  cultured	  HDLECs	  depends	  on	  Dll4	  
Notch	  signaling	  can	  occur	  between	  two	  cells	  of	  the	  same	  type,	  or	  heterotypically	  
between	  two	  different	  cell	  types.	  Heterotypic	  Notch	  signaling	  between	  pericytes	  and	  BECs	  has	  
been	  demonstrated	  to	  help	  stabilize	  and	  mature	  vasculature[80,	  81],	  while	  heterotypic	  Notch	  
signaling	  between	  macrophages	  and	  angiogenic	  tip	  cells	  has	  been	  suggested	  to	  aid	  in	  vessel	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anastomosis[82].	  Although	  our	  expression	  analysis	  did	  not	  detect	  Jag1	  in	  lymphatic	  vasculature,	  
we	  wanted	  to	  rule	  out	  the	  possibility	  that	  Jag1	  expressed	  by	  another	  cell	  type	  could	  
heterotypically	  activate	  Notch	  signaling	  in	  LECs.	  To	  determine	  which	  ligands	  can	  activate	  Notch	  
in	  lymphatic	  endothelial	  cell,	  we	  performed	  a	  Notch	  reporter	  assay	  using	  a	  luciferase	  reporter	  
consisting	  of	  11	  tandems	  of	  a	  CSL	  responsive	  domain	  (11	  CSL-­‐luc).	  As	  HDLECs	  express	  Notch1,	  
Notch4,	  Dll4,	  and	  Jag1,	  Notch	  signaling	  should	  occur	  endogenously	  in	  confluent	  monolayers	  of	  
HDLECs.	  To	  maximize	  ligand	  expression	  levels	  and	  to	  isolate	  and	  identify	  differences	  between	  
Dll4	  and	  Jag1-­‐induced	  Notch	  signaling,	  we	  chose	  to	  express	  either	  Dll4	  or	  Jag1	  in	  HeLa	  cells,	  
which	  have	  low	  endogenous	  levels	  of	  Notches	  and	  ligands.	  HeLa	  cells	  were	  lipofected	  with	  
plasmids	  expressing	  Dll4,	  Jag1,	  or	  control	  (ctrl,	  GFP).	  Quantitative	  Real	  Time	  PCR	  (qRT-­‐PCR)	  
confirmed	  that	  HeLa	  cells	  were	  strongly	  expressing	  the	  lipofected	  plasmids	  (Figure	  4B).	  HDLECs	  
were	  lipofected	  with	  11	  CSL-­‐luc	  and	  co-­‐cultured	  in	  a	  1:1	  ratio	  with	  the	  HeLa	  cells,	  as	  shown	  in	  
the	  schematic	  (Figure	  4A).	  Dll4	  presented	  by	  HeLa	  cells	  induced	  Notch	  reporter	  activity	  over	  
baseline	  in	  HDLECs	  (Figure	  4C),	  demonstrating	  the	  ability	  of	  Dll4	  to	  activate	  Notch	  in	  HDLECs.	  
Jag1	  neither	  induced	  nor	  repressed	  Notch	  signaling	  in	  HDLECs	  (Figure	  4C).	  Dll4	  and	  Jag1	  
presented	  together	  achieved	  the	  same	  level	  of	  induction	  as	  Dll4	  alone	  (Figure	  4C).	  These	  
findings,	  in	  conjunction	  with	  the	  results	  of	  our	  expression	  analysis	  in	  dermal	  lymphatics,	  suggest	  






VEGF	  receptor	  activation	  regulates	  Notch	  signaling	  in	  HDLECs	  
In	  the	  blood	  vasculature,	  it	  is	  well	  known	  that	  Notch	  signaling	  is	  induced	  in	  response	  to	  
VEGFR-­‐2	  signaling,	  and	  it	  has	  been	  suggested	  that	  Notch	  signaling	  is	  also	  induced	  in	  response	  to	  
VEGFR-­‐3	  signaling[59,	  60].	  	  To	  date,	  one	  report	  has	  suggested	  that	  HDLECs	  exhibit	  this	  same	  
induction	  response[73].	  We	  confirmed	  this	  through	  qRT-­‐PCR	  analysis	  of	  HDLEC	  cultures	  treated	  
with	  equal	  concentrations	  of	  VEGF	  or	  VEGF-­‐C,	  using	  HUVEC	  cultures	  as	  a	  control.	  Both	  VEGF	  
and	  VEGF-­‐C	  induced	  Dll4,	  as	  well	  as	  Notch	  effector	  HES1	  (Figure	  5A).	  At	  the	  concentrations	  used,	  
Dll4	  was	  more	  strongly	  induced	  by	  VEGF,	  HEY1	  was	  only	  induced	  in	  response	  to	  VEGF,	  and	  HEY2	  
was	  only	  induced	  in	  response	  to	  VEGF-­‐C	  (Figure	  5A).	  We	  observed	  a	  similar	  pattern	  of	  induction	  
in	  HUVEC	  (Figure	  5B).	  Thus,	  we	  demonstrate	  that	  VEGF	  receptor	  signaling	  can	  induce	  Notch	  
signaling	  in	  HDLECs.	  This	  provided	  us	  with	  a	  link	  between	  these	  two	  important	  signaling	  
pathways,	  and	  suggested	  that	  both	  may	  be	  critical	  in	  regulating	  LEC	  behavior.	  	  
	  
Notch	  regulates	  HDLEC	  behavior	  
In	  sprouting	  lymphangiogenesis,	  LECs	  undergo	  several	  cellular	  processes	  in	  order	  to	  
grow	  new	  vessels.	  LECs	  proliferate	  to	  add	  to	  the	  growing	  lymphatic	  sprout,	  migrate	  directionally	  
towards	  VEGF-­‐C	  and	  other	  cues,	  and	  fuse	  with	  neighboring	  LECs	  to	  form	  a	  network.	  We	  decided	  
to	  test	  whether	  Notch	  signaling	  plays	  a	  role	  in	  some	  or	  all	  of	  these	  steps	  by	  subjecting	  HDLECs	  
to	  assays	  designed	  to	  mimic	  these	  cellular	  processes.	  We	  overexpressed	  activated	  forms	  of	  
Notch	  (N1IC	  or	  N4/int3,	  Chapter	  2,	  Figure	  2)	  or	  control	  (ctrl,	  GFP)	  using	  lentivirus-­‐mediated	  
stable	  transduction	  of	  cultured	  HDLECs	  and	  determined	  their	  effects	  on	  proliferation,	  migration,	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and	  network	  formation.	  The	  N1IC	  lentiviral	  plasmid,	  which	  expresses	  the	  intracellular	  domain	  of	  
Notch1,	  and	  the	  N4/int3	  lentiviral	  plasmid,	  which	  expresses	  the	  transmembrane	  and	  
intracellular	  domains	  of	  Notch4,	  are	  both	  constitutively	  active.	  Thus	  they	  will	  be	  referred	  to	  
from	  hereon	  as	  “Notch	  activation”.	  N1IC	  and	  N4/int3	  lentiviral	  plasmids	  effectively	  
overexpressed	  active	  forms	  of	  Notch1	  and	  Notch4,	  respectively	  (data	  not	  shown).	  We	  found	  
that	  Notch	  activation	  suppressed	  HDLEC	  proliferation	  over	  72hrs	  (Figure	  6A).	  Notch	  activation	  
suppressed	  HDLEC	  migration	  over	  a	  24hr	  period	  in	  a	  monolayer	  wounding	  assay	  (Figure	  6B).	  
Notch	  activation	  also	  inhibited	  lymphatic	  capillary-­‐like	  network	  formation	  over	  a	  72hr	  period	  
when	  HDLECs	  were	  seeded	  between	  two	  collagen	  gel	  layers	  (Figure	  6C).	  Dll4/Notch	  signaling	  
has	  been	  shown	  to	  be	  a	  negative	  regulator	  of	  sprouting	  in	  the	  blood	  vasculature,	  at	  least	  partly	  
through	  its	  ability	  to	  regulate	  VEGFR	  expression	  and	  responsiveness	  to	  VEGF	  ligand	  
stimulation[59,	  60].	  Our	  results	  in	  HDLECs	  suggest	  that	  Notch	  is	  also	  a	  negative	  regulator	  of	  
multiple	  steps	  of	  sprouting	  lymphangiogenesis,	  namely	  proliferation,	  migration,	  and	  network	  
formation.	  
	  
Notch	  regulates	  VEGFR-­‐3	  in	  a	  dynamic	  temporal	  manner	  
In	  sprouting	  angiogenesis,	  the	  ability	  of	  Notch	  signaling	  to	  repress	  VEGFR-­‐2	  is	  critical[59,	  
60].	  However,	  the	  data	  on	  the	  role	  of	  Notch	  in	  sprouting	  lymphangiogenesis,	  and	  whether	  this	  
involves	  regulation	  of	  VEGFR-­‐3	  or	  VEGFR-­‐2,	  has	  yet	  to	  reach	  a	  consensus.	  Given	  the	  dramatic	  
effects	  seen	  on	  HDLEC	  proliferation,	  migration,	  and	  network	  formation	  with	  Notch	  
overexpression,	  and	  given	  the	  critical	  role	  VEGFR-­‐3	  plays	  in	  sprouting	  lymphangiogenesis,	  we	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set	  out	  to	  explore	  the	  possibility	  that	  Notch	  suppresses	  sprouting	  lymphangiogenesis	  through	  
regulation	  of	  VEGFR-­‐3	  expression.	  We	  first	  validated	  that	  Notch	  activation	  constructs	  could	  
induce	  downstream	  effectors	  HEY1	  and	  HEY2	  when	  introduced	  into	  HDLECs	  (Figure	  7A).	  We	  
also	  validated	  ectopic	  expression	  of	  HEY1	  and	  HEY2	  overexpression	  constructs	  (Figure	  7A).	  
VEGFR-­‐2	  transcripts	  were	  repressed	  by	  Notch	  activation	  (Figure	  7B)	  and	  by	  overexpression	  of	  
Notch	  effectors	  HEY1	  or	  HEY2	  (Figure	  7C)	  in	  HDLECs.	  Repression	  of	  VEGFR-­‐2	  transcripts	  upon	  
Notch	  activation	  (Figure	  7B)	  agrees	  with	  what	  has	  been	  reported	  in	  the	  blood	  vasculature[59,	  60].	  
In	  contrast	  to	  VEGFR-­‐2	  transcripts,	  VEGFR-­‐3	  transcripts	  were	  induced	  by	  Notch	  activation	  in	  
HDLECs	  (Figure	  7B).	  However,	  overexpression	  of	  Notch	  effectors	  HEY1	  or	  HEY2	  repressed	  
VEGFR-­‐3	  transcripts	  (Figure	  7C).	  That	  Notch	  and	  its	  effectors	  could	  transcriptionally	  induce	  and	  
suppress	  VEGFR-­‐3	  indicated	  that	  VEGFR-­‐3	  is	  regulated	  by	  multiple	  mechanisms.	  It	  also	  indicated	  
that	  tight	  regulation	  of	  VEGFR-­‐3	  plays	  a	  significant	  role	  in	  LECs.	  We	  hypothesized	  that	  Notch	  
both	  induces	  and	  represses	  VEGFR-­‐3	  transcripts,	  and	  that	  this	  may	  be	  important	  in	  the	  process	  
of	  sprouting	  lymphangiogenesis.	  To	  test	  this	  hypothesis,	  we	  performed	  time	  course	  analysis.	  	  
Endogenous	  Notch	  signaling	  was	  suppressed	  overnight	  by	  treating	  confluent	  HDLEC	  
cultures	  with	  a	  γ-­‐secretase	  inhibitor	  (compound	  E).	  The	  next	  day,	  cells	  were	  washed	  to	  remove	  
compound	  E	  and	  endogenous	  Notch	  signaling	  was	  activated	  (time	  0’)	  by	  treatment	  with	  EDTA,	  a	  
chelating	  agent	  that	  dissociates	  the	  Notch	  heterodimer	  and	  releases	  the	  Notch	  intracellular	  
domain	  (NICD)[27].	  RNA	  was	  collected	  at	  multiple	  time	  points	  starting	  at	  time	  0’	  and	  analyzed	  by	  
qRT-­‐PCR.	  This	  experimental	  design	  allows	  for	  analysis	  of	  dynamic	  time-­‐dependent	  responses	  to	  
Notch	  signaling,	  which	  are	  lost	  in	  standard	  transcript	  or	  protein	  analysis.	  In	  this	  assay,	  we	  found	  
VEGFR-­‐3	  transcripts	  to	  be	  an	  early	  responder	  to	  Notch	  activation,	  with	  significant	  induction	  as	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early	  as	  5	  minutes	  and	  peaking	  at	  10	  minutes	  after	  Notch	  activation	  (Figure	  8A)[79].	  This	  
supports	  previous	  observations	  from	  our	  group	  that	  VEGFR-­‐3	  is	  a	  direct	  transcriptional	  target	  of	  
NICD/CSL	  in	  BECs[71].	  A	  second	  wave	  of	  induction	  was	  observed	  between	  25	  and	  30	  minutes,	  
which	  returned	  to	  baseline	  by	  120	  minutes	  (Figure	  8A)[79].	  	  
A	  bi-­‐phasic	  response	  to	  Notch	  activation	  was	  also	  observed	  for	  HEY1	  and	  HEY2	  
transcripts,	  with	  induction	  between	  5	  and	  10	  minutes	  after	  Notch	  activation,	  followed	  by	  return	  
to	  baseline	  levels	  between	  15	  and	  30	  minutes	  after	  Notch	  activation	  (Figure	  8B).	  A	  second,	  
more	  pronounced	  induction	  was	  observed	  at	  60	  and	  120	  minutes	  (Figure	  8B)[79].	  	  
Here	  we	  show	  that	  NICD/CSL	  and	  the	  downstream	  effectors	  HEY1/HEY2	  can	  
transcriptionally	  regulate	  VEGFR-­‐3	  in	  opposing	  manners.	  We	  propose	  a	  temporal	  model,	  in	  
which	  NICD/CSL	  directly	  induces	  VEGFR-­‐3	  as	  well	  as	  HEY1/HEY2	  between	  5	  to	  10	  minutes	  post-­‐
activation.	  Modest	  HEY1/HEY2	  induction	  at	  this	  time	  point	  may	  not	  be	  enough	  to	  overcome	  
direct	  induction	  of	  VEGFR-­‐3	  transcripts	  by	  Notch.	  A	  second	  wave	  of	  VEGFR-­‐3	  induction	  between	  
25	  and	  30	  minutes	  after	  Notch	  activation	  is	  dampened	  by	  VEGFR-­‐3	  downregulation	  by	  
HEY1/HEY2	  beginning	  at	  30	  minutes	  after	  Notch	  activation[71].	  We	  hypothesize	  that	  this	  
dynamic	  profile	  of	  VEGFR-­‐3	  transcripts	  in	  response	  to	  Notch	  activation	  may	  be	  key	  in	  regulating	  






Notch	  deficiency	  induces	  lymphangiogenesis	  in	  embryonic	  murine	  dermis	  
We	  turned	  to	  the	  embryonic	  dorsal	  dermis	  to	  study	  how	  Notch	  deficiency	  in	  lymphatic	  
endothelial	  cells	  affects	  sprouting	  lymphangiogenesis	  in	  vivo.	  We	  utilized	  the	  inducible	  
Prox1CreERT2	  driver	  line,	  which	  allowed	  us	  to	  target	  lymphatic	  endothelial	  cells	  without	  
affecting	  blood	  endothelial	  cells	  [4].	  To	  block	  Notch	  signaling,	  we	  used	  the	  DNMAML	  transgenic	  
line,	  which	  expresses	  a	  dominant	  negative	  form	  of	  MAML1	  that	  binds	  NICD/CSL	  but	  lacks	  the	  
ability	  to	  recruit	  the	  transcriptional	  co-­‐activators	  necessary	  to	  activate	  transcription	  of	  Notch	  
target	  genes[58]	  (Figure	  9).	  Thus,	  DNMAML	  blocks	  signaling	  mediated	  by	  all	  Notch	  proteins	  and	  
Notch	  ligands,	  allowing	  us	  to	  inhibit	  both	  Notch1	  and	  Notch4	  signaling	  in	  LECs.	  Furthermore,	  
DNMAML	  does	  not	  interfere	  with	  the	  role	  of	  CSL	  as	  a	  transcriptional	  repressor	  prior	  to	  Notch	  
activation.	  We	  crossed	  Prox1CreERT2	  driver	  mice	  with	  DNMAMLfl/fl	  mice.	  DNMAMLfl/+	  embryos	  
were	  used	  as	  controls	  (ctrl)	  and	  compared	  to	  Prox1CreERT2;DNMAMLfl/+	  mutant	  embryos.	  To	  
circumvent	  the	  effects	  on	  early	  lymphatic	  specification	  caused	  by	  loss	  of	  Notch	  in	  LECs[79],	  we	  
administered	  tamoxifen	  to	  pregnant	  females	  at	  E12.5,	  just	  as	  lymph	  sacs	  are	  undergoing	  
sprouting	  lymphangiogenesis.	  Dorsal	  skin	  was	  isolated	  at	  E14.5	  for	  analysis.	  	  
Whole-­‐mount	  immunohistochemistry	  at	  E14.5	  focusing	  on	  the	  skin	  in	  the	  dorsal	  thoracic	  
region	  revealed	  that	  Notch	  deficiency	  in	  LECs	  results	  in	  increased	  lymphangiogenesis	  (Figure	  
10B)	  compared	  to	  ctrl	  (Figure	  10A).	  Unlike	  Niessen	  et	  al.,	  we	  did	  not	  observe	  changes	  in	  LYVE1	  
expression	  in	  LECs	  deficient	  for	  Notch	  (data	  not	  shown),	  which	  gave	  us	  confidence	  to	  use	  LYVE1	  
as	  an	  immunohistochemical	  marker	  for	  lymphatic	  vasculature.	  Overall	  lymphatic	  vessel	  density	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(LVD)	  was	  significantly	  increased	  in	  mutant	  mice	  (Figure	  10C).	  Blood	  vessel	  density	  (BVD)	  was	  
unchanged	  (Figure	  10A’,B’,D).	  	  
To	  determine	  what	  contributes	  to	  increased	  lymphatic	  vessel	  area,	  we	  divided	  the	  
dorsal	  dermis	  into	  the	  lymphatic	  front,	  comprising	  the	  area	  occupied	  by	  lymphangiogenic	  
sprouts,	  and	  the	  lymphatic	  plexus,	  comprising	  the	  region	  following	  behind	  the	  lymphatic	  front.	  
At	  the	  lymphatic	  front,	  branch	  points	  (Figure	  11C)	  and	  sprouts	  (Figure	  11D)	  were	  significantly	  
increased	  in	  mutant	  mice.	  Thus,	  loss	  of	  Notch	  signaling	  in	  the	  developing	  lymphatic	  vasculature	  
at	  E12.5	  causes	  hypersprouting	  at	  the	  lymphatic	  front	  (Figure	  11A-­‐B)	  characterized	  by	  increases	  
in	  lymphatic	  vessel	  area,	  branching,	  and	  sprouting.	  	  
At	  the	  lymphatic	  plexus,	  we	  discovered	  a	  distinct	  phenotype	  from	  the	  phenotype	  at	  the	  
lymphatic	  front.	  We	  observed	  an	  increase	  in	  the	  diameter	  of	  the	  lymphatic	  vessels	  in	  mutant	  
mice	  (Figure	  12B)	  compared	  to	  control	  mice	  (Figure	  12A).	  Unlike	  at	  the	  front	  (Figure	  11C),	  
lymphatic	  branch	  points	  in	  the	  plexus	  were	  unchanged	  between	  the	  two	  groups	  (Figure	  12C).	  
Thus,	  loss	  of	  Notch	  signaling	  in	  developing	  lymphatic	  vasculature	  at	  E12.5	  causes	  increased	  
lymphatic	  vessel	  diameter	  at	  the	  lymphatic	  plexus	  (Figure	  12A-­‐B),	  without	  affecting	  sprouting	  or	  
branching.	  	  	  
In	  order	  to	  determine	  molecular	  mechanism	  by	  which	  loss	  of	  Notch	  causes	  lymphatic	  
hypersprouting,	  we	  compared	  lymphatic	  VEGFR-­‐3	  expression	  levels	  in	  mutant	  and	  control	  mice.	  
There	  were	  no	  obvious	  differences	  in	  overall	  lymphatic	  VEGFR-­‐3	  expression	  between	  control	  
(Figure	  13A)	  and	  mutant	  (Figure	  13B)	  mice.	  We	  believe	  that	  these	  results	  are	  not	  incompatible	  
with	  the	  results	  of	  our	  time-­‐course	  analysis	  (Figure	  8),	  as	  standard	  immunohistochemistry	  and	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microscopy	  may	  lack	  the	  sensitivity	  to	  detect	  dynamic	  and	  subtle	  changes	  in	  VEGFR-­‐3	  
expression.	  Although	  we	  have	  not	  yet	  definitively	  confirmed	  that	  Notch	  dynamically	  regulates	  
VEGFR-­‐3	  in	  vivo,	  we	  can	  conclude	  that	  Notch	  signaling	  is	  necessary	  to	  regulate	  developmental	  
sprouting	  lymphangiogenesis	  in	  the	  murine	  dermis.	  
	  
DISCUSSION	  
Here,	  we	  establish	  Notch	  as	  a	  negative	  regulator	  of	  developmental	  sprouting	  
lymphangiogenesis	  in	  a	  lymphatic	  endothelial	  cell-­‐autonomous	  manner.	  Loss	  of	  Notch	  in	  LECs	  
results	  in	  lymphatic	  hypersprouting	  during	  the	  formation	  of	  the	  dermal	  lymphatic	  capillary	  
network.	  	  
Notch1,	  Notch4,	  Dll4,	  and	  Jag1	  have	  been	  detected	  in	  cultured	  HDLECs[73].	  In	  developing	  
lymphatic	  capillaries	  of	  the	  murine	  embryonic	  dermis,	  we	  detected	  Dll4	  expression,	  but	  did	  not	  
detect	  Jag1	  expression.	  High	  Dll4	  expression	  has	  been	  observed	  in	  angiogenic	  tip	  cells[33,	  38,	  39],	  
and	  others	  have	  observed	  high	  Dll4	  expression	  in	  lymphatic	  “tip	  cells”	  in	  culture[73].	  We	  provide	  
the	  first	  description	  of	  Dll4	  enrichment	  in	  lymphangiogenic	  tips	  in	  vivo.	  The	  similarity	  in	  Dll4	  
expression	  patterns	  between	  lymphangiogenic	  sprouts	  and	  angiogenic	  sprouts	  suggests	  that	  
Dll4	  may	  function	  similarly	  in	  sprouting	  lymphangiogenesis	  as	  in	  sprouting	  angiogenesis.	  	  
We	  establish	  that	  Dll4	  can	  functionally	  activate	  Notch	  signaling	  in	  lymphatics,	  a	  property	  
not	  associated	  with	  Jag1.	  Dll4	  activated	  Notch	  signaling	  in	  HDLECs,	  but	  Jag1	  neither	  activated	  
nor	  inhibited	  Notch	  signaling.	  In	  the	  blood	  vasculature,	  Jag1/Notch	  signaling	  is	  important,	  as	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loss	  of	  Jag1	  inhibits	  angiogenesis,	  but	  the	  mechanism	  by	  which	  this	  occurs	  is	  unclear.	  One	  
model	  suggests	  that	  Jag1	  and	  Dll4	  both	  activate	  Notch	  signaling,	  but	  when	  Notch	  is	  post-­‐
translationally	  modified	  by	  the	  Fringe	  family	  of	  glycosyltransferases,	  Jag1	  antagonizes	  
Dll4/Notch	  signaling[34].	  Our	  lab	  proposed	  an	  alternate	  model	  suggesting	  that	  Jag1	  and	  Dll4	  both	  
activate	  Notch	  signaling	  but	  have	  unique	  downstream	  effectors	  and	  thus	  individually	  regulate	  
angiogenesis	  in	  opposing	  manners[83].	  Both	  models	  could	  explain	  the	  hyposprouting	  phenotype	  
upon	  Jag1	  inhibition[34,	  83].	  Furthermore,	  although	  the	  models	  propose	  different	  mechanisms,	  
both	  agree	  that	  Jag1	  can	  induce	  or	  inhibit	  Notch	  signaling.	  Our	  finding	  that	  Jag1	  neither	  
activates	  Notch	  signaling	  alone	  nor	  inhibits	  Dll4/Notch	  signaling,	  in	  conjunction	  with	  our	  finding	  
that	  Jag1	  is	  not	  expressed	  in	  developing	  lymphatic	  capillaries	  in	  vivo,	  strongly	  suggest	  that	  Jag1	  
is	  not	  a	  functional	  ligand	  within	  the	  lymphatic	  capillary	  endothelium	  or	  in	  the	  context	  of	  
sprouting	  lymphangiogenesis.	  Thus,	  we	  identify	  a	  key	  difference	  in	  Notch	  signaling	  in	  lymphatic	  
vasculature,	  which	  does	  not	  seem	  to	  depend	  on	  Jag1.	  	  
HDLEC	  cultures	  treated	  with	  VEGF	  or	  VEGF-­‐C	  both	  induce	  the	  tip	  cell	  marker	  DLL4,	  as	  
well	  as	  Notch	  effectors,	  placing	  VEGF	  receptors	  upstream	  of	  Notch	  signaling	  in	  HDLECs.	  
Although	  we	  show	  that	  Notch	  signaling	  is	  downstream	  of	  VEGF	  and	  VEGF-­‐C,	  several	  questions	  
remain.	  VEGF	  and	  VEGF-­‐C	  possess	  differential	  binding	  affinities	  and	  kinetics	  of	  activation	  for	  
their	  cognate	  receptors[62,	  84],	  thus	  further	  investigation	  is	  necessary	  to	  compare	  the	  efficiency	  
of	  Notch	  activation	  elicited	  by	  VEGF	  and	  VEGF-­‐C.	  Furthermore,	  this	  experiment	  utilized	  fully	  
processed	  VEGF-­‐C	  (21kD),	  which	  strongly	  activates	  VEGFR-­‐3	  but	  can	  also	  more	  weakly	  activate	  
VEGFR-­‐2[62].	  Therefore	  it	  is	  possible	  that	  VEGF-­‐C	  activates	  Notch	  signaling	  by	  activating	  both	  
VEGFR-­‐3	  and	  VEGFR-­‐2[62].	  Finally,	  VEGF	  and	  VEGF-­‐C	  are	  capable	  of	  inducing	  VEGFR-­‐2/VEGFR-­‐3	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heterodimer	  formation[65].	  Whether	  signaling	  downstream	  of	  VEGFR	  heterodimers	  can	  induce	  
Notch	  signaling	  and	  how	  this	  compares	  to	  signaling	  downstream	  of	  VEGFR	  homodimers	  will	  also	  
help	  us	  to	  better	  understand	  this	  feedback	  mechanism.	  	  
Loss	  of	  Notch	  signaling	  in	  the	  lymphatic	  vasculature	  during	  developmental	  sprouting	  
lymphangiogenesis	  of	  the	  dermis	  results	  in	  increased	  overall	  lymphatic	  vessel	  density	  (LVD)	  
with	  no	  change	  in	  blood	  vessel	  density	  (BVD).	  We	  observed	  hypersprouting	  at	  the	  lymphatic	  
front	  characterized	  by	  increased	  lymphatic	  vessel	  area,	  sprouting,	  and	  branching.	  In	  the	  plexus,	  
sprouting	  was	  unaffected,	  as	  there	  was	  no	  change	  in	  the	  number	  of	  branch	  points.	  Rather,	  an	  
increase	  in	  lymphatic	  vessel	  diameter	  was	  appreciated.	  Several	  mechanisms	  are	  proposed	  here	  
that	  could	  explain	  our	  phenotypes.	  They	  are	  discussed	  in	  further	  detail	  below:	  1)	  Lymphatic	  
hypersprouting	  caused	  by	  Notch	  inhibition	  may	  correct	  itself	  over	  time	  in	  the	  plexus	  as	  the	  
vasculature	  in	  this	  region	  stabilizes	  and	  matures;	  2)	  Notch	  inhibition	  may	  increase	  proliferation,	  
migration,	  and	  network	  formation	  of	  LECs,	  resulting	  in	  hyperplasia	  at	  the	  lymphatic	  plexus	  and	  
contributing	  to	  hypersprouting	  at	  the	  lymphatic	  front;	  3)	  Notch	  inhibition	  may	  result	  in	  
increased	  expression	  of	  VEGFR-­‐2	  in	  the	  stalk	  cells	  of	  the	  lymphatic	  plexus,	  leading	  to	  
hyperplasia	  at	  the	  lymphatic	  plexus;	  4)	  Notch	  dynamically	  regulates	  VEGFR-­‐3	  to	  regulate	  
sprouting	  lymphangiogenesis,	  and	  inhibition	  of	  Notch	  may	  lead	  to	  deregulation	  of	  VEGFR-­‐3	  
expression,	  causing	  lymphatic	  hypersprouting.	  
Lymphatic	  hypersprouting	  caused	  by	  Notch	  inhibition	  may	  correct	  itself	  over	  time	  in	  the	  
plexus	  as	  the	  vasculature	  in	  this	  region	  stabilizes	  and	  matures	  (#1).	  Hypersprouting	  may	  be	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corrected	  in	  the	  plexus	  as	  the	  lymphatic	  endothelium	  in	  this	  region	  becomes	  stabilized	  and	  the	  
“tip”	  and	  “stalk”	  cell	  identities	  become	  less	  relevant.	  
Notch	  inhibition	  may	  increase	  proliferation,	  migration,	  and	  network	  formation	  of	  LECs,	  
resulting	  in	  hyperplasia	  at	  the	  lymphatic	  plexus	  and	  contributing	  to	  hypersprouting	  at	  the	  
lymphatic	  front	  (#2).	  Sprouting	  lymphangiogenesis	  is	  a	  concerted	  effort	  that	  requires	  LECs	  to	  
proliferate,	  migrate,	  form	  networks,	  and	  identify	  as	  tip	  or	  stalk	  cells.	  We	  showed	  that	  
exogenous	  Notch	  activation	  in	  HDLECs	  inhibits	  their	  proliferation,	  migration,	  and	  network	  
formation.	  Thus,	  one	  explanation	  for	  our	  phenotype	  is	  that	  loss	  of	  Notch	  signaling	  in	  the	  
lymphatic	  vasculature	  causes	  hypersprouting	  due	  to	  excessive	  LEC	  proliferation.	  Furthermore,	  
excessive	  LEC	  proliferation,	  migration,	  and	  network	  formation	  may	  increase	  lymphatic	  vessel	  
diameter.	  Immunohistochemical	  analysis	  of	  a	  proliferation	  marker	  such	  as	  BrdU	  could	  confirm	  
whether	  loss	  of	  Notch	  causes	  LEC	  hyperproliferation	  in	  the	  lymphatic	  front	  and	  plexus.	  
Notch	  inhibition	  may	  result	  in	  increased	  expression	  of	  VEGFR-­‐2	  in	  the	  stalk	  cells	  of	  the	  
lymphatic	  plexus,	  leading	  to	  hyperplasia	  at	  the	  lymphatic	  plexus	  (#3).	  Our	  transcript	  analysis	  in	  
HDLECs	  showed	  that	  Notch	  activation	  represses	  VEGFR-­‐2	  transcripts	  in	  HDLECs.	  LECs	  in	  the	  
lymphatic	  plexus	  are	  stalk	  cells;	  inferring	  from	  the	  sprouting	  angiogenesis	  model,	  Notch	  may	  
function	  in	  these	  cells	  to	  suppress	  VEGFR-­‐2	  expression.	  It	  is	  plausible	  that	  when	  Notch	  is	  lost	  in	  
the	  lymphatic	  vasculature,	  VEGFR-­‐2	  expression	  may	  increase	  specifically	  in	  plexus	  LECs,	  
resulting	  in	  increased	  lymphatic	  vessel	  diameter.	  VEGFR-­‐2	  has	  been	  demonstrated	  to	  promote	  
lymphatic	  vessel	  thickening	  without	  affecting	  sprouting	  in	  dermal	  lymphatic	  vasculature[85].	  This	  
phenotype	  was	  induced	  by	  VEGFR-­‐2-­‐specific	  activation,	  and	  could	  not	  be	  inhibited	  by	  blocking	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VEGFR-­‐3	  signaling[85].	  Analysis	  of	  changes	  in	  VEGFR-­‐2	  expression	  in	  control	  and	  mutant	  mice	  will	  
be	  critical	  in	  proving	  this	  hypothesis.	  	  
Notch	  dynamically	  regulates	  VEGFR-­‐3	  to	  regulate	  sprouting	  lymphangiogenesis,	  and	  
inhibition	  of	  Notch	  may	  lead	  to	  deregulation	  of	  VEGFR-­‐3	  expression,	  causing	  lymphatic	  
hypersprouting	  (#4).	  Our	  transcript	  analysis	  in	  HDLECs	  showed	  that	  VEGFR-­‐3,	  HEY1,	  and	  HEY2	  
are	  dynamically	  regulated	  by	  Notch	  activation	  in	  a	  biphasic	  manner.	  VEGFR-­‐3	  transcripts	  are	  
immediately	  upregulated	  after	  Notch	  activation,	  likely	  through	  direct	  binding	  of	  NICD/CSL	  to	  
the	  VEGFR-­‐3	  promoter[71].	  Subsequently,	  VEGFR-­‐3	  is	  downregulated,	  likely	  through	  the	  
transcriptional	  repressors	  HEY1	  and	  HEY2[72,	  79],	  both	  of	  which	  are	  induced	  by	  Notch.	  Oscillating	  
expression	  of	  HEYs	  and	  HES	  has	  been	  reported	  in	  other	  developmental	  settings	  in	  
vertebrates[86-­‐89].	  Therefore	  it	  is	  plausible	  that	  the	  oscillatory	  patterns	  of	  HEY1	  and	  HEY2	  we	  
observed	  after	  Notch	  activation	  in	  cultured	  HDLECs	  are	  also	  important	  in	  regulating	  VEGFR-­‐3.	  
Sprouting	  angiogenesis	  is	  a	  highly	  dynamic	  process	  in	  which	  endothelial	  cells	  are	  constantly	  
shifting	  between	  tip	  and	  stalk	  cell	  positions[40].	  	  The	  ability	  of	  BECs	  to	  differentially	  express	  
Notch	  and	  VEGF	  receptors	  was	  shown	  to	  be	  critical	  for	  the	  dynamics	  of	  position	  shifting[40].	  We	  
postulate	  that	  sprouting	  lymphangiogenesis	  is	  also	  a	  dynamic	  process	  that	  requires	  LECs	  to	  shift	  
positions	  and	  compete	  with	  each	  other	  to	  obtain	  the	  tip	  or	  stalk	  cell	  positions.	  We	  suggest	  that	  
differential	  regulation	  of	  VEGFR-­‐3	  may	  be	  critical	  for	  this	  process,	  and	  that	  inhibition	  of	  Notch	  in	  
LECs	  deregulates	  this	  process,	  leading	  to	  lymphatic	  hypersprouting.	  
Whole-­‐mount	  immunohistochemistry	  for	  VEGFR-­‐3	  was	  unable	  to	  capture	  these	  
dynamics	  in	  embryonic	  dermal	  lymphatics.	  However,	  we	  believe	  that	  these	  results	  do	  not	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disqualify	  a	  role	  for	  Notch	  in	  dynamically	  regulating	  VEGFR-­‐3	  to	  control	  sprouting	  
lymphangiogenesis.	  Our	  Immunohistochemical	  methods	  may	  not	  yet	  be	  sensitive	  enough	  to	  
detect	  subtle	  changes	  in	  VEGFR-­‐3	  expression	  levels.	  Live	  imaging	  may	  provide	  further	  clues	  
about	  how	  loss	  of	  Notch	  signaling	  affects	  VEGFR-­‐3	  expression	  in	  vivo	  during	  lymphangiogenesis.	  
Comparing	  and	  contrasting	  phenotypes	  of	  Notch	  inhibition,	  VEGFR-­‐3	  inhibition,	  and	  VEGFR-­‐2	  
inhibition	  may	  also	  provide	  genetic	  evidence	  linking	  the	  pathways	  to	  each	  other	  in	  the	  
embryonic	  dermal	  lymphangiogenesis	  model.	  
Taken	  together,	  we	  have	  demonstrated	  that	  Notch	  signaling	  suppresses	  sprouting	  
lymphangiogenesis,	  and	  we	  have	  identified	  VEGFR-­‐3	  and	  VEGFR-­‐2	  as	  two	  potential	  Notch	  
targets	  responsible	  for	  regulating	  sprouting	  lymphangiogenesis.	  Thus,	  we	  propose	  that	  
sprouting	  lymphangiogenesis	  can	  be	  explained	  by	  the	  same	  tip/stalk	  model	  that	  explains	  
sprouting	  angiogenesis	  (Figure	  14):	  VEGF-­‐C	  and	  VEGF	  activate	  VEGFR-­‐3	  and	  VEGFR-­‐2	  in	  the	  
lymphatic	  tip	  cell;	  VEGFR-­‐3	  and	  VEGFR-­‐2	  signaling	  induce	  Dll4	  expression	  in	  the	  lymphatic	  tip	  
cell;	  Dll4	  expressed	  by	  the	  lymphatic	  tip	  cell	  activates	  Notch	  signaling	  in	  lymphatic	  stalk	  cell;	  
Notch	  dynamically	  regulates	  VEGFR-­‐3	  expression	  and	  suppresses	  VEGFR-­‐2	  expression	  in	  the	  
























Figure 1. HDLECs express Notches and ligands. Cultured HDLEC express Notch1, Notch4, Dll4, and 




Figure 2. The embryonic murine dermis as a model of sprouting lymphangiogenesis. E14.5 dorsal 
murine dermis whole-mount stained for blood vasculature (CD31, green) and lymphatic vasculature 
(LYVE1, red) shows vasculature growing medially towards the midline (marked with dashed white 
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Figure 3. Physiological lymphatic vasculature expresses Dll4. (A-B) Murine embryonic dermises were 
whole-mount stained at E14.5 in the dorsal thoracic region for lymphatic vasculature (LYVE1, red), 
Dll4 or Jag1 (green), and blood vasculature (CD31, blue); scale bars=100μm. (A) Dll4 is detected in 
murine dermal lymphatics (arrowheads), as well as in neighboring blood vessels (arrows). (B) Jag1 is 
not detected in murine dermal lymphatics (arrowheads), but is detected in neighboring blood vessels 
(arrows). (C-D) Boxed areas in A and B; scale bars=100μm. Dll4 (C’) is enriched in lymphatic tip cells 
(C). Jag (D’) is not detected in lymphatic tip cells (D). 
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Figure 4. Dll4 activates Notch in HDLECs. (A) HDLEC lipofected with a luciferase Notch reporter 
containing 11 repeats of CSL-responsive elements (11 CSL-luc) are co-cultured with HeLa lipofected 
with Dll4, Jag1, or both. (B) Quantitative RT-PCR shows Dll4 and Jag1 are induced in lipofected HeLa. 
(C) A luciferase reporter assay shows Dll4 activates Notch signaling in HDLECs (p=0.05), while Jag1 
neither activates nor antagonizes Notch signaling in HDLECs. Dll4+Jag1 together activate Notch 
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Figure 5. Notch signaling is responsive to VEGF receptor activation. (A) Quantitative RT-PCR with 
HDLEC cDNA shows Notch ligand DLL4, as well as Notch effectors HEY1 and HES1, are induced in 
HDLEC cultures treated with VEGF or VEGF-C. Notch effector HEY2 is only induced in HDLEC cultures 
treated with VEGF-C. (B) Quantitative RT-PCR with HUVEC cDNA shows Notch ligand DLL4, as well as 
Notch effector HEY1, are induced in HUVEC cultures treated with VEGF or VEGF-C. Notch effector 
HES1 is only induced in HUVEC cultures treated with VEGF. Error bars represent standard deviation of 

















































Figure 6. Notch regulates HDLEC proliferation, migration, and network formation. (A) Notch activa-
tion (N1IC or N4/int3) inhibits HDLEC proliferation over a 72hr period. (B) Notch activation (N1IC or 
N4/int3) inhibits HDLEC migration in a monolayer scratch assay over a 25hr period; scale bars=5μm. 
(C) Notch activation (N1IC or N4/int3) inhibits HDLEC network formation on a collagen gel over a 72hr 














































Figure 7. Notch induces VEGFR-3, but Notch effectors HEY1 and HEY2 repress VEGFR-3. Quantitative 
RT-PCR with HDLEC cDNA. (A) qPCR validates that Notch activation lentiviral constructs (N1IC and 
N4/int3) and HEY overexpression lentiviral constructs (HEY1 and HEY2) increase HEY1 and HEY2 
levels. (B) Notch activation represses VEGFR-2 but induces VEGFR-3. (C) Notch effectors HEY1 and 





























































Figure 8. Notch dynamically regulates VEGFR-3. Quantitative RT-PCR with HDLEC cDNA. (A) VEGFR-3 
is an early responder to Notch activation, with significant induction seen as early as 5 minutes after 
Notch activation. Levels return to below baseline between 20 and 25 minutes. A second wave of 
induction is seen between 25 and 30minutes, which returns to below baseline by 120 minutes. (B) 
HEY1 and HEY2 show the strongest induction starting at 30 minutes after Notch activation. Error bars 
represent standard deviation of the mean, *p<0.05, **p<0.001. (C) Proposed model of transcriptional 
regulation of VEGF receptors by Notch in lymphatic endothelial cells.
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Figure 9. DNMAML inhibits Notch signaling. DNMAML can bind Notch IC and CSL, but is missing the 
domain necessary to recruit co-activators necessary for transcription of Notch target genes. Adapted 
from McElhinny, A.S., J.L. Li, and L. Wu, Mastermind-like transcriptional co-activators: emerging roles 












Figure 10. Loss of Notch signaling causes lymphatic hypersprouting in the embryonic murine 
dermis. (A-B) Tamoxifen was administered to pregnant dams (10mg/kg) at E12.5 and dermises of 
embryos were whole-mount stained at E14.5 for lymphatic vasculature (LYVE1, red) and blood 
vasculature (CD31, green). Dashed white line marks the midline; scale bars=1000μm. Mutant mice 
(Prox1CreERT2;DNMAMLfl/+) (B), display lymphatic hypersprouting when compared to control litter-
mates (DNMAMLfl/+) (A). Blood vessel density in mutant mice (Prox1CreERT2;DNMAMLfl/+) (B’), is 
unchanged when compared to control littermates (DNMAMLfl/+) (A’). (C) Quantification of overall 
lymphatic vessel area. (D) Quantification of overall blood vessel area.Error bars represent standard 



















































Figure 11. Loss of Notch signaling increases branch points and sprouts at the lymphatic front. (A-B) 
Tamoxifen was administered to pregnant dams (10mg/kg) at E12.5 and dermises of embryos were 
whole-mount stained at E14.5 for lymphatic vasculature (LYVE1, red) and blood vasculature (CD31, 
green); scale bars=100μm. Lymphatic sprouts marked with arrowheads, branch points marked with 
asterisks. Mutant mice (Prox1CreERT2;DNMAMLfl/+) (B), display increased lymphatic sprouts and 
branch points at the front compared to control littermates (DNMAMLfl/+) (A). Blood vasculature is 
unaffected (A’,B’). (C) Quantification of lymphatic branch points. (D) Quantification of lymphatic 





























































































Figure 12. Loss of Notch signaling does not affect branch points but increases vessel diameter at 
the lymphatic plexus. (A-B) Tamoxifen was administered to pregnant dams (10mg/kg) at E12.5 and 
dermises of embryos were whole-mount stained at E14.5 for lymphatic vasculature (LYVE1, red) and 
blood vasculature (CD31, green); scale bars=100μm. Lymphatic branch points marked with asterisks, 
vessel width marked with cyan lines. Mutant mice (Prox1CreERT2;DNMAMLfl/+) (B), display increased 
lymphatic vessel diameter at the plexus compared to control littermates (DNMAMLfl/+) (A). Lymphatic 
branch points (A,B) and blood vasculature (A’,B’) are unaffected. (C) Quantification of lymphatic 

























































































Figure 13. Loss of Notch signaling does not alter VEGFR-3 expression in developing lymphatic 
vasculature. (A-B) Tamoxifen was administered to pregnant dams (10mg/kg) at E12.5 and dermises 
of embryos were whole-mount stained at E14.5 for VEGFR-3 (green), lymphatic vasculature (LYVE1, 
red), and blood vasculature (CD31, green); scale bars=200μm. Overall VEGFR-3 expression is 























Figure 14. Notch and VEGF feedback loop. (A) Proposed model of the feedback loop between Notch 
































Inhibition	  of	  Dll/Notch	  signaling	  causes	  hypersprouting	  of	  











Manipulating	  Notch	  signaling	  in	  cultured	  HDLECs	  and	  in	  the	  mouse	  embryo,	  we	  found	  
that	  Notch	  functions	  to	  suppress	  developmental	  sprouting	  lymphangiogenesis.	  We	  identified	  
Dll4	  as	  a	  lymphatic	  tip	  cell	  marker,	  suggesting	  a	  specialized	  function	  for	  Dll4	  in	  lymphatic	  tip	  
cells	  –	  possibly	  to	  induce	  Notch	  signaling	  in	  lymphatic	  stalk	  cells	  and	  thereby	  suppress	  sprouting	  
of	  stalk	  cells.	  We	  also	  identified	  a	  key	  difference	  between	  lymphatic	  and	  blood	  vasculature	  by	  
finding	  that	  Jag1	  is	  not	  expressed	  by	  developing	  lymphatic	  vessels	  in	  vivo.	  We	  found	  that	  the	  
Notch	  and	  VEGF	  signaling	  pathways	  regulate	  each	  other	  in	  a	  feedback	  loop,	  suggesting	  a	  
potential	  mechanism	  by	  which	  Notch	  suppresses	  developmental	  sprouting	  lymphangiogenesis.	  
Here	  we	  focused	  on	  how	  Notch	  functions	  in	  pathological	  lymphangiogenesis.	  Based	  on	  our	  
studies	  of	  physiological/developmental	  lymphangiogenesis,	  we	  hypothesized	  that	  Notch	  also	  
functions	  to	  suppress	  lymphangiogenesis	  in	  pathological	  conditions,	  and	  that	  loss	  of	  Notch	  
signaling	  would	  result	  in	  hypersprouting,	  or	  increased	  sprouting	  and	  branching,	  of	  pathological	  
lymphatic	  vasculature.	  	  
To	  date,	  only	  one	  report	  has	  described	  the	  effects	  of	  Notch	  inhibition	  in	  pathological	  
lymphangiogenesis.	  Niessen	  et	  al.,	  whose	  work	  is	  also	  described	  in	  Chapter	  3,	  utilized	  a	  Dll4	  
neutralizing	  antibody	  (αDll4)	  to	  inhibit	  Notch	  signaling	  and	  observed	  hyposprouting	  of	  
lymphatics	  in	  a	  wound	  healing	  model[74].	  Dll4	  inhibition	  has	  been	  studied	  extensively	  in	  the	  
blood	  vasculature	  and	  has	  been	  shown	  to	  cause	  hypersprouting	  in	  physiological	  angiogenesis	  in	  
the	  postnatal	  retina[33,	  83],	  as	  well	  as	  in	  pathological	  angiogenesis	  in	  tumors[83,	  90-­‐94],	  thus	  serving	  
as	  an	  internal	  control	  in	  this	  experiment.	  As	  expected,	  the	  authors	  found	  that	  αDll4	  treatment	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increased	  pathological	  angiogenesis	  as	  determined	  by	  staining	  for	  CD31[74],	  whereas	  αDll4	  
treatment	  decreased	  pathological	  lymphangiogenesis	  as	  determined	  by	  staining	  for	  LYVE1[74].	  
Thus	  they	  concluded	  that	  Notch	  inhibition	  suppresses	  pathological	  lymphangiogenesis.	  Niessen	  
et	  al.’s	  results	  suggest	  that	  pathological	  lymphangiogenesis,	  at	  least	  in	  wound	  healing,	  is	  not	  a	  
secondary	  response	  to	  primary	  effects	  on	  pathological	  angiogenesis.	  Secondly,	  these	  results	  
suggest	  that	  Dll4/Notch	  signaling	  has	  unique	  functions	  in	  lymphatic	  and	  blood	  vasculatures.	  
The	  cornea	  is	  a	  commonly	  used	  model	  for	  the	  study	  of	  pathological	  
lymphangiogenesis[21].	  It	  is	  one	  of	  the	  few	  tissues	  in	  the	  body	  that	  is	  devoid	  of	  vasculature[22]	  
(Figure	  1A,B),	  which	  is	  critical	  in	  maintaining	  corneal	  transparency	  and	  visual	  acuity[22].	  The	  
neighboring	  conjunctiva	  and	  the	  limbus,	  which	  marks	  the	  border	  between	  the	  cornea	  and	  
conjunctiva,	  are	  vascularized	  with	  lymphatic	  and	  blood	  vessels[22]	  (Figure	  1A,B).	  In	  pathological	  
settings,	  such	  as	  keratitis	  (i.e.,	  inflammation	  of	  the	  cornea)	  or	  complications	  following	  corneal	  
implant	  surgery,	  lymphatic	  and	  blood	  vessels	  from	  the	  neighboring	  limbus	  invade	  into	  the	  
cornea[21,	  22].	  This	  leads	  to	  compromised	  vision,	  exacerbated	  inflammation	  as	  antigen-­‐
presenting	  cells	  are	  provided	  with	  easy	  access	  between	  the	  cornea	  and	  draining	  lymph	  nodes,	  
and	  graft	  rejection	  in	  the	  case	  of	  corneal	  implants[21,	  22].	  Thus,	  understanding	  how	  
lymphangiogenesis	  occurs	  in	  corneal	  inflammation	  may	  provide	  insights	  about	  pathological	  
lymphangiogenesis	  in	  general.	  It	  can	  also	  provide	  opportunities	  for	  the	  development	  of	  
therapeutics.	  	  
The	  murine	  corneal	  suture	  assay	  mimics	  human	  corneal	  pathologies	  by	  inducing	  
vascularization	  of	  the	  cornea	  (Figure	  1A’,B’).	  Here	  too,	  as	  in	  the	  embryonic	  dermis,	  a	  lymphatic	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front	  can	  be	  observed,	  which	  arrests	  once	  the	  vessels	  reach	  the	  suture.	  Newly	  formed	  
lymphatic	  and	  blood	  vessels	  can	  be	  seen	  in	  the	  cornea	  as	  early	  as	  2	  days	  after	  suture	  placement,	  
and	  at	  times,	  lymphangiogenesis	  into	  the	  cornea	  can	  even	  outpace	  angiogenesis[21].	  
Lymphangiogenesis	  can	  also	  occur	  independently	  of	  angiogenesis	  in	  the	  cornea	  –	  low	  doses	  of	  
FGF-­‐2	  in	  a	  corneal	  pellet	  assay	  were	  shown	  to	  selectively	  induce	  lymphangiogenesis	  without	  
inducing	  angiogenesis[95].	  These	  features	  make	  the	  corneal	  suture	  assay	  a	  useful	  model	  for	  the	  
study	  of	  pathological	  lymphangiogenesis.	  	  
Macrophages	  are	  important	  mediators	  of	  developmental	  lymphangiogenesis[9,	  11,	  12,	  96].	  
They	  also	  play	  a	  crucial	  role	  in	  corneal	  suture-­‐induced	  lymphangiogenesis[22],	  whether	  by	  
transdifferentiating	  into	  lymphatic	  endothelial	  cells[97],	  or	  by	  secreting	  pro-­‐lymphangiogenic	  
molecules	  like	  VEGF-­‐C	  or	  VEGF-­‐D[98].	  Interestingly,	  although	  the	  stroma	  of	  the	  uninjured	  cornea	  
is	  home	  to	  many	  resident	  macrophages[99,	  100],	  lymphatic	  and	  blood	  vessels	  are	  not	  present	  in	  
the	  cornea	  under	  normal	  conditions.	  This	  is	  likely	  due	  to	  the	  secretion	  of	  anti-­‐lymphangiogenic	  
and	  anti-­‐angiogenic	  factors	  by	  the	  corneal	  epithelium[101-­‐103].	  	  
VEGF	  receptors	  1,	  2,	  and	  3	  are	  expressed	  endogenously	  by	  the	  corneal	  epithelium	  and	  
are	  critical	  in	  maintaining	  corneal	  avascularity[101-­‐103].	  Soluble	  VEGFR-­‐1	  (sVEGFR-­‐1)[102]	  and	  full-­‐
length	  VEGFR-­‐3[103]	  are	  expressed	  by	  corneal	  epithelial	  cells	  and	  function	  as	  anti-­‐angiogenic	  
factors	  by	  competing	  with	  blood	  vessels	  to	  bind	  VEGF	  and	  VEGF-­‐C,	  respectively.	  Meanwhile,	  
corneal	  epithelial	  cells	  express	  soluble	  VEGFR-­‐2,	  which	  competitively	  binds	  VEGF	  and	  VEGF-­‐C	  
but	  functions	  solely	  as	  an	  anti-­‐lymphangiogenic	  factor,	  with	  no	  inhibitory	  effects	  on	  
angiogenesis[101].	  Loss	  of	  expression	  of	  any	  of	  these	  three	  receptor	  variants	  causes	  infiltration	  of	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vasculature	  into	  the	  cornea[101-­‐103].	  These	  observations	  highlight	  the	  importance	  of	  VEGF	  
receptors	  in	  controlling	  corneal	  lymphangiogenesis	  and	  angiogenesis,	  and	  given	  that	  Notch	  
signaling	  can	  regulate	  transcription	  of	  VEGFR-­‐3	  and	  VEGFR-­‐2	  in	  HDLECs	  (Chapter	  3),	  we	  
postulated	  that	  this	  may	  be	  a	  mechanism	  by	  which	  Notch	  regulates	  pathological	  
lymphangiogenesis	  and	  angiogenesis	  in	  the	  corneal	  suture	  assay.	  	  
	   	  To	  elucidate	  the	  role	  of	  Notch	  signaling	  in	  pathological	  lymphangiogenesis	  in	  the	  
corneal	  suture	  assay,	  we	  utilized	  pharmacological	  tools	  to	  inhibit	  Notch	  signaling.	  A	  class	  of	  
Notch	  inhibitors	  known	  as	  the	  Notch1	  decoys	  (N1ECDFc,	  Chapter	  2,	  Figure	  3)	  were	  previously	  
designed	  and	  created	  by	  our	  group[83,	  91].	  Notch1	  decoys	  are	  composed	  of	  the	  EGF-­‐like	  repeats	  
of	  the	  human	  Notch1	  receptor	  fused	  to	  human	  Fc	  (hFc)	  and	  can	  bind	  ligands,	  but	  lack	  the	  
transmembrane	  and	  intracellular	  domains	  necessary	  for	  signal	  transduction[83,	  91].	  They	  thereby	  
act	  as	  competitive	  inhibitors	  of	  endogenous	  Notches.	  The	  full-­‐length	  Notch1	  decoy,	  or	  
N1ECDFc1-­‐36,	  comprises	  all	  36	  EGF-­‐like	  repeats	  of	  human	  Notch1	  and	  has	  been	  shown	  to	  
function	  as	  a	  pan-­‐ligand	  inhibitor[83,	  91].	  The	  smaller	  N1ECDFc1-­‐24	  variant	  possesses	  the	  same	  
pan-­‐ligand	  inhibiting	  capabilities	  but	  demonstrates	  improved	  extravasation	  from	  the	  blood	  
vessels	  and	  diffusion	  into	  tissues[83].	  The	  N1ECDFc1-­‐13	  variant	  possesses	  specific	  inhibitory	  
functions	  against	  signaling	  mediated	  by	  ligands	  of	  the	  Dll	  class	  (i.e.,	  Dll1,	  Dll3,	  and	  Dll4)[83].	  The	  
N1ECDFc10-­‐24	  variant	  possesses	  specific	  inhibitory	  functions	  against	  signaling	  mediated	  by	  
ligands	  of	  the	  Jag	  class	  (i.e.,	  Jag1	  and	  Jag2)[83].	  
	   The	  Notch1	  decoys	  have	  been	  tested	  in	  multiple	  settings	  of	  physiological	  and	  
pathological	  angiogenesis[81,	  83,	  91].	  Treatment	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  gives	  a	  classical	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Dll4	  inhibition	  phenotype[33,	  93]	  and	  induces	  angiogenic	  sprouting	  in	  the	  retina[83]	  and	  in	  multiple	  
tumor	  types[83].	  Treatment	  with	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  suppresses	  angiogenic	  sprouting	  in	  
the	  retina[83],	  the	  ovarian	  corpus	  luteum[81],	  and	  in	  multiple	  tumor	  types[83].	  Although	  two	  
hypotheses	  have	  been	  posed	  to	  explain	  the	  angiogenic	  hyposprouting	  phenotype[33,	  83]	  
(discussed	  in	  Chapter	  3),	  the	  mechanism	  by	  which	  Jag	  inhibition	  suppresses	  angiogenesis	  is	  
currently	  unknown.	  Treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  has	  differential	  effects	  on	  
the	  vasculature	  that	  appear	  to	  be	  dependent	  on	  the	  setting.	  In	  the	  retina,	  treatment	  with	  
N1ECDFc1-­‐24	  induces	  angiogenic	  sprouting,	  suggesting	  that	  Dll-­‐mediated	  signaling	  is	  dominant	  in	  
this	  setting	  (Kangsamaksin,	  unpublished	  data).	  In	  multiple	  tumor	  types,	  treatment	  with	  
N1ECDFc1-­‐24	  suppresses	  angiogenic	  sprouting,	  suggesting	  that	  Jag-­‐mediated	  signaling	  is	  
dominant	  in	  these	  models[83].	  	  
The	  lack	  of	  information	  on	  how	  Notch	  signaling	  regulates	  pathological	  
lymphangiogenesis	  called	  for	  further	  investigation.	  In	  choosing	  a	  pathological	  model	  of	  
lymphangiogenesis,	  we	  took	  into	  consideration	  the	  unique	  features	  of	  the	  cornea,	  including	  its	  
avascularity	  under	  normal	  conditions,	  the	  rapid	  growth	  of	  lymphatic	  vasculature	  in	  response	  to	  
suture	  placement,	  and	  the	  importance	  of	  the	  VEGF	  signaling	  pathway	  in	  regulating	  corneal	  
lymphangiogenesis.	  We	  utilized	  pharmacological	  intervention	  with	  Notch1	  decoys	  to	  inhibit	  
Notch	  signaling.	  Our	  findings	  in	  HDLECs	  and	  in	  developmental	  lymphangiogenesis	  led	  us	  to	  
hypothesize	  that	  Dll4	  expressed	  by	  lymphatic	  tip	  cells	  activates	  Notch	  signaling	  in	  lymphatic	  
stalk	  cells	  to	  inhibit	  excessive	  sprouting	  during	  lymphangiogenesis,	  while	  Jag1	  is	  not	  expressed	  
by	  lymphatics	  and	  therefore	  does	  not	  play	  a	  significant	  role	  in	  sprouting	  lymphangiogenesis.	  We	  
hypothesized	  that	  this	  lymphatic	  tip/stalk	  model	  would	  be	  maintained	  in	  pathological	  sprouting	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lymphangiogenesis	  in	  the	  corneal	  suture	  model.	  We	  predicted	  that	  treatment	  with	  N1ECDFc1-­‐24	  
(Dll/Jag	  inhibitor)	  and	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  would	  induce	  lymphatic	  hypersprouting	  in	  the	  




Characterization	  of	  suture-­‐induced	  lymphatic	  vasculature	  
Lymphatic	  vessels	  recruited	  in	  the	  corneal	  suture	  assay	  expressed	  LYVE1	  and	  were	  not	  
covered	  by	  NG2+	  pericytes	  (data	  not	  shown)	  or	  αSMA+	  smooth	  muscle	  cells	  (data	  not	  shown),	  
suggesting	  a	  lymphatic	  capillary	  phenotype.	  However,	  corneal	  lymphatic	  vessels	  contained	  
integrinα9+	  lymphatic	  valves	  (data	  not	  shown),	  suggesting	  a	  lymphatic	  collecting	  duct	  
phenotype.	  The	  high	  levels	  of	  LYVE1	  expression,	  lack	  of	  mural	  cell	  coverage,	  and	  presence	  of	  
valves	  led	  us	  to	  identify	  these	  vessels	  as	  hybrids	  between	  lymphatic	  capillaries	  and	  pre-­‐
collecting	  lymphatic	  vessels.	  	  
We	  first	  sought	  to	  establish	  which	  Notch	  proteins	  and	  Notch	  ligands	  are	  expressed	  by	  
corneal	  suture-­‐induced	  lymphatics.	  We	  performed	  whole-­‐mount	  staining	  sutured	  corneas	  for	  
Dll4	  or	  Jag1,	  LYVE1,	  a	  lymphatic	  endothelial	  marker,	  and	  CD31,	  a	  pan-­‐endothelial	  marker	  that	  is	  
expressed	  strongly	  by	  blood	  vasculature	  and	  weakly	  by	  lymphatic	  vasculature	  (Figure	  2).	  Dll4	  
was	  expressed	  by	  pathological	  lymphatic	  vessels	  (Figure	  2A)	  and	  neighboring	  pathological	  blood	  
vessels	  (Figure	  2A).	  Jag1	  was	  not	  detected	  in	  pathological	  lymphatic	  vessels	  (Figure	  2B),	  though	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it	  was	  expressed	  by	  the	  neighboring	  pathological	  blood	  vessels	  (Figure	  2B).	  Consistent	  with	  
previous	  publications[77-­‐79],	  strong	  Dll4	  expression	  was	  observed	  in	  the	  arterial	  endothelium	  
(Figure	  2A)	  and	  strong	  Jag1	  expression	  was	  observed	  in	  arterial	  endothelium	  and	  vascular	  
smooth	  muscle	  cells	  (Figure	  2B).	  Expression	  of	  Dll4	  in	  corneal	  suture-­‐induced	  lymphatics	  was	  
lower	  than	  Dll4	  expression	  in	  corneal	  suture-­‐induced	  blood	  vessels	  (Figure	  2A).	  	  
Closer	  examination	  of	  pathological	  lymphatic	  vasculature	  revealed	  enriched	  Dll4	  
expression	  (Figure	  2C’)	  in	  the	  lymphatic	  tip	  cells	  at	  the	  lymphangiogenic	  front	  (Figure	  2C).	  
Enriched	  Dll4	  expression	  could	  also	  be	  appreciated	  at	  the	  angiogenic	  front	  (Figure	  2A,	  Figure	  
2C’).	  Closer	  examination	  confirmed	  that	  Jag1	  (Figure	  3D’)	  was	  not	  expressed	  in	  pathological	  
lymphangiogenic	  fronts	  (Figure	  3D).	  In	  summary,	  our	  ligand	  expression	  analysis	  of	  suture-­‐
induced	  lymphatic	  vasculature	  reveals	  the	  same	  expression	  patterns	  as	  those	  we	  observed	  in	  
physiological	  lymphatic	  capillaries	  (Chapter	  3).	  	  
	  
Notch1	  decoys	  are	  detected	  in	  the	  circulation	  after	  adenovirus	  administration	  
	   We	  delivered	  Notch1	  decoys	  to	  adult	  female	  C57BL/6J	  mice	  through	  retro-­‐orbital	  
injection	  of	  adenovirus.	  Once	  delivered	  to	  the	  bloodstream,	  the	  adenovirus	  travels	  to	  the	  liver	  
and	  infects	  the	  hepatocytes,	  which	  are	  particularly	  receptive	  to	  adenoviral	  infection.	  Large	  
amounts	  of	  the	  protein	  encoded	  by	  the	  adenovirus	  are	  subsequently	  produced	  and	  secreted,	  
without	  adverse	  effects	  on	  the	  liver.	  The	  protein	  is	  shed	  into	  the	  circulation	  and	  travels	  
systemically	  throughout	  the	  mouse.	  Previous	  work	  from	  our	  lab	  showed	  efficient	  extravasation	  
of	  Notch1	  decoys	  into	  the	  tissue[83].	  After	  delivery	  of	  5x108	  ffu	  of	  adenovirus/mouse,	  Notch1	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decoy	  variants	  and	  hFc	  (ctrl)	  were	  easily	  detected	  by	  Western	  blot	  in	  as	  little	  as	  0.5μL	  of	  serum,	  
and	  as	  soon	  as	  2	  days	  post-­‐delivery	  (Figure	  3).	  Smaller	  size	  Notch1	  decoy	  variants	  were	  
detected	  at	  higher	  levels	  in	  the	  circulation	  (Figure	  3).	  These	  results	  gave	  us	  confidence	  to	  
continue	  forward	  with	  this	  method	  of	  Notch	  inhibition.	  	  
	  
Inhibition	  of	  Dll/Notch	  signaling	  induces	  lymphangiogenesis	  in	  the	  corneal	  suture	  model	  
We	  tested	  ligand-­‐specific	  Notch1	  decoys	  as	  well	  as	  a	  pan-­‐ligand	  inhibitor	  (N1ECDFc1-­‐24)	  
in	  the	  corneal	  suture	  model	  to	  identify	  differences	  resulting	  from	  Dll	  blockade	  (N1ECDFc1-­‐13)	  or	  
Jag	  blockade	  (N1ECDFc10-­‐24).	  We	  whole-­‐mount	  stained	  sutured	  corneas	  at	  end	  point	  to	  visualize	  
invading	  lymphatic	  vessels	  (LYVE1)	  and	  blood	  vessels	  (CD31).	  We	  observed	  pathological	  
lymphangiogenesis	  (Figure	  4A)	  and	  angiogenesis	  (Figure	  4A’)	  into	  control	  (ctrl,	  hFc)	  sutured	  
corneas.	  Corneas	  of	  mice	  treated	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  revealed	  significantly	  
increased	  area	  vascularized	  by	  lymphatic	  vessels	  (Figure	  4B,E)	  and	  blood	  vessels	  (Figure	  4B’,E)	  
as	  compared	  to	  ctrl.	  Corneas	  of	  mice	  treated	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  also	  revealed	  
significantly	  increased	  area	  vascularized	  by	  lymphatic	  vessels	  (Figure	  4C,F)	  and	  blood	  vessels	  
(Figure	  4C’,F)	  as	  compared	  to	  ctrl.	  The	  area	  vascularized	  by	  lymphatic	  and	  blood	  vessels	  did	  not	  
differ	  between	  N1ECDFc1-­‐13	  and	  N1ECDFc1-­‐24	  corneas.	  Corneas	  of	  mice	  treated	  with	  N1ECDFc10-­‐
24	  (Jag	  inhibitor)	  showed	  no	  change	  in	  area	  vascularized	  by	  lymphatic	  vessels	  (Figure	  4D),	  but	  
significantly	  reduced	  area	  vascularized	  by	  blood	  vessels	  (Figure	  4D’,G)	  as	  compared	  to	  ctrl.	  Our	  
results	  suggested	  that	  Jag1/Notch	  signaling	  does	  not	  play	  a	  significant	  role	  in	  pathological	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lymphangiogenesis	  in	  the	  corneal	  suture	  model,	  while	  Dll4/Notch	  signaling	  functions	  to	  
suppress	  pathological	  lymphangiogenesis	  in	  the	  corneal	  suture	  model.	  	  
	  
F4/80+	  macrophage	  content	  is	  unaffected	  in	  Notch1	  decoy	  treated	  corneas	  
	   Macrophages	  play	  a	  crucial	  role	  in	  inducing	  lymphangiogenesis	  and	  angiogenesis	  in	  the	  
corneal	  suture	  model,	  and	  removal	  of	  macrophages	  or	  inhibition	  of	  their	  function	  in	  the	  corneal	  
suture	  model	  can	  also	  have	  secondary	  effects	  on	  the	  vasculature[22,	  97,	  98,	  104].	  Given	  the	  
promiscuity	  of	  Notch1	  decoys,	  we	  wanted	  to	  determine	  whether	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  
N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  enhance	  corneal	  suture-­‐induced	  lymphangiogenesis	  by	  affecting	  
macrophage	  recruitment	  or	  function.	  We	  whole-­‐mount	  stained	  sutured	  corneas	  at	  end	  point	  to	  
visualize	  macrophages	  (F4/80).	  F4/80	  staining	  revealed	  no	  differences	  in	  macrophage	  density	  
upon	  treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor,	  Figure	  5B,C)	  compared	  to	  ctrl	  (Figure	  5A,C).	  
Neither	  N1ECDFc1-­‐13	  (data	  not	  shown)	  nor	  N1ECDFc10-­‐24	  (data	  not	  shown)	  affected	  macrophage	  
density	  compared	  to	  ctrl.	  We	  concluded	  that	  increased	  sprouting	  lymphangiogenesis	  and	  
angiogenesis	  in	  the	  cornea	  upon	  treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  or	  N1ECDFc1-­‐13	  
(Dll	  inhibitor)	  and	  decreased	  corneal	  angiogenesis	  upon	  treatment	  with	  N1ECDFc10-­‐24	  (Jag	  






N1ECDFc1-­‐24	  causes	  lymphatic	  hypersprouting	  in	  the	  corneal	  suture	  model	  
We	  sought	  to	  identify	  the	  underlying	  changes	  in	  the	  lymphatic	  vasculature	  that	  
contribute	  to	  increased	  area	  vascularized	  by	  lymphatics	  upon	  treatment	  with	  N1ECDFc1-­‐24	  
(Dll/Jag	  inhibitor)	  or	  N1ECDFc1-­‐13	  (Dll	  inhibitor).	  We	  quantified	  lymphatic	  sprouts	  and	  lymphatic	  
branch	  points	  in	  Notch1	  decoy-­‐treated	  corneas	  and	  compared	  them	  to	  lymphatic	  sprouts	  and	  
lymphatic	  branch	  points	  in	  ctrl	  corneas	  (Figures	  6-­‐8).	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  treatment	  
caused	  lymphatic	  hypersprouting	  (Figure	  6B)	  compared	  to	  control	  (Figure	  6A),	  characterized	  by	  
an	  increased	  number	  of	  lymphatic	  sprouts	  (Figure	  6C)	  and	  branch	  points	  (Figure	  6D).	  N1ECDFc1-­‐
13	  (Dll	  inhibitor)	  treatment	  did	  not	  alter	  lymphatic	  sprouting	  (Figure	  7B)	  compared	  to	  ctrl	  (Figure	  
7A),	  and	  the	  number	  of	  lymphatic	  sprouts	  (Figure	  7C)	  and	  branch	  points	  (Figure	  7D)	  were	  
unchanged	  with	  treatment.	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  treatment	  did	  not	  alter	  lymphatic	  
sprouting	  (Figure	  8B)	  compared	  to	  ctrl	  (Figure	  8A),	  and	  he	  number	  of	  lymphatic	  sprouts	  (Figure	  
8C)	  and	  branch	  points	  (Figure	  8D)	  were	  unchanged	  with	  treatment.	  
	  
DISCUSSION	  
Here,	  we	  have	  identified	  a	  role	  for	  Notch	  signaling	  in	  regulating	  pathological	  sprouting	  
lymphangiogenesis	  in	  the	  corneal	  suture	  assay.	  We	  report	  that	  suture	  placement	  in	  the	  murine	  
cornea	  induces	  pathological	  lymphangiogenesis.	  Corneal	  suture-­‐induced	  lymphatics	  express	  the	  
Notch	  ligand	  Dll4	  strongly	  at	  lymphatic	  tips,	  but	  do	  not	  express	  Jag1.	  Corneal	  suture-­‐induced	  
lymphatic	  vessels	  displayed	  the	  same	  expression	  patterns	  of	  Dll4	  as	  developing	  dermal	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lymphatics	  (Chapter	  3),	  which	  suggested	  that	  Dll4/Notch	  signaling	  regulates	  sprouting	  
lymphangiogenesis	  similarly	  in	  both	  lymphatic	  vascular	  beds.	  
Treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  and	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  
comparably	  increased	  corneal	  area	  occupied	  by	  pathological	  lymphatics,	  while	  treatment	  with	  
N1ECDFc10-­‐24	  (Jag	  inhibitor)	  did	  not	  alter	  corneal	  area	  occupied	  by	  pathological	  lymphatics.	  Jag1	  
is	  not	  detected	  in	  corneal	  pathological	  lymphatic	  vasculature.	  Furthermore,	  Niessen	  et	  al.	  
reported	  that	  Jag1	  neutralizing	  antibodies	  had	  no	  effect	  on	  physiological	  sprouting	  
lymphangiogenesis	  in	  tail	  and	  ear	  dermises[74].	  Thus	  we	  feel	  comfortable	  excluding	  Jag1	  as	  a	  
functional	  ligand	  in	  this	  model.	  We	  postulate	  that	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  functions	  
primarily	  in	  the	  corneal	  suture	  assay	  to	  inhibit	  Dll/Notch	  signaling.	  
We	  hypothesized	  that	  increased	  corneal	  area	  occupied	  by	  lymphatics	  upon	  N1ECDFc1-­‐24	  
(Dll/Jag	  inhibitor)	  or	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  treatment	  was	  a	  result	  of	  lymphatic	  
hypersprouting.	  Treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  caused	  lymphatic	  
hypersprouting,	  but	  treatment	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  did	  not.	  Pan-­‐ligand	  inhibitor	  
N1ECDFc1-­‐24	  has	  demonstrated	  increased	  potency	  over	  either	  ligand-­‐specific	  inhibitor	  alone,	  
despite	  being	  present	  in	  the	  circulation	  at	  lower	  levels[83].	  Thus,	  the	  difference	  in	  lymphatic	  
sprouting	  phenotypes	  between	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  and	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  
treatments	  may	  be	  due	  to	  increased	  potency	  of	  N1ECDFc1-­‐24	  compared	  to	  N1ECDFc1-­‐13	  in	  
blocking	  Dll/Notch	  signaling.	  An	  interesting	  possibility	  is	  that	  new	  phenotypes	  may	  emerge	  as	  
Dll4/Notch	  signaling	  is	  increasingly	  inhibited.	  Sprouting	  lymphangiogenesis	  not	  only	  requires	  
tip/stalk	  cell	  identification,	  but	  also	  requires	  LEC	  proliferation,	  migration,	  and	  network	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formation.	  Thus,	  it	  is	  plausible	  that	  weaker	  inhibition	  of	  Dll4/Notch	  signaling	  is	  sufficient	  to	  
enhance	  certain	  LEC	  behaviors	  while	  not	  affecting	  other	  LEC	  behaviors.	  For	  example,	  weaker	  
inhibition	  of	  Dll4/Notch	  signaling	  (N1ECDFc1-­‐13)	  may	  be	  sufficient	  to	  enhance	  migration	  of	  LECs,	  
which	  could	  account	  for	  increased	  lymphatic	  vascular	  coverage.	  As	  Dll4/Notch	  signaling	  is	  more	  
strongly	  inhibited	  (N1ECDFc1-­‐24),	  additional	  phenotypes,	  such	  as	  lymphatic	  hypersprouting,	  may	  
be	  acquired.	  We	  would	  like	  to	  test	  these	  hypotheses	  in	  the	  future	  using	  Notch1	  decoys	  in	  their	  
purified	  protein	  form.	  Using	  purified	  proteins	  will	  allow	  us	  to	  develop	  dose-­‐response	  curves	  for	  
LEC	  behaviors	  such	  as	  proliferation,	  migration,	  network	  formation,	  or	  lymphatic	  tip	  cell	  
formation.	  	  
We	  cannot	  definitively	  conclude	  that	  increased	  pathological	  sprouting	  
lymphangiogenesis	  in	  the	  corneal	  suture	  model	  upon	  treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  
inhibitor)	  is	  a	  LEC-­‐autonomous	  response.	  To	  discern	  LEC-­‐autonomous	  functions	  of	  Notch	  
signaling	  would	  require	  genetic	  inhibition	  of	  Notch	  specifically	  in	  LECs	  (Prox1CreERT2).	  However,	  
the	  fact	  that	  we	  also	  observe	  lymphatic	  hypersprouting	  in	  the	  embryonic	  dermis	  upon	  LEC-­‐
specific	  inhibition	  of	  Notch	  signaling	  (Prox1CreERT2;DNMAMLfl/+,	  Chapter	  3)	  provides	  evidence	  
to	  support	  the	  claim	  that	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  treatment	  induces	  pathological	  
sprouting	  lymphangiogenesis	  by	  targeting	  the	  lymphatic	  vasculature.	  The	  observation	  that	  
corneal	  lymphangiogenesis	  can	  occur	  independently	  of	  angiogenesis[95]	  also	  strengthens	  the	  
argument	  that	  pathological	  sprouting	  lymphangiogenesis	  in	  the	  corneal	  suture	  model	  is	  not	  
solely	  a	  secondary	  response	  to	  pathological	  sprouting	  angiogenesis.	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We	  plan	  to	  analyze	  the	  contribution	  of	  VEGFR-­‐3	  or	  VEGFR-­‐2	  to	  the	  phenotype	  we	  found	  
in	  corneal	  suture-­‐induced	  lymphangiogenesis.	  Based	  on	  our	  observations	  thus	  far,	  we	  would	  
speculate	  that	  Notch	  inhibition	  with	  Notch1	  decoy	  treatment	  induces	  lymphangiogenesis	  
through	  regulation	  of	  VEGFR-­‐3	  and	  VEGFR-­‐2.	  To	  validate	  this,	  future	  experiments	  should	  
include	  careful	  analysis	  of	  VEGFR-­‐3	  and	  VEGFR-­‐2	  expression	  in	  Notch1	  decoy	  treated	  corneal	  
lymphatics.	  Comparing	  and	  contrasting	  the	  effects	  of	  Notch	  inhibition,	  VEGFR-­‐3	  blockade,	  and	  
VEGFR-­‐2	  blockade	  in	  the	  corneal	  suture	  model	  may	  provide	  evidence	  linking	  the	  pathways	  to	  
each	  other.	  As	  corneal	  epithelium	  also	  strongly	  express	  VEGFR-­‐3	  and	  soluble	  VEGFR-­‐2	  (sVEGFR-­‐
2),	  and	  soluble	  VEGFR-­‐1	  (sVEGFR-­‐1),	  it	  would	  be	  interesting	  to	  compare	  and	  contrast	  how	  
Notch	  inhibition	  affects	  lymphatic	  vasculature,	  blood	  vasculature,	  and	  corneal	  epithelium.	  	  
Here	  we	  demonstrate	  that	  Notch	  signaling	  regulates	  pathological	  sprouting	  
lymphangiogenesis	  in	  the	  corneal	  suture	  model.	  Taken	  together,	  our	  data	  suggests	  that	  
Dll4/Notch	  signaling	  functions	  in	  a	  cell-­‐autonomous	  manner	  within	  the	  lymphatic	  endothelium	  


























Figure 1. The corneal suture assay as a model of pathological sprouting lymphangiogenesis. Visual 
acuity requires a transparent and avascular cornea. The conjunctiva is richly vascularized with blood 
(green) and lymphatic (red) vessels. The limbus, or the border of the cornea, also has vasculature. We 
used two methods of suture placement (dark gray). In the first method, placement of a single 
continuous suture covering at least 180° (A), caused lymphatic vessel and blood vessel growth into 
the cornea (A’). In the second method, placement of 3 sutures in the nasal, superior, and inferior 












Figure 2. Suture-induced pathological lymphatic vasculature expresses Dll4. (A-B) Murine adult 
corneas were whole-mount stained after suture placement (S) for lymphatic
vasculature (LYVE1, red), Dll4 or Jag1 (green), and blood vasculature (CD31, blue); scale bars=100μm. 
(A) Dll4 is detected in murine pathological lymphatics (arrowheads), as well as in neighboring blood 
vessels (arrows). (B) Jag1 is not detected in murine pathological lymphatics (arrowheads), but is 
detected in neighboring blood vessels (arrows). (C-D) Boxed areas in A and B; scale bars=100μm. Dll4 
(C’) is enriched in lymphatic tip cells (C). Jag (D’) is not detected in lymphatic tip cells (D).
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Figure 3. N1ECDFc’s are detected in circulation after adenovirus administration. Mice retro-orbitally 
administered adenoviruses (5x108 ffu/mouse) expressing N1ECDFc’s (Notch1 decoys) or hFc (ctrl). 2 
days after adenovirus delivery, blood was collected and 0.5μL serum was resolved by SDS-PAGE, then 
probed with an Fc antibody. (A) Representative Western blot showing relative circulating levels of 
hFc, N1ECDFc1-13 (Dll inhibitor) and N1ECDFc1-24 (Dll and Jag inhibitor). (B) Representative Western blot 











Figure 4. Dll/Notch blockade enhances pathological lymphangiogenesis. (A-D) Murine adult corneas 
were whole-mount stained after suture placement for lymphatic vasculature (LYVE1, red) and blood 
vasculature (CD31, green); scale bars=500μm. Corneas demarcated with white dotted line, lymphatic 
vessels demarcated with cyan dotted line, blood vessels demarcated with magenta dotted line, 
yellow asterisk denotes unsutured leaflet. N1ECDFc
1-24
 (Dll and Jag inhibitor) treated corneas (B,B’) 
and N1ECDFc
1-13
 (Dll inhibitor) treated corneas (C,C’) display increased area vascularized by lymphatic 
vessels and blood vessels compared to hFc (ctrl) corneas (A, A’). N1ECDFc
10-24
 (Jag inhibitor) treated 
corneas (D,D’) display no change in area vascularized by lymphatic vessels but decreased area vascu-
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Figure 5. N1ECDFc1-24 treatment does not affect macrophage density in the cornea. (A-B) Murine 
adult corneas were whole-mount stained after suture placement (S) for lymphatic vasculature (LYVE1, 
red) and macrophages (F4/80, green); scale bars=200μm. There are no dramatic differences in F4/80+ 
macrophage content between ctrl corneas (A) and N1ECDFc
1-24
 (Dll and Jag inhibitor) treated corneas 



























Figure 6. N1ECDFc1-24 treatment results in hypersprouting of pathological lymphatics. (A-B) Murine 
adult corneas were whole-mount stained after suture placement (S) for lymphatic vasculature (LYVE1, 
red); scale bars=200μm. Sprouts marked with arrowheads and branch points marked with asterisks. 
N1ECDFc
1-24
 (Dll and Jag inhibitor) treated corneas (B) display increased lymphatic sprouts and 
lymphatic branchpoints compared to ctrl corneas (A). (C) Quantification of lymphatic sprouts. (D) 


















































































Figure 7. N1ECDFc1-13 treatment does not result in hypersprouting of pathological lymphatics. (A-B) 
Murine adult corneas were whole-mount stained after suture placement (S) for lymphatic vascula-
ture (LYVE1, red); scale bars=200μm. Sprouts marked with arrowheads and branch points marked 
with asterisks. N1ECDFc1-13 (Dll inhibitor) treated corneas (B) display similar numbers of lymphatic 
sprouts and lymphatic branch points compared to ctrl corneas (A). (C) Quantification of lymphatic 









































































Figure 8. N1ECDFc10-24 treatment does not result in hypersprouting of pathological lymphatics. (A-B) 
Murine adult corneas were whole-mount stained after suture placement (S) for lymphatic vascula-
ture (LYVE1, red); scale bars=200μm. Sprouts marked with arrowheads and branch points marked 
with asterisks. N1ECDFc10-24 (Jag inhibitor) treated corneas (B) display similar numbers of lymphatic 
sprouts and lymphatic branch points compared to ctrl corneas (A). (C) Quantification of lymphatic 














































































Inhibition	  of	  Notch	  signaling	  does	  not	  alter	  growth	  or	  metastasis	  of	  an	  











The	  abilities	  of	  malignant	  tumors	  to	  induce	  angiogenesis	  and	  metastasize	  are	  two	  of	  the	  
ten	  hallmarks	  of	  cancer	  that	  were	  first	  described	  by	  Hanahan	  and	  Weinberg[105,	  106].	  The	  concept	  
of	  tumor	  angiogenesis	  was	  first	  suggested	  in	  1971	  by	  Judah	  Folkman,	  who	  postulated	  that	  
tumors	  require	  blood	  vasculature	  to	  grow	  and	  to	  metastasize[107].	  Since	  this	  first	  description	  of	  
tumor	  angiogenesis,	  research	  on	  this	  process	  and	  how	  it	  contributes	  to	  cancer	  progression	  has	  
thrived.	  This	  has	  lead	  to	  the	  identification	  of	  key	  regulators	  of	  tumor	  angiogenesis,	  most	  
importantly	  VEGF[108].	  	  
In	  addition	  to	  recruiting	  blood	  vessels,	  many	  tumors	  induce	  lymphangiogenesis[18,	  109-­‐112].	  
While	  it	  is	  known	  that	  tumor	  blood	  vasculature	  provides	  oxygen,	  nutrients,	  and	  a	  route	  for	  
metastasis	  to	  distant	  organs,	  the	  role	  that	  the	  tumor	  lymphatic	  vasculature	  plays	  in	  cancer	  
progression	  is	  debated[18,	  109-­‐112].	  Tumor	  lymphatics	  provide	  a	  route	  for	  metastasis	  to	  the	  first	  
lymph	  nodes	  that	  drain	  the	  primary	  tumor,	  also	  known	  as	  the	  sentinel	  lymph	  nodes[18,	  109-­‐112].	  
The	  incidence	  and	  clinical	  significance	  of	  sentinel	  lymph	  node	  metastasis	  range	  across	  different	  
tumor	  types[113].	  Thus,	  whether	  sentinel	  lymph	  node	  metastasis	  is	  a	  necessary	  first	  step	  in	  a	  
series	  of	  events	  that	  ultimately	  brings	  metastatic	  tumor	  cells	  to	  distant	  lymph	  nodes	  or	  other	  
organs	  is	  a	  matter	  of	  intense	  debate[18,	  109-­‐112].	  Another	  possibility	  is	  that	  lymphatic	  metastasis	  
to	  sentinel	  lymph	  nodes	  occurs	  concurrently	  with	  hematogenous	  metastasis	  to	  distant	  organs.	  
This	  would	  suggest	  that	  the	  presence	  of	  metastases	  in	  the	  sentinel	  lymph	  nodes	  is	  simply	  a	  
prognostic	  indicator	  of	  a	  more	  aggressive	  and	  metastatic	  tumor[18,	  109-­‐112].	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In	  the	  case	  of	  breast	  cancer,	  up	  to	  80%	  of	  tumors	  are	  estimated	  to	  first	  metastasize	  to	  
sentinel	  lymph	  nodes	  before	  metastasizing	  to	  distant	  organs[113].	  A	  large	  body	  of	  literature	  
correlates	  tumor	  VEGF-­‐C	  expression	  levels	  with	  lymphatic	  vessel	  density	  (LVD)	  and	  lymph	  node	  
metastasis	  in	  human	  breast	  cancer[111,	  114-­‐118].	  Tumor	  VEGF-­‐C	  expression,	  LVD,	  and	  lymph	  node	  
metastasis	  also	  correlate	  with	  poor	  prognosis	  in	  breast	  cancer[111,	  114-­‐118].	  Multiple	  tumor	  models	  
in	  the	  mouse	  have	  demonstrated	  a	  role	  for	  VEGF-­‐C	  in	  promoting	  tumor	  lymphangiogenesis	  and	  
metastasis	  to	  sentinel	  lymph	  nodes	  as	  well	  as	  to	  distant	  organs[18,	  109-­‐112,	  119-­‐123].	  Furthermore,	  
blockade	  of	  VEGFR-­‐3	  signaling	  or	  VEGFR-­‐3	  interaction	  with	  VEGF-­‐C	  effectively	  inhibits	  tumor	  
lymphangiogenesis	  and	  metastasis[124-­‐126].	  	  
Notch	  signaling	  has	  emerged	  as	  a	  target	  for	  anti-­‐angiogenic	  therapy	  in	  cancer[83,	  90-­‐94,	  127].	  
In	  developing	  blood	  vasculature,	  genetic	  or	  pharmacological	  blockade	  of	  Dll4/Notch	  signaling	  
consistently	  induces	  hypersprouting[33,	  34,	  38,	  83].	  Genetic	  and	  pharmacological	  blockade	  of	  
Jag1/Notch	  signaling	  in	  developing	  blood	  vasculature	  has	  been	  shown	  to	  inhibit	  retinal	  
angiogenesis[34,	  83].	  In	  agreement	  with	  the	  function	  of	  Dll4/Notch	  signaling	  in	  restricting	  
angiogenic	  tip	  cell	  formation	  during	  developmental	  sprouting	  angiogenesis,	  Dll4-­‐blockade	  also	  
causes	  hypersprouting	  of	  tumor	  blood	  vasculature[83,	  90-­‐94].	  Although	  Dll4-­‐blockade	  causes	  
tumor	  blood	  vessel	  hyperplasia,	  tumor	  burden	  is	  reduced[83,	  90-­‐94].	  This	  is	  due	  to	  the	  nature	  of	  
tumor	  neo-­‐vessels,	  which	  are	  disorganized,	  not	  perfused,	  and	  thus,	  non-­‐functional[83,	  90-­‐94].	  
Notably,	  Dll4-­‐blockade	  with	  a	  Dll4	  decoy	  (Dll4-­‐Fc)	  was	  able	  to	  reduce	  tumor	  growth	  in	  HT1080-­‐
RM	  tumors,	  a	  line	  that	  is	  resistant	  to	  VEGF	  inhibition[93].	  This	  result	  is	  significant,	  as	  it	  suggests	  
that	  Notch	  might	  be	  an	  attractive	  target	  for	  tumors	  refractory	  to	  other	  conventional	  angiogenic	  
inhibitors.	  Of	  the	  Notch1	  decoys	  developed	  by	  our	  group	  (Chapter	  2,	  Figure	  3),	  N1ECDFc1-­‐13	  (Dll	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inhibitor)	  mimics	  Dll4-­‐blockade	  by	  inducing	  tumor	  blood	  vessel	  hyperplasia	  and	  inhibiting	  
subcutaneous	  growth	  of	  multiple	  mouse	  and	  human	  tumors	  in	  immunocompromised	  mice[83].	  
The	  Jag	  inhibitor	  N1ECDFc10-­‐24	  inhibits	  tumor	  angiogenesis	  and	  tumor	  growth[83].	  N1ECDFc1-­‐36	  
and	  N1ECDFc1-­‐24,	  both	  of	  which	  are	  pan-­‐ligand	  inhibitors,	  inhibit	  tumor	  angiogenesis	  and	  tumor	  
growth.	  This	  suggests	  that	  N1ECDFc1-­‐36	  and	  N1ECDFc1-­‐24	  predominantly	  block	  Jag/Notch	  
signaling	  in	  the	  tumor	  models	  tested.	  	  
Given	  the	  success	  of	  Notch1	  decoys	  in	  targeting	  tumor	  angiogenesis,	  preliminary	  studies	  
were	  performed	  by	  our	  group	  to	  determine	  the	  effects	  of	  Notch1	  decoys	  on	  tumor	  
lymphangiogenesis.	  Immunohistochemical	  analysis	  of	  human	  breast	  carcinoma	  samples	  
revealed	  that	  Notch1	  and	  Notch4	  are	  expressed	  by	  human	  tumor	  lymphatics[71].	  Mice	  deficient	  
for	  Notch4	  (Notch4-­‐/-­‐)	  displayed	  reduced	  Prox1+	  lymphatic	  vessel	  density	  (LVD)	  at	  the	  periphery	  
of	  Colo-­‐38	  melanomas	  orthotopically	  implanted	  adjacent	  to	  the	  cecum	  (Yasuhiro	  Funahashi	  and	  
Carrie	  Shawber,	  unpublished	  data).	  Immunocompromised	  mice	  treated	  with	  N1ECDFc1-­‐36	  
displayed	  reduced	  LYVE1+	  LVD	  in	  orthotopically	  implanted	  SKNEP	  kidney	  tumors	  (Xing	  Wang	  
and	  Carrie	  Shawber,	  unpublished	  data).	  Thus,	  our	  group	  demonstrated	  in	  two	  tumor	  models	  
that	  genetic	  or	  pharmacological	  inhibition	  of	  pan-­‐ligand	  Notch	  signaling	  inhibits	  tumor	  
lymphangiogenesis.	  
Inhibition	  of	  Notch	  signaling	  caused	  lymphatic	  hypersprouting	  in	  the	  embryonic	  dermis	  
(Chapter	  3)	  and	  corneal	  suture	  assay	  (Chapter	  4),	  consistent	  with	  a	  role	  for	  Dll4/Notch	  signaling	  
in	  restricting	  lymphangiogenic	  tip	  cell	  formation.	  These	  two	  lymphatic	  vascular	  beds	  expressed	  
Dll4,	  but	  not	  Jag1.	  The	  observation	  that	  Notch	  inhibition	  suppressed	  sprouting	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lymphangiogenesis	  in	  Colo-­‐38	  and	  SKNEP	  tumors	  was	  intriguing,	  as	  it	  is	  not	  a	  classical	  
Dll4/Notch	  inhibition	  phenotype.	  We	  postulated	  Jag/Notch	  signaling	  may	  possess	  pro-­‐
lymphangiogenic	  functions	  in	  tumors,	  and	  that	  Jag1	  expressed	  by	  tumor	  lymphatic	  endothelial	  
cells	  (LECs)	  or	  tumor	  cells	  could	  activate	  Notch	  in	  tumor	  lymphatic	  endothelial	  cells.	  	  
Several	  observations	  support	  our	  hypothesis	  that	  Notch	  signaling	  functions	  in	  tumor	  
lymphangiogenesis.	  First,	  VEGFR-­‐3/VEGF-­‐C	  signaling	  has	  been	  identified	  as	  a	  critical	  mediator	  of	  
tumor	  lymphangiogenesis	  and	  metastasis[18,	  109-­‐112,	  119-­‐126],	  and	  we	  showed	  that	  Notch	  regulates	  
VEGFR-­‐3	  in	  HDLECs	  (Chapter	  3).	  Second,	  we	  showed	  that	  Notch	  signaling	  functions	  to	  suppress	  
sprouting	  lymphangiogenesis	  in	  the	  embryonic	  murine	  dermis	  (Chapter	  3)	  and	  the	  corneal	  
suture	  assay	  (Chapter	  4).	  Third,	  preliminary	  work	  suggests	  that	  Notch	  signaling	  promotes	  
lymphangiogenesis	  (Yasuhiro	  Funahashi	  and	  Xing	  Wang,	  unpublished	  data).	  Together,	  this	  
suggests	  that	  Notch1	  decoy	  treatment	  would	  affect	  tumor	  lymphangiogenesis	  and	  metastasis,	  
although	  it	  is	  difficult	  to	  predict	  precisely	  what	  the	  outcome	  would	  be.	  One	  could	  hypothesize	  
that	  Dll4/Notch	  signaling	  suppresses	  tumor	  lymphangiogenesis,	  while	  Jag1/Notch	  signaling	  
induces	  tumor	  lymphangiogenesis.	  Based	  on	  this	  hypothesis,	  one	  would	  predict	  that	  treatment	  
with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  would	  cause	  increased	  but	  non-­‐productive	  tumor	  
lymphangiogenesis	  and	  angiogenesis,	  inhibit	  tumor	  growth,	  and	  inhibit	  tumor	  metastasis.	  In	  
contrast,	  treatment	  with	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  or	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  would	  






Lymphatics	  recruited	  by	  tumors	  express	  Notch	  proteins	  and	  ligands	  
MDA-­‐MB-­‐231	  is	  a	  human	  breast	  carcinoma	  cell	  line	  that	  is	  commonly	  used	  for	  tumor	  
modeling	  in	  immunocompromised	  mice.	  MDA-­‐MB-­‐231	  cells	  were	  stably	  transfected	  to	  express	  
luciferase	  and	  be	  antibiotic	  resistant,	  then	  single	  cell	  clones	  were	  generated	  and	  expanded,	  
followed	  by	  several	  rounds	  of	  in	  vitro	  and	  in	  vivo	  selection[56].	  This	  ultimately	  resulted	  in	  the	  
MDA-­‐MB-­‐231-­‐luc-­‐D3H2LN	  subline,	  which	  was	  isolated	  from	  a	  spontaneous	  lymph	  node	  
metastasis	  of	  a	  primary	  tumor	  implanted	  in	  the	  mammary	  fat	  pad	  of	  an	  immunocompromised	  
mouse[56].	  D3H2LN	  cells	  express	  high	  levels	  of	  VEGF-­‐C	  and	  VEGF-­‐D	  (data	  not	  shown),	  and	  
preferentially	  metastasize	  to	  axillary	  lymph	  nodes	  when	  implanted	  into	  immunocompromised	  
mice[56].	  These	  qualities,	  as	  well	  as	  their	  stable	  expression	  of	  luciferase,	  make	  D3H2LN	  cells	  a	  
useful	  model	  for	  studying	  tumor	  lymphangiogenesis	  and	  metastasis	  to	  lymph	  nodes.	  For	  our	  
experiments,	  we	  used	  either	  the	  MDA-­‐MB-­‐231	  parental	  cell	  line	  (231)	  or	  the	  MDA-­‐MB-­‐231-­‐luc-­‐
D3H2LN	  (D3H2LN)	  subline.	  	  
We	  first	  sought	  to	  establish	  which	  Notch	  proteins	  and	  Notch	  ligands	  are	  expressed	  in	  
the	  tumor	  microenvironment	  of	  orthotopically	  grown	  231	  tumors.	  We	  performed	  
immunohistochemistry	  on	  thin	  (7μm)	  sections	  of	  231	  tumors	  that	  had	  been	  orthotopically	  
implanted	  into	  the	  mammary	  fat	  pads	  of	  female	  immunocompromised	  mice.	  Our	  
immunohistochemical	  analysis	  demonstrated	  that	  Notch1	  (Figure	  1A,A”),	  Notch4	  (Figure	  1B,B”),	  
and	  Dll4	  (Figure	  1C,C”)	  are	  expressed	  by	  tumor	  lymphatics	  (Figure	  1A’,B’,C’)	  of	  231	  tumors	  
grown	  orthotopically	  in	  the	  mammary	  fat	  pads	  of	  nude	  mice.	  Interestingly,	  Jag1	  (Figure	  1D,D”)	  
101
	  
was	  expressed	  by	  tumor	  lymphatics	  (Figure	  1D’).	  Neighboring	  tumor	  blood	  vessels	  expressed	  
Notch1	  (Figure	  1A,A”),	  Dll4	  (Figure	  1C,C”),	  and	  Jag1	  (Figure	  1D,D”).	  As	  seen	  in	  both	  
developmental	  vasculature	  (Chapter	  3,	  Figure	  3)	  and	  pathological	  vasculature	  (Chapter	  4,	  Figure	  
2),	  expression	  of	  Notch	  components	  was	  consistently	  higher	  in	  blood	  vessels	  (Figure	  
1A”,B”,C”,D”)	  and	  lower	  in	  lymphatics	  (Figure	  1A’,B’,C’,D’)	  of	  231	  tumors.	  Notch1	  (Figure	  1A”),	  
Notch4	  (Figure	  1B”),	  Dll4	  (Figure	  1C”),	  and	  Jag1	  (Figure	  1D”)	  were	  also	  detected	  at	  varying	  
levels	  of	  expression	  in	  other	  cells,	  which	  we	  postulate	  to	  be	  231	  tumor	  cells.	  In	  summary,	  
lymphatic	  vessels	  of	  the	  embryonic	  dermis,	  the	  sutured	  cornea,	  and	  the	  orthotopically	  grown	  
231	  tumor	  express	  Notch1,	  Notch4,	  and	  Dll4.	  In	  contrast,	  lymphatic	  vessels	  of	  the	  embryonic	  
dermis	  and	  the	  sutured	  cornea	  do	  not	  express	  Jag1,	  whereas	  lymphatic	  vessels	  of	  the	  
orthotopically	  grown	  231	  tumor	  express	  Jag1.	  Non-­‐endothelial	  cell	  types	  in	  231	  orthotopic	  
tumors	  also	  express	  Notch1,	  Notch4,	  Dll4,	  and	  Jag1.	  	  
	  
D3H2LN	  tumors	  express	  Notch	  proteins	  and	  ligands	  
Multiple	  cell	  types,	  including	  tumor	  cells,	  express	  Notch	  signaling	  components,	  and	  
alterations	  in	  Notch	  signaling	  or	  expression	  have	  been	  implicated	  in	  tumorigenesis	  of	  multiple	  
hematological	  and	  solid	  tumors[127,	  128].	  In	  human	  breast	  cancers,	  Notch1	  and	  Jag1	  have	  been	  
implicated	  as	  oncogenic	  factors,	  while	  Notch2	  has	  been	  implicated	  as	  a	  tumor	  suppressor[128].	  
Our	  immunohistochemical	  analysis	  revealed	  expression	  of	  Notch1,	  Notch4,	  Dll4,	  and	  Jag1	  by	  
non-­‐endothelial	  cells	  in	  231	  tumors	  (Figure	  1).	  To	  determine	  whether	  these	  were	  231	  tumor	  
cells,	  and	  to	  perform	  a	  more	  thorough	  analysis	  of	  Notches	  and	  ligands,	  we	  performed	  a	  PCR	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survey,	  using	  cDNA	  isolated	  from	  cultured	  D3H2LN	  and	  231	  cells.	  Semi-­‐quantitative	  PCR	  
showed	  that	  D3H2LN	  cells	  (Figure	  2)	  and	  231	  cells	  (data	  not	  shown)	  contain	  transcripts	  for	  
NOTCH1,	  NOTCH2,	  NOTCH3,	  DLL4,	  JAG1,	  and	  JAG2.	  Low	  levels	  of	  NOTCH4	  transcripts	  were	  
detected	  (Figure	  2).	  D3H2LN	  cells	  (Figure	  2)	  had	  the	  same	  expression	  profile	  as	  parental	  MDA-­‐
MB-­‐231	  cells	  (data	  not	  shown).	  These	  results	  suggested	  that	  231	  tumor	  cells	  could	  be	  partially	  
responsible	  for	  non-­‐endothelial	  expression	  of	  Notch1	  (Figure	  1A),	  Dll4	  (Figure	  1B),	  and	  Jag1	  
(Figure	  1C).	  These	  results	  also	  suggested	  that	  the	  strong	  non-­‐endothelial	  expression	  of	  Notch4	  
(Figure	  1B)	  was	  not	  coming	  from	  231	  tumor	  cells,	  but	  from	  another	  cell	  type.	  
Given	  the	  oncogenic	  or	  tumor-­‐suppressive	  roles	  of	  Notch	  in	  primary	  tumors,	  we	  tested	  
whether	  inhibition	  of	  Notch	  signaling	  affects	  behavior	  of	  231	  cells.	  We	  lentivirally	  transduced	  
231	  cells	  to	  express	  N1ECDFc1-­‐36	  (Chapter	  2,	  Figure	  3),	  which	  comprises	  EGF-­‐like	  repeats	  1-­‐36	  of	  
human	  Notch1	  and	  inhibits	  Notch	  signaling.	  We	  validated	  expression	  of	  N1ECDFc1-­‐36	  in	  231	  cells,	  
and	  found	  that	  it	  did	  not	  alter	  proliferation,	  migration,	  or	  anchorage-­‐independent	  growth	  of	  
231	  cells	  in	  culture	  (data	  not	  shown).	  Given	  the	  identical	  Notch	  expression	  profiles	  of	  231	  cells	  
and	  D3H2LN	  cells	  as	  determined	  by	  PCR	  (Figure	  2),	  we	  hypothesized	  that	  Notch1	  decoy	  
(N1ECDFc)	  treatment	  would	  also	  not	  affect	  D3H2LN	  behavior	  in	  culture	  or	  D3H2LN	  cell	  growth	  
in	  vivo.	  Rather,	  we	  hypothesized	  that	  Notch1	  decoys	  would	  affect	  tumor	  lymphangiogenesis	  






N1ECDFc1-­‐13	  and	  N1ECDFc10-­‐24	  do	  not	  affect	  D3H2LN	  tumor	  progression	  
We	  tested	  ligand-­‐specific	  Notch1	  decoys	  in	  the	  D3H2LN	  tumor	  model	  to	  identify	  
differences	  resulting	  from	  Dll	  blockade	  (N1ECDFc1-­‐13)	  or	  Jag	  blockade	  (N1ECDFc10-­‐24).	  1.5x106	  
D3H2LN	  cells	  were	  orthotopically	  implanted	  into	  the	  4th	  mammary	  fat	  pad	  of	  adult	  female	  
immunocompromised	  mice.	  Tumors	  were	  allowed	  to	  establish	  in	  the	  mammary	  fat	  pad	  for	  8	  
days	  before	  5x108	  ffu	  of	  adenovirus/mouse	  was	  administered	  retro-­‐orbitally.	  Adenoviruses	  
expressing	  N1ECDFc1-­‐13	  (Dll	  inhibitor),	  N1ECDFc10-­‐24	  (Jag	  inhibitor),	  or	  control	  (ctrl,	  hFc)	  were	  
administered	  on	  day	  9	  and	  day	  21	  of	  the	  tumor	  study.	  As	  early	  as	  2	  days	  post-­‐delivery,	  Notch1	  
decoy	  variants	  and	  ctrl	  were	  easily	  detectable	  in	  1μL	  of	  serum	  (Figure	  3A).	  Tumor	  progression	  
was	  followed	  weekly	  using	  caliper	  measurements.	  Tumor	  luminescence	  was	  measured	  after	  
intraperitoneal	  injection	  of	  luciferin	  using	  the	  IVIS	  imaging	  system.	  Luminescence	  imaging	  
allowed	  us	  to	  monitor	  for	  axillary	  lymph	  node	  metastases	  in	  vivo	  throughout	  the	  study.	  
Treatment	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  did	  not	  affect	  tumor	  
size	  as	  determined	  by	  caliper	  measurements	  (Figure	  3B),	  tumor	  viability	  as	  determined	  by	  
luminescence	  measurements	  (Figure	  3C),	  or	  tumor	  weight	  at	  time	  of	  sacrifice	  (Figure	  3D).	  	  
To	  determine	  if	  Notch1	  decoys	  affect	  metastatic	  potential	  of	  D3H2LN	  tumors	  despite	  
not	  affecting	  primary	  tumor	  growth,	  we	  monitored	  mice	  for	  axillary	  lymph	  node	  metastases	  in	  
vivo	  throughout	  the	  study.	  We	  also	  screened	  for	  metastases	  in	  axillary	  lymph	  nodes	  and	  lungs	  
at	  time	  of	  sacrifice.	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  and	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  had	  no	  effect	  on	  
incidence	  of	  metastasis	  to	  axillary	  lymph	  nodes	  or	  lungs	  (Figure	  4A).	  Ex	  vivo	  luminescence	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measurements	  of	  excised	  axillary	  lymph	  nodes	  at	  time	  of	  sacrifice	  uncovered	  no	  significant	  
differences	  in	  average	  metastatic	  burden	  (Figure	  4B).	  	  
	  
N1ECDFc1-­‐13	  and	  N1ECDFc10-­‐24	  do	  not	  affect	  D3H2LN	  tumor	  or	  axillary	  lymph	  node	  
microenvironments	  
Although	  D3H2LN	  tumor	  progression	  and	  metastasis	  were	  not	  altered	  under	  the	  given	  
conditions,	  we	  reasoned	  that	  other	  components	  of	  the	  tumor	  microenvironment,	  such	  as	  the	  
vasculature,	  might	  be	  affected	  by	  Notch	  inhibition.	  Thus,	  we	  investigated	  whether	  Notch1	  
decoy	  treatment	  could	  induce	  changes	  in	  the	  tumor	  microenvironment.	  
To	  analyze	  the	  tumor	  lymphatic	  vasculature,	  we	  performed	  immunohistochemistry	  on	  
7μm	  thin	  tumor	  sections	  for	  LYVE1.	  Lymphatic	  vessels	  recruited	  by	  D3H2LN	  tumors	  were	  
sporadic	  and	  mostly	  situated	  at	  the	  tumor	  periphery	  across	  all	  treatments	  (Figure	  5A).	  No	  major	  
changes	  in	  lymphatic	  vessel	  morphology	  or	  distribution	  were	  observed	  upon	  treatment	  with	  
N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  (Figure	  5A).	  Furthermore,	  
quantification	  of	  lymphatic	  vessel	  density	  (LVD)	  did	  not	  uncover	  any	  differences	  upon	  
treatment	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  (Figure	  5B).	  	  
Lymph	  nodes	  are	  known	  to	  prime	  themselves	  to	  provide	  a	  favorable	  metastatic	  niche	  by	  
inducing	  lymphangiogenesis,	  sometimes	  even	  prior	  to	  tumor	  arrival[119,	  129].	  To	  test	  whether	  
Notch1	  decoy	  treatment	  could	  induce	  changes	  in	  lymph	  node	  LVD,	  we	  performed	  
immunohistochemistry	  on	  7μm	  thin	  sections	  of	  axillary	  lymph	  nodes	  for	  LYVE1.	  Dense	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lymphatic	  vasculature	  was	  found	  in	  axillary	  lymph	  nodes	  of	  mice	  from	  all	  treatments	  (Figure	  6A).	  
Neither	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  treatment	  nor	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  treatment	  had	  any	  
effect	  on	  lymphatic	  vessel	  density	  or	  distribution	  in	  axillary	  lymph	  nodes	  (Figure	  6A,B).	  	  
To	  analyze	  the	  tumor	  blood	  vasculature,	  we	  performed	  immunohistochemistry	  on	  7μm	  
thin	  tumor	  sections	  for	  CD31.	  D3H2LN	  tumors	  were	  densely	  populated	  with	  blood	  vessels	  
throughout	  the	  tumor	  across	  all	  treatments	  (Figure	  7A).	  We	  observed	  no	  major	  changes	  in	  
blood	  vessel	  morphology	  or	  distribution	  in	  D3H2LN	  tumors	  upon	  treatment	  with	  N1ECDFc1-­‐13	  
(Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  (Figure	  7A).	  Furthermore,	  quantification	  of	  blood	  
vessel	  density	  (BVD)	  did	  not	  uncover	  any	  differences	  upon	  treatment	  with	  N1ECDFc1-­‐13	  (Dll	  
inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  (Figure	  7B).	  	  
Tumor-­‐associated	  macrophages	  polarized	  to	  the	  M2	  phenotype	  can	  play	  a	  pro-­‐tumor	  
role	  by	  facilitating	  tumor	  angiogenesis,	  lymphangiogenesis,	  growth,	  and	  metastasis[15].	  To	  
analyze	  macrophage	  content	  in	  D3H2LN	  tumors,	  we	  performed	  immunohistochemistry	  on	  7μm	  
thin	  tumor	  sections	  for	  F4/80.	  D3H2LN	  tumors	  recruited	  a	  large	  number	  of	  F4/80+	  macrophages	  
(Figure	  8A).	  We	  observed	  no	  major	  changes	  in	  macrophage	  distribution	  in	  D3H2LN	  tumors	  upon	  
treatment	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  (Figure	  8A).	  
Quantification	  of	  macrophage	  density	  did	  not	  uncover	  any	  differences	  upon	  treatment	  with	  
N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  (Figure	  8B).	  	  
In	  summary,	  treatment	  of	  D3H2LN	  tumors	  with	  adenoviruses	  expressing	  ligand-­‐specific	  
Notch1	  decoys	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  did	  not	  affect	  tumor	  
growth,	  metastasis,	  lymphangiogenesis,	  angiogenesis,	  or	  macrophage	  recruitment.	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N1ECDFc1-­‐24	  does	  not	  affect	  D3H2LN	  tumor	  progression	  
	   In	  both	  developmental	  and	  pathological	  settings,	  pan-­‐ligand	  inhibitor	  N1ECDFc1-­‐24	  has	  at	  
times	  demonstrated	  increased	  potency	  over	  either	  ligand-­‐specific	  inhibitor	  alone,	  despite	  being	  
present	  in	  the	  circulation	  at	  lower	  levels[83].	  Therefore,	  we	  tested	  whether	  N1ECDFc1-­‐24	  (Dll/Jag	  
inhibitor)	  treatment	  affects	  D3H2LN	  tumor	  progression	  although	  treatment	  with	  N1ECDFc1-­‐13	  
(Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  did	  not.	  In	  addition,	  we	  modified	  several	  
experimental	  parameters,	  implanting	  fewer	  cells	  and	  starting	  treatment	  concurrently	  with	  
tumor	  implantation.	  Implantation	  of	  1.5x106	  cells	  in	  the	  previous	  experiment	  resulted	  in	  tumors	  
reaching	  a	  size	  of	  700mm3	  in	  4	  weeks.	  This	  was	  a	  much	  faster	  growth	  rate	  than	  what	  was	  
previously	  reported,	  in	  which	  2x106	  cells	  were	  implanted	  and	  reached	  a	  size	  of	  700mm3	  in	  5	  
weeks[56].	  Thus,	  we	  reduced	  the	  number	  of	  cells	  implanted	  to	  5x105	  cells.	  In	  the	  previous	  
experiment,	  we	  allowed	  for	  tumors	  to	  establish	  in	  the	  mammary	  fat	  pad	  before	  starting	  
treatment.	  Here	  we	  treated	  tumors	  concurrently	  with	  tumor	  implantation,	  and	  again	  on	  day	  21.	  	  
	   We	  tested	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  in	  the	  D3H2LN	  tumor	  model	  to	  determine	  if	  it	  
could	  elicit	  changes	  in	  tumor	  progression.	  5x105	  D3H2LN	  cells	  were	  orthotopically	  implanted	  
into	  the	  4th	  mammary	  fat	  pad	  of	  adult	  female	  immunocompromised	  mice.	  Adenoviruses	  
expressing	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  or	  hFc	  (ctrl)	  were	  administered	  retro-­‐orbitally	  at	  
5x108ffu	  of	  adenovirus/mouse	  on	  day	  0	  and	  day	  21	  of	  the	  tumor	  study.	  3	  days	  post-­‐delivery,	  
N1ECDFc1-­‐24	  and	  hFc	  were	  easily	  detectable	  in	  1μL	  of	  serum	  (Figure	  9A).	  Tumor	  progression	  was	  
followed	  weekly	  using	  caliper	  measurements.	  Tumor	  luminescence	  was	  measured	  after	  
intraperitoneal	  injection	  of	  luciferin	  using	  the	  IVIS	  imaging	  system.	  Luminescence	  imaging	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allowed	  us	  to	  monitor	  for	  axillary	  lymph	  node	  metastases	  in	  vivo	  throughout	  the	  study.	  
Treatment	  with	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  did	  not	  affect	  tumor	  size	  as	  determined	  by	  
caliper	  measurements	  (Figure	  9B),	  tumor	  viability	  as	  determined	  by	  luminescence	  
measurements	  (Figure	  9C),	  or	  tumor	  weight	  at	  time	  of	  sacrifice	  (Figure	  9D).	  
To	  determine	  if	  N1ECDFc1-­‐24	  affects	  metastatic	  potential	  of	  D3H2LN	  tumors	  despite	  not	  
affecting	  primary	  tumor	  growth,	  we	  monitored	  mice	  for	  axillary	  lymph	  node	  metastases	  in	  vivo	  
throughout	  the	  study.	  We	  also	  screened	  for	  metastases	  in	  axillary	  lymph	  nodes	  and	  lungs	  at	  
time	  of	  sacrifice.	  N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  had	  no	  effect	  on	  incidence	  of	  metastasis	  to	  
axillary	  lymph	  nodes	  or	  lungs	  (Figure	  10A).	  Ex	  vivo	  luminescence	  measurements	  of	  excised	  
axillary	  lymph	  nodes	  at	  the	  time	  of	  sacrifice	  uncovered	  no	  significant	  differences	  in	  average	  
metastatic	  burden	  (Figure	  10B).	  	  
Our	  results	  show	  that	  inhibition	  of	  Dll/Notch	  signaling	  (N1ECDFc1-­‐13),	  inhibition	  of	  
Jag/Notch	  signaling	  (N1ECDFc10-­‐24),	  or	  pan-­‐ligand	  inhibition	  (N1ECDFc1-­‐24)	  does	  not	  affect	  
D3H2LN	  primary	  tumor	  progression	  in	  this	  setting.	  Subsequent	  analysis	  will	  determine	  whether	  
N1ECDFc1-­‐24	  (Dll/Jag	  inhibitor)	  treatment	  can	  induce	  changes	  in	  the	  tumor	  microenvironment.	  
However,	  results	  upon	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  treatment	  and	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  
treatment,	  as	  well	  as	  the	  lack	  of	  change	  in	  tumor	  growth	  and	  metastasis	  with	  N1ECDFc1-­‐24	  
(Dll/Jag	  inhibitor)	  treatment,	  suggest	  that	  N1ECDFc1-­‐24	  will	  not	  induce	  changes	  in	  tumor	  
lymphangiogenesis,	  tumor	  angiogenesis,	  or	  axillary	  lymph	  node	  lymphangiogenesis	  in	  the	  





We	  report	  that	  D3H2LN	  human	  mammary	  carcinoma	  cells	  orthotopically	  implanted	  into	  
the	  4th	  mammary	  fat	  pad	  of	  immunocompromised	  mice	  recruit	  lymphatic	  vessels	  and	  
metastasize	  preferentially	  to	  the	  axillary	  lymph	  nodes.	  The	  MDA-­‐MB-­‐231	  tumor	  
microenvironment	  expressed	  high	  levels	  of	  Notch	  components.	  Given	  that	  multiple	  cell	  types	  
express	  Notch	  family	  proteins	  in	  the	  D3H2LN	  tumor	  microenvironment,	  Notch	  signaling	  could	  
theoretically	  occur	  between	  tumor	  cells,	  between	  tumor	  lymphatic	  endothelial	  cells	  (LECs),	  and	  
heterotypically	  between	  tumor	  cells	  and	  tumor	  LECs.	  MDA-­‐MB-­‐231	  tumor	  lymphatics	  
expressed	  Notch	  components.	  We	  have	  identified	  a	  difference	  in	  231	  tumor	  lymphatics	  
compared	  to	  developmental	  dermal	  lymphatics	  (Chapter	  3)	  and	  pathological	  corneal	  suture	  
lymphatics	  (Chapter	  4)	  in	  our	  observation	  that	  231	  tumor	  lymphatics	  express	  Jag1.	  This	  
suggests	  that	  Jag1	  may	  play	  a	  specialized	  role	  in	  231	  tumor	  lymphatics,	  if	  not	  all	  tumor	  
lymphatics.	  We	  suggest	  several	  possibilities	  that	  may	  explain	  why	  Jag1	  is	  expressed	  in	  231	  
tumor	  lymphatics:	  1)	  Notch	  expression	  by	  231	  tumor	  cells	  may	  induce	  Jag1	  expression	  in	  tumor	  
lymphatics;	  2)	  231	  tumors	  may	  secrete	  factors	  that	  induce	  Jag1	  expression	  in	  lymphatics;	  3)	  231	  
tumor	  lymphatics	  may	  be	  mis-­‐specified	  and	  thus	  possess	  characteristics	  of	  blood	  vessels,	  
including	  Jag1	  expression.	  
Previous	  work	  from	  our	  group	  found	  that	  inhibition	  of	  Notch	  signaling	  suppressed	  tumor	  
lymphangiogenesis	  in	  the	  Colo-­‐38	  model	  (Yasuhiro	  Funahashi	  and	  Carrie	  Shawber,	  unpublished	  
data)	  and	  SKNEP	  model	  (Xing	  Wang	  and	  Carrie	  Shawber,	  unpublished	  data).	  We	  speculate	  that	  
reduced	  tumor	  lymphangiogenesis	  is	  a	  result	  of	  reduced	  Jag1/Notch	  signaling.	  Jag1/Notch	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signaling	  may	  occur	  between	  tumor	  cells	  and	  tumor	  LECs,	  or	  among	  tumor	  LECs,	  to	  induce	  
tumor	  lymphangiogenesis.	  It	  will	  be	  necessary	  to	  determine	  whether	  tumor	  lymphatics	  and/or	  
tumor	  cells	  in	  the	  Colo-­‐38	  and	  SKNEP	  models	  express	  Jag1	  to	  support	  this	  hypothesis.	  More	  
broadly,	  determining	  the	  Notch	  and	  ligand	  expression	  profiles	  of	  various	  tumors	  may	  help	  us	  
identify	  the	  contributions	  from	  the	  tumor	  cell	  component,	  tumor	  LEC	  component,	  and	  other	  
cell	  components	  that	  activate	  Notch	  signaling	  within	  the	  tumor	  microenvironments.	  This	  
information	  may	  be	  useful	  in	  predicting	  if	  a	  tumor	  will	  respond	  to	  Notch	  inhibition,	  and	  how	  it	  
will	  respond.	  	  
	   Adenovirus-­‐mediated	  Notch1	  decoy	  treatment	  had	  no	  effect	  on	  primary	  D3H2LN	  
tumors	  or	  their	  microenvironments.	  We	  conclude	  that	  Notch1	  decoys	  as	  used	  in	  these	  studies	  
do	  not	  affect	  growth,	  metastasis,	  or	  microenvironment	  of	  D3H2LN	  tumors.	  But	  given	  the	  strong	  
evidence	  from	  our	  work	  (Chapters	  3	  and	  4)	  and	  others[83,	  90-­‐94,	  127]	  (Yasuhiro	  Funahashi,	  Xing	  
Wang,	  and	  Carrie	  Shawber,	  unpublished	  data)	  implicating	  Notch	  signaling	  in	  regulating	  
lymphatic	  and	  blood	  vasculature,	  we	  believe	  the	  results	  in	  the	  D3H2LN	  model	  are	  an	  exception.	  
Several	  possibilities	  are	  listed	  here	  that	  may	  explain	  why	  adenovirus-­‐mediated	  Notch1	  decoy	  
treatment	  did	  not	  affect	  D3H2LN	  tumor	  progression,	  and	  are	  described	  in	  further	  detail	  below:	  
1)	  The	  mammary	  fat	  pad	  microenvironment	  may	  provide	  advantages	  to	  tumors	  that	  allow	  them	  
to	  overcome	  Notch	  inhibition;	  2)	  Orthotopic	  implantation	  in	  general	  may	  provide	  advantages	  
over	  subcutaneous	  implantation	  that	  allows	  tumors	  to	  overcome	  Notch	  inhibition;	  3)	  
Adenoviral	  delivery	  of	  Notch1	  decoys	  may	  not	  achieve	  the	  necessary	  serum	  levels	  to	  affect	  
tumor	  lymphangiogenesis;	  4)	  Notch1	  decoy	  treatment	  may	  need	  to	  be	  used	  as	  combination	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therapy	  with	  another	  lymphangiogenic	  inhibitor;	  5)	  D3H2LN	  tumors	  may	  be	  refractory	  to	  Notch	  
inhibition.	  
The	  mammary	  fat	  pad	  microenvironment	  may	  provide	  advantages	  to	  tumors	  that	  allow	  
them	  to	  overcome	  Notch	  inhibition	  (#1),	  Orthotopic	  implantation	  in	  general	  may	  provide	  
advantages	  over	  subcutaneous	  implantation	  that	  allows	  tumors	  to	  overcome	  Notch	  inhibition	  
(#2).	  The	  tumor	  microenvironment	  undeniably	  plays	  a	  role	  in	  tumor	  progression	  by	  providing	  
important	  cues	  to	  tumors.	  Interaction	  between	  tumor	  cells	  and	  other	  accessory	  cells	  (e.g.,	  
endothelial	  cells,	  immune	  cells,	  and	  fibroblasts,	  to	  name	  a	  few)	  provides	  structural	  support	  and	  
can	  modulate	  tumor	  behavior.	  Cytokines	  and	  growth	  factors	  secreted	  by	  tumor	  cells	  or	  
accessory	  cells	  contribute	  to	  tumor	  progression,	  and	  the	  extracellular	  matrix	  also	  contains	  pro	  
and	  anti-­‐tumor	  factors	  that	  can	  regulate	  tumor	  progression.	  The	  majority	  of	  the	  tumor	  
experiments	  described	  above	  using	  Notch	  inhibitors	  were	  xenografted	  subcutaneously,	  with	  
the	  exception	  of	  the	  Colo-­‐38	  and	  SKNEP	  tumor	  models,	  which	  were	  orthotopically	  implanted.	  In	  
our	  studies,	  however,	  D3H2LN	  tumors	  were	  orthotopically	  implanted	  into	  the	  mammary	  fat	  pad.	  
One	  can	  speculate	  that	  the	  microenvironment	  in	  the	  subcutaneous	  region	  differs	  in	  multiple	  
ways	  from	  the	  mammary	  fat	  pad,	  and	  from	  other	  microenvironments	  in	  the	  mouse.	  
Experiments	  comparing	  D3H2LN	  implantation	  in	  the	  subcutaneous	  layer	  to	  implantation	  in	  the	  
mammary	  fat	  pad	  could	  elucidate	  key	  differences	  between	  the	  two	  microenvironments	  that	  




Adenoviral	  delivery	  of	  Notch1	  decoys	  may	  not	  achieve	  the	  necessary	  serum	  levels	  to	  
affect	  tumor	  lymphangiogenesis	  (#3),	  D3H2LN	  tumors	  may	  be	  refractory	  to	  Notch	  inhibition	  (#5).	  
The	  Notch1	  decoys	  could	  be	  ineffective	  in	  the	  D3H2LN	  tumor	  model	  for	  reasons	  specific	  to	  how	  
they	  behave	  in	  this	  model.	  One	  possibility	  is	  the	  bioavailability	  of	  the	  Notch1	  decoys	  upon	  
adenovirus	  injection.	  While	  we	  are	  able	  to	  readily	  detect	  circulating	  Notch1	  decoys	  after	  
adenovirus	  injection	  using	  Western	  blot,	  we	  have	  yet	  to	  quantify	  these	  levels.	  Studies	  to	  
understand	  the	  pharmacokinetics	  of	  Notch1	  decoys	  in	  the	  mouse	  system	  (e.g.,	  absorption,	  
distribution,	  metabolism,	  excretion)	  have	  not	  yet	  been	  performed.	  Median	  effective	  doses	  
(ED50),	  half	  maximal	  inhibitory	  concentrations	  (IC50),	  dose	  limiting	  toxicities,	  and	  other	  
characteristics	  have	  not	  yet	  been	  determined.	  To	  that	  end,	  we	  believe	  that	  the	  future	  of	  Notch1	  
decoys	  lies	  in	  utilizing	  them	  as	  purified	  proteins	  and	  identifying	  these	  characteristics	  to	  optimize	  
dosing	  conditions.	  It	  is	  also	  possible	  that	  D3H2LN	  tumors	  are	  refractory	  to	  Notch	  inhibition	  
treatment.	  Alternative	  methods	  of	  Notch	  inhibition,	  genetic	  or	  pharmacological,	  may	  help	  us	  
identify	  whether	  D3H2LN	  growth	  in	  the	  mammary	  fat	  pad	  is	  unresponsive	  to	  Notch	  inhibition	  in	  
general,	  or	  specifically	  unresponsive	  to	  Notch1	  decoy	  treatment.	  Determining	  the	  benefits	  and	  

























Figure 1. Tumor lymphatic vasculature expresses Notch1, Notch4, Dll4, and Jag1. (A-D) MDA-MB-
231 tumors orthotopically implanted into the mammary fat pads of immunocompromised mice were 
stained for lymphatic vasculature (LYVE1, green) and Notch components (red), nuclei are stained with 
DAPI (blue); scale bars=20μm. Lymphatic vessels (A’,B’,C’,D’) recruited by MDA-MB-231 tumors 
express Notch1 (A”), Notch4 (B”), Dll4 (C”), and Jag1 (D”). (A-D) Higher expression of Notch compo-
nents is observed in blood vessels (arrows) than in lymphatics (arrowheads), and expression of Notch 

























Figure 2. D3H2LN tumor cells express Notches and ligands. Semi-quantitative PCR (35 cycles) was 
performed using 1μL cDNA from cultured D3H2LN cells, which are a subline of the MDA-MB-231 
parental human breast carcinoma tumor cell line. D3H2LN tumor cells express Notch1, Notch2, 
Notch3, Dll4, Jag1, and Jag2. 
Notch1 Notch2 Notch3 Notch4 Dll1 Dll3 Dll4 Jag1 Jag2
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Figure 3. Neither N1ECDFc1-13 nor N1ECDFc10-24 affect D3H2LN tumor growth, viability, or weight. 
Mice were implanted with 1.5x106 D3H2LN tumor cells and retro-orbitally administered adenovirus 
(5x108 ffu/mouse). (A) Western blot showing relative circulating levels of hFc (ctrl), N1ECDFc1-13 (Dll 
inhibitor) and N1ECDFc10-24 (Jag inhibitor) in 1μL serum, 2 days after adenovirus delivery. (B) 
N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibitor) treatments do not affect tumor volume. 
Adenovirus was administered at days 8 and 21 (red squares). (C) N1ECDFc1-13 (Dll inhibitor) and 
N1ECDFc10-24 (Jag inhibitor) treatments do not affect tumor luminescence. Adenovirus was adminis-
tered at days 8 and 21 (red squares). (D) N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibitor) 


































































Figure 4. Neither N1ECDFc1-13 nor N1ECDFc10-24 affect D3H2LN tumor metastasis. Mice were 
implanted with 1.5x106 D3H2LN tumor cells and retro-orbitally administered adenovirus (5x108 
ffu/mouse). (A) N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibitor) treatments do not affect 
tumor rate of metastasis to axillary lymph nodes (LN) and lungs. (B) N1ECDFc1-13 (Dll inhibitor) and 
N1ECDFc10-24 (Jag inhibitor) treatments do not affect metastatic burden in axillary lymph nodes. Error 
bars represent standard deviation of the mean, n=8.
BA
Group Axillary LN 
Mets
Lung Mets
ctrl 5 of 8 0 of 8
1-13 (Dll) 4 of 8 1 of 8
10-24 (Jag) 5 of 8 0 of 8


















Figure 5. Neither N1ECDFc1-13 nor N1ECDFc10-24 affect D3H2LN tumor lymphatic vessel density. Mice 
were implanted with 1.5x106 D3H2LN tumor cells and retro-orbitally administered adenovirus (5x108 
ffu/mouse). (A) Tumors were stained for lymphatic vasculature (LYVE1, red), nuclei are stained with 
DAPI (blue); scale bars=200μm. (B) N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibitor) treat-
ments do not affect tumor lymphatic vessel density (LVD). Error bars represent standard deviation of 
the mean, n=8.
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ctrl 1-13 (Dll) 10-24 (Jag)
B
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Figure 6. Neither N1ECDFc1-13 nor N1ECDFc10-24 affect axillary lymph node lymphatic vessel density. 
Mice were implanted with 1.5x106 D3H2LN tumor cells and retro-orbitally administered adenovirus 
(5x108 ffu/mouse). (A) Axillary lymph nodes were stained for lymphatic vasculature (LYVE1, red), 
nuclei are stained with DAPI (blue). (B) N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibitor) 
treatments do not affect lymphatic vessel density (LVD) in axillary lymph nodes. Error bars represent 
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Figure 7. Neither N1ECDFc1-13 nor N1ECDFc10-24 affect D3H2LN tumor blood vessel density. Mice were 
implanted with 1.5x106 D3H2LN tumor cells and retro-orbitally administered adenovirus (5x108 
ffu/mouse). (A) Tumors were stained for blood vasculature (CD31, brown), nuclei are counterstained 
with hematoxylin (blue); scale bars=50μm. (B) N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibi-
tor) treatments do not affect tumor blood vessel density (BVD). Error bars represent standard devia-
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Figure 8. Neither N1ECDFc1-13 nor N1ECDFc10-24 affect D3H2LN tumor macrophage density. Mice were 
implanted with 1.5x106 D3H2LN tumor cells and retro-orbitally administered adenovirus (5x108 
ffu/mouse). (A) Tumors were stained for macrophages (F4/80), nuclei are stained with DAPI (blue); 
scale bars=20μm. (B) N1ECDFc1-13 (Dll inhibitor) and N1ECDFc10-24 (Jag inhibitor) treatments do not 
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Figure 9. N1ECDFc1-24 does not affect D3H2LN tumor growth, viability, or weight. Mice were 
implanted with 5x105 D3H2LN tumor cells and retro-orbitally administered adenovirus (5x108 
ffu/mouse). (A) Western blot showing relative circulating levels of hFc (ctrl) and N1ECDFc1-24 (Dll and 
Jag inhibitor) in 1μL serum, 3 days after adenovirus delivery. (B) N1ECDFc1-24 (Dll and Jag inhibitor) 
treatment does not affect tumor volume. Adenovirus was administered at days 0 and 19 (red 
squares). (C) N1ECDFc1-24 (Dll and Jag inhibitor) treatment does not affect tumor luminescence. 
Adenovirus was administered at days 0 and 19 (red squares). (D) N1ECDFc1-24 (Dll and Jag inhibitor) 







































Figure 10. N1ECDFc1-24 does not affect D3H2LN tumor metastasis. Mice were implanted with 5x10
5 
D3H2LN tumor cells and retro-orbitally administered adenovirus (5x108 ffu/mouse). (A) N1ECDFc1-24 
(Dll and Jag inhibitor) treatment does not affect tumor rate of metastasis to axillary lymph nodes (LN) 
and lungs. (B) N1ECDFc1-24 (Dll and Jag inhibitor) treatment does not affect metastatic burden in 
axillary lymph nodes.Error bars represent standard deviation of the mean, n=5-6.
BA
Group Axillary LN Mets Lung Mets
ctrl 3 of 6 1 of 6
1-24 (Dll/Jag) 3 of 5 1 of 5























Notch	  signaling	  suppresses	  lymphatic	  specification	  and	  separation	  but	  
induces	  lymphatic	  valve	  formation	  by	  regulating	  lymphatic	  










The	  field	  of	  lymphatic	  vascular	  biology	  has	  benefited	  greatly	  from	  the	  identification	  of	  
genes	  that	  are	  specific	  to	  or	  highly	  expressed	  by	  lymphatic	  endothelium.	  The	  proteins	  encoded	  
by	  these	  genes	  regulate	  different	  stages	  of	  lymphatic	  development,	  including	  lymphatic	  
specification	  and	  separation	  of	  blood	  and	  lymphatic	  vasculature,	  sprouting	  lymphangiogenesis,	  
and	  collecting	  duct	  valve	  formation[10,	  11,	  41].	  In	  addition	  to	  understanding	  the	  molecular	  
functions	  and	  expression	  patterns	  of	  these	  lymphatic	  regulatory	  genes,	  it	  is	  important	  to	  
understand	  how	  they	  are	  transcriptionally	  regulated.	  Several	  of	  the	  key	  players	  are	  discussed	  in	  
this	  chapter,	  and	  a	  more	  comprehensive	  list	  of	  the	  genes	  required	  for	  lymphatic	  vascular	  
development	  and	  function	  is	  provided	  in	  Chapter	  1,	  Table	  1.	  	  
Prox1	  is	  the	  master	  regulator	  of	  lymphatic	  endothelial	  cell	  (LEC)	  fate[7,	  72,	  130-­‐132].	  Mice	  
nullizygous	  for	  Prox1	  die	  between	  E14.5-­‐15	  with	  no	  lymphatic	  specification	  from	  the	  cardinal	  
vein[7].	  Ectopic	  Prox1	  expression	  in	  the	  blood	  endothelium	  is	  sufficient	  to	  induce	  a	  lymphatic	  
endothelial	  phenotype,	  while	  deletion	  of	  Prox1	  reverts	  lymphatic	  endothelium	  to	  a	  blood	  
endothelial	  phenotype[130-­‐132].	  Another	  important	  player	  in	  the	  separation	  of	  the	  lymphatic	  
vasculature	  from	  the	  blood	  vasculature	  is	  podoplanin	  (Pdpn),	  a	  transmembrane	  glycoprotein[44].	  
LEC’s	  express	  podoplanin	  to	  induce	  platelet	  aggregation,	  which	  is	  necessary	  for	  proper	  
separation	  of	  the	  lymph	  sacs	  from	  the	  cardinal	  vein[44].	  Loss	  of	  podoplanin	  results	  in	  defective	  
separation	  of	  lymphatic	  and	  blood	  vasculature	  and	  thus,	  blood-­‐filled	  lymphatics[44].	  Once	  the	  
lymph	  sacs	  have	  separated	  off	  of	  the	  cardinal	  vein,	  they	  go	  on	  to	  form	  the	  lymphatic	  plexus	  
through	  developmental	  sprouting	  lymphangiogenesis	  (covered	  in	  Chapter	  3).	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After	  lymphatic	  specification/separation	  and	  sprouting	  lymphangiogenesis	  occurs,	  the	  
primary	  lymphatic	  plexus	  is	  further	  remodeled	  to	  develop	  the	  complete	  lymphatic	  vascular	  
system	  of	  small	  capillaries,	  intermediate	  pre-­‐collecting	  ducts,	  and	  large	  collecting	  vessels.	  One	  
of	  the	  defining	  features	  that	  distinguish	  lymphatic	  collecting	  vessels	  from	  lymphatic	  capillaries	  
is	  the	  presence	  of	  intraluminal	  valves,	  which	  serve	  to	  move	  lymph	  in	  a	  unidirectional	  manner[9-­‐
12].	  In	  mice,	  lymphatic	  valve	  formation	  initiates	  at	  E15.5	  with	  the	  clustering	  of	  LECs	  expressing	  
high	  levels	  of	  Prox1	  and	  FoxC2	  at	  future	  valve	  sites,	  followed	  by	  local	  deposition	  of	  the	  
extracellular	  matrix	  (ECM)	  proteins	  Lamininα5	  and	  Fibronectin-­‐EIIIA	  (FN-­‐EIIIA)[49].	  The	  pre-­‐
mRNA	  of	  Fibronectin	  (FN)	  has	  three	  potential	  sites	  for	  alternative	  splicing	  (EIIIA,	  EIIIB,	  and	  IIICS)	  
that	  produce	  several	  splice	  variants[133].	  FN-­‐EIIIA,	  which	  contains	  the	  EIIIA	  domain,	  is	  a	  ligand	  of	  
the	  matrix	  adhesion	  protein	  Integrinα9,	  which	  is	  highly	  expressed	  by	  lymphatic	  valve	  
endothelial	  cells	  as	  they	  reorient	  themselves	  within	  the	  collecting	  duct	  and	  migrate	  into	  the	  
lumen	  to	  form	  the	  lymphatic	  valves[133].	  A	  properly	  formed	  lymphatic	  valve	  has	  two	  leaflets,	  
each	  of	  which	  consists	  of	  two	  layers	  of	  Integrinα9+	  LECs	  tightly	  associated	  with	  an	  ECM	  core	  
containing	  Lamininα5	  and	  FN-­‐EIIIA[49].	  Gap	  junction	  protein	  Connexin37	  (Cx37),	  which	  is	  first	  
detected	  in	  the	  jugular	  lymph	  sacs	  at	  E13.5,	  gradually	  becomes	  upregulated	  in	  lymphatic	  
collecting	  ducts	  and	  can	  be	  detected	  in	  lymphatic	  collecting	  duct	  valves	  at	  E18.5[47].	  Mice	  
lacking	  any	  of	  the	  aforementioned	  genes	  display	  defective	  lymphatic	  valve	  formation[47,	  49].	  	  
Prox1	  and	  Pdpn	  are	  restricted	  to	  the	  LEC	  progenitor	  cell	  population	  during	  lymphatic	  
specification	  and	  separation.	  Meanwhile,	  Prox1,	  FoxC2,	  Lamininα5,	  FN-­‐EIIIA,	  Integrinα9,	  and	  
Cx37	  are	  restricted	  to	  or	  highly	  expressed	  by	  the	  valve	  LEC	  population	  during	  lymphatic	  valve	  
formation.	  The	  specific	  induction	  of	  these	  genes	  in	  discrete	  cell	  populations	  suggests	  that	  both	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lymphatic	  specification	  and	  separation,	  as	  well	  as	  lymphatic	  valve	  formation,	  require	  cell	  fate	  
decisions.	  During	  lymphatic	  specification	  and	  separation,	  LECs	  need	  to	  be	  defined	  from	  the	  
blood	  endothelium,	  and	  during	  lymphatic	  valve	  formation,	  valve	  lymphatic	  endothelial	  cells	  
need	  to	  be	  defined	  from	  the	  lymphatic	  collecting	  duct	  endothelium.	  Notch	  is	  required	  for	  cell-­‐
fate	  decisions	  in	  multiple	  settings,	  including	  in	  the	  blood	  vasculature[24-­‐26].	  Notch	  also	  plays	  an	  
important	  role	  in	  heart	  valve	  development[134,	  135].	  Furthermore,	  our	  work	  suggests	  a	  role	  for	  
Notch	  signaling	  in	  defining	  tip	  and	  stalk	  cell	  fates	  during	  sprouting	  lymphangiogenesis	  (Chapters	  
3	  and	  4).	  Given	  the	  importance	  of	  cell-­‐fate	  determination	  in	  the	  development	  of	  the	  lymphatic	  
vasculature,	  and	  given	  the	  importance	  of	  Notch	  in	  cell-­‐fate	  decisions,	  we	  hypothesized	  that	  
Notch	  regulates	  lymphatic	  specification/separation	  from	  the	  blood	  vasculature	  and	  lymphatic	  
valve	  formation.	  We	  postulated	  Notch	  regulates	  these	  processes	  by	  transcriptional	  regulation	  
of	  lymphatic	  genes	  important	  for	  these	  processes.	  
	  
RESULTS	  
Notch	  regulates	  genes	  critical	  for	  development	  of	  the	  lymphatic	  vasculature	  
Lymphatic	  specification	  from	  the	  venous	  vasculature	  initiates	  with	  polarized	  expression	  
of	  the	  transcription	  factor	  Prox1	  between	  E9.5-­‐10.	  Expression	  analysis	  in	  the	  developing	  
embryo	  from	  our	  group	  detected	  Notch1	  in	  the	  cardinal	  vein	  at	  E9.75,	  also	  with	  polarized	  
expression	  but	  in	  a	  pattern	  opposing	  that	  of	  Prox1[79].	  The	  polarized	  and	  opposing	  expression	  
patterns	  of	  Notch1	  and	  Prox1	  suggested	  that	  Notch1	  and	  Prox1	  might	  possess	  opposing	  
functions	  in	  lymphatic	  specification.	  We	  hypothesized	  that	  Notch1	  suppresses	  Prox1	  in	  a	  subset	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of	  ECs	  in	  the	  cardinal	  vein	  so	  that	  a	  different	  subset	  of	  ECs	  lacking	  Notch	  can	  commit	  to	  the	  LEC	  
fate.	  To	  test	  this	  hypothesis,	  we	  overexpressed	  activated	  forms	  of	  Notch	  (N1IC	  or	  N4/int3,	  
Chapter	  2,	  Figure	  2),	  HEY	  overexpression	  constructs,	  or	  the	  Notch1	  decoy	  inhibitor	  (N1ECDFc1-­‐36,	  
Chapter	  2,	  Figure	  3),	  using	  lentivirus-­‐mediated	  stable	  transduction	  of	  cultured	  HDLECs.	  The	  
N1IC	  lentiviral	  plasmid,	  which	  expresses	  the	  intracellular	  domain	  of	  Notch1,	  and	  the	  N4/int3	  
lentiviral	  plasmid,	  which	  expresses	  the	  transmembrane	  and	  intracellular	  domains	  of	  Notch4,	  
are	  both	  constitutively	  active.	  Thus	  they	  will	  be	  referred	  to	  from	  hereon	  as	  “Notch	  activation”.	  
The	  N1ECDFc1-­‐36	  lentiviral	  plasmid,	  which	  expresses	  all	  36	  EGF-­‐like	  repeats	  in	  the	  extracellular	  
domain	  of	  human	  Notch1	  fused	  to	  human	  Fc,	  will	  be	  referred	  to	  from	  hereon	  as	  “Notch	  
inhibition”.	  
We	  first	  confirmed	  that	  our	  Notch	  activation	  plasmids	  and	  HEY	  overexpression	  
constructs	  resulted	  in	  increased	  expression	  of	  HEY1	  and	  HEY2	  (Figure	  1A).	  We	  also	  validated	  
that	  our	  Notch1	  decoy	  inhibition	  plasmid	  represses	  these	  effectors	  in	  cultured	  HDLECs	  (Figure	  
1B).	  Next,	  we	  used	  qRT-­‐PCR	  to	  determine	  if	  Notch	  has	  transcriptional	  control	  over	  genes	  that	  
are	  important	  in	  lymphatic	  specification.	  Indeed,	  activation	  of	  Notch1	  or	  Notch4	  strongly	  
repressed	  PROX1	  transcripts	  in	  HDLECs	  (Figure	  1C)[79].	  Overexpression	  of	  HEY1	  or	  HEY2	  was	  also	  
able	  to	  repress	  PROX1	  transcripts,	  but	  not	  as	  dramatically	  as	  Notch1	  or	  Notch4	  (Figure	  1C)[79].	  
This	  suggested	  that	  while	  downstream	  effectors	  HEY1	  and	  HEY2	  mediate	  PROX1	  repression	  
upon	  Notch	  activation,	  there	  might	  be	  other	  effectors	  involved	  in	  repressing	  PROX1	  after	  Notch	  
activation.	  We	  then	  asked	  if	  Notch	  inhibition	  results	  in	  an	  increase	  in	  PROX1	  transcripts.	  qRT-­‐
PCR	  analysis	  determined	  that	  Notch	  inhibition	  in	  cultured	  HDLECs	  does	  not	  alter	  PROX1	  
transcript	  levels	  (data	  not	  shown).	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Once	  the	  lymph	  sacs	  have	  migrated	  out	  from	  the	  cardinal	  vein	  during	  lymphatic	  
specification,	  podoplanin	  is	  required	  to	  keep	  the	  blood	  and	  lymphatic	  vessels	  separate[44].	  We	  
showed	  that	  Notch	  can	  suppress	  Prox1	  transcripts,	  and	  we	  hypothesized	  that	  Notch	  may	  also	  
suppress	  podoplanin	  during	  separation	  of	  the	  lymphatic	  vasculature	  from	  the	  cardinal	  vein.	  To	  
test	  this	  hypothesis,	  we	  activated	  or	  inhibited	  Notch	  using	  the	  aforementioned	  lentiviral	  
plasmids	  (Chapter	  2,	  Figure	  2)	  in	  cultured	  HDLECs.	  Indeed,	  Notch	  activation	  strongly	  repressed	  
PDPN	  (podoplanin)	  transcripts	  in	  HDLECs	  (Figure	  6C)[79].	  Overexpression	  of	  HEY1	  or	  HEY2	  did	  
not	  repress	  PDPN	  transcripts	  (Figure	  6C)[79].	  	  This	  suggests	  that	  PDPN	  repression	  upon	  Notch	  
activation	  involves	  alternate	  effectors	  instead	  of	  or	  in	  addition	  to	  HEY1	  and	  HEY2.	  One	  
candidate	  is	  Prox1,	  which	  has	  been	  shown	  to	  induce	  expression	  of	  podoplanin	  in	  blood	  
endothelial	  cells	  (BECs)[136].	  It	  is	  plausible	  that	  repression	  of	  PDPN	  transcripts	  upon	  Notch	  
activation	  is	  secondary	  to	  repression	  of	  PROX1	  transcripts.	  As	  such,	  HEY1	  and	  HEY2	  
overexpression	  may	  be	  unable	  to	  repress	  PDPN	  transcripts	  because	  they	  do	  not	  repress	  PROX1	  
as	  effectively	  as	  does	  Notch	  activation.	  We	  then	  asked	  if	  Notch	  inhibition	  results	  in	  increased	  
expression	  of	  podoplanin.	  qRT-­‐PCR	  analysis	  determined	  that	  Notch	  inhibition	  in	  HDLECs	  does	  
not	  alter	  PDPN	  transcript	  levels	  (data	  not	  shown).	  	  
	  
Notch	  regulates	  genes	  critical	  for	  maturation	  of	  the	  lymphatic	  vasculature	  
A	  fully	  developed	  lymphatic	  valve	  has	  two	  leaflets,	  each	  consisting	  of	  a	  Lamininα5/FN-­‐
EIIIA	  ECM	  core	  surrounded	  by	  LECs	  expressing	  Prox1,	  Integrinα9,	  Connexin37,	  and	  FoxC2,	  and	  
mice	  lacking	  the	  genes	  for	  any	  of	  these	  markers	  exhibit	  defects	  in	  lymphatic	  valve	  formation[47,	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49].	  Work	  from	  our	  group	  found	  that	  Notch1	  is	  highly	  expressed	  in	  lymphatic	  valves	  at	  E17.5	  
(Murtomaki	  et	  al.,	  submitted).	  Furthermore,	  a	  transgenic	  Notch	  reporter	  mouse	  revealed	  that	  
Notch	  signaling	  was	  concentrated	  in	  lymphatic	  valve	  ECs	  at	  the	  same	  time	  point	  (Murtomaki	  et	  
al.,	  submitted).	  	  
Given	  the	  role	  we	  determined	  for	  Notch	  in	  regulating	  PROX1	  and	  PDPN,	  as	  well	  as	  our	  
observations	  in	  lymphatic	  collecting	  ducts	  during	  valve	  formation,	  we	  hypothesized	  that	  Notch	  
functions	  to	  regulate	  genes	  critical	  for	  lymphatic	  valve	  formation.	  To	  test	  this	  hypothesis,	  we	  
activated	  or	  inhibited	  Notch	  using	  the	  aforementioned	  lentiviral	  plasmids	  (Chapter	  2,	  Figure	  2)	  
in	  cultured	  HDLECs	  and	  determined	  expression	  of	  Fibronectin	  (FN),	  FN-­‐EIIIA,	  Connexin37,	  and	  
Integrinα9.	  	  
Notch1	  activation	  induced	  expression	  of	  valve	  ECM	  protein	  FN-­‐EIIIA	  (Figure	  2A).	  Notch4	  
activation,	  though	  to	  a	  lesser	  degree,	  also	  induced	  expression	  of	  FN-­‐EIIIA	  (Figure	  2A).	  We	  also	  
observed	  increased	  expression	  of	  total	  FN	  (Figure	  2A).	  Because	  the	  total	  FN	  antibody	  recognizes	  
EIIIA-­‐containing	  as	  well	  as	  EIIIA-­‐lacking	  FN,	  our	  expression	  analysis	  could	  not	  determine	  
whether	  increased	  expression	  of	  total	  FN	  was	  solely	  due	  to	  increase	  in	  FN-­‐EIIIA,	  or	  other	  FN	  
splice	  variants.	  Expression	  of	  gap	  junction	  protein	  Connexin37	  was	  also	  induced	  by	  Notch1	  
activation	  (Figure	  2B).	  However,	  we	  did	  not	  observe	  changes	  in	  Connexin37	  expression	  upon	  
Notch4	  activation	  (Figure	  2B).	  Cell	  surface	  expression	  of	  Integrinα9,	  a	  binding	  partner	  of	  FN-­‐
EIIIA,	  was	  induced	  upon	  Notch1	  activation	  (Figure	  2C).	  However,	  we	  did	  not	  observe	  changes	  in	  
cell	  surface	  expression	  of	  Integrinα9	  upon	  Notch4	  activation	  (Figure	  2C).	  Based	  on	  our	  protein	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expression	  analysis,	  we	  concluded	  that	  Notch1,	  and	  possibly	  Notch4,	  induces	  expression	  of	  
proteins	  essential	  for	  proper	  lymphatic	  valve	  morphogenesis.	  
To	  determine	  whether	  Notch	  induces	  valve	  markers	  by	  transcriptional	  regulation,	  we	  
performed	  qRT-­‐PCR	  using	  primer	  sets	  that	  recognize	  EIIIA-­‐containing	  (FN-­‐EIIIA+)	  and	  EIIIA-­‐
lacking	  (FN-­‐EIIIA-­‐)	  FN	  transcripts	  (Figure	  3,	  Murtomaki	  et	  al.,	  submitted).	  We	  found	  that	  Notch1	  
activation	  induced	  both	  transcripts	  (Figure	  3A).	  Notch4	  activation	  also	  induced	  both	  transcripts,	  
though	  to	  a	  lesser	  degree	  (Figure	  3A).	  Thus,	  we	  concluded	  that	  Notch	  induces	  transcription	  of	  
FN,	  which	  leads	  to	  increased	  levels	  of	  both	  EIIIA-­‐containing	  (FN-­‐EIIIA+)	  and	  EIIIA-­‐lacking	  (FN-­‐
EIIIA-­‐)	  splice	  variants.	  Overexpression	  of	  Notch	  effectors	  HEY1	  or	  HEY2	  did	  not	  give	  the	  same	  
response	  (Figure	  3A).	  Rather,	  HEY1	  repressed	  FN-­‐EIIIA+	  and	  FN-­‐EIIIA-­‐	  transcripts,	  while	  HEY2	  
repressed	  FN-­‐EIIIA-­‐	  transcripts	  (Figure	  3A).	  This	  suggests	  that	  FN	  is	  a	  direct	  target	  of	  NICD/CSL	  
transcriptional	  activation.	  Alternatively,	  FN	  induction	  upon	  Notch	  activation	  could	  involve	  
alternate	  effectors	  instead	  of	  or	  in	  addition	  to	  HEY1	  and	  HEY2.	  	  
Notch1	  activation	  induced	  CX37	  transcripts	  (Figure	  3B).	  Although	  we	  did	  not	  detect	  
increased	  protein	  expression	  of	  Connexin37	  upon	  Notch4	  activation	  (Figure	  2B),	  Notch4	  
activation	  induced	  CX37	  transcripts,	  though	  to	  a	  lesser	  degree	  than	  did	  Notch1	  (Figure	  3B).	  
Overexpression	  of	  Notch	  effectors	  HEY1	  or	  HEY2	  repressed	  CX37	  transcripts	  (Figure	  3B).	  This	  
suggests	  that	  CX37	  is	  a	  direct	  target	  of	  Notch.	  Alternatively,	  its	  induction	  upon	  Notch	  activation	  
could	  involve	  alternate	  effectors	  instead	  of	  or	  in	  addition	  to	  HEY1	  and	  HEY2.	  	  
Notch1	  activation	  induced	  ITGA9	  transcripts	  (Figure	  3C).	  Although	  we	  did	  not	  detect	  
increased	  protein	  expression	  of	  Integrinα9	  upon	  Notch4	  activation	  (Figure	  2C),	  Notch4	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activation	  induced	  ITGA9	  transcripts,	  though	  to	  a	  lesser	  degree	  than	  did	  Notch1	  (Figure	  3C).	  
Overexpression	  of	  Notch	  effectors	  HEY1	  or	  HEY2	  did	  not	  significantly	  alter	  ITGA9	  transcripts	  
(Figure	  3C).	  This	  suggests	  that	  ITGA9	  is	  a	  direct	  target	  of	  NICD/CSL	  transcriptional	  activation.	  
Alternatively,	  its	  induction	  upon	  Notch	  activation	  could	  involve	  alternate	  effectors.	  	  
Next,	  we	  asked	  if	  Notch	  inhibition	  results	  in	  decreased	  expression	  of	  FN,	  FN-­‐EIIIA,	  
Connexin37,	  or	  Integrinα9.	  Notch	  inhibition	  in	  HDLECs	  did	  not	  affect	  transcript	  or	  protein	  levels	  
of	  these	  valve	  components	  (data	  not	  shown).	  As	  HDLECs	  are	  isolated	  from	  lymphatic	  capillaries,	  
they	  have	  very	  low	  endogenous	  expression	  of	  proteins	  involved	  in	  lymphatic	  valve	  formation.	  
Thus,	  it	  is	  not	  surprising	  that	  Notch	  inhibition	  could	  not	  further	  reduce	  expression	  of	  these	  
proteins	  in	  HDLECs.	  	  
	  
DISCUSSION	  
We	  have	  demonstrated	  a	  role	  for	  Notch	  in	  transcriptionally	  suppressing	  expression	  of	  
Prox1	  and	  Pdpn	  during	  lymphatic	  specification/separation	  from	  the	  venous	  vasculature.	  We	  
showed	  that	  activation	  of	  Notch1	  or	  Notch4	  in	  HDLECs	  suppresses	  both	  PROX1	  and	  PDPN	  
transcripts.	  These	  results	  agree	  with	  in	  vivo	  observations	  made	  by	  our	  group,	  in	  which	  ectopic	  
Notch1	  activation	  in	  Prox1+	  LEC	  progenitors	  (Prox1CreERT2;N1IC)	  at	  E9.75	  resulted	  in	  death	  by	  
E15.5	  along	  with	  defects	  in	  lymphatic	  vascular	  formation,	  blood-­‐filled	  lymphatics,	  and	  edema[79].	  
This	  also	  correlated	  with	  reduced	  expression	  of	  Prox1[79].	  Work	  from	  our	  group	  also	  found	  that	  
ectopic	  Notch1	  activation	  in	  Prox1+	  LEC	  progenitors	  (Prox1CreERT2;N1IC)	  at	  E9.75	  correlated	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with	  reduced	  expression	  of	  podoplanin[79].	  Taken	  together,	  these	  results	  suggest	  a	  role	  for	  
Notch1	  as	  a	  negative	  regulator	  of	  lymphatic	  specification.	  
Previous	  studies	  reported	  that	  Prox1	  expression	  was	  unchanged	  at	  E10	  upon	  
endothelial-­‐specific	  removal	  of	  the	  RBP-­‐Jk/CSL	  component	  of	  the	  Notch	  transcriptional	  complex	  
(Tie2-­‐Cre;	  Rbpjfl/fl)[6].	  The	  number	  of	  Prox1+	  cells	  in	  the	  cardinal	  vein	  was	  also	  unchanged	  at	  the	  
same	  time	  point[6].	  The	  authors	  concluded	  that	  Notch	  is	  not	  important	  for	  Prox1	  expression	  in	  
the	  cardinal	  vein.	  However,	  several	  weaknesses	  should	  be	  pointed	  out	  regarding	  this	  analysis.	  
First,	  analysis	  of	  the	  Tie2-­‐Cre;	  Rbpjfl/fl	  genotype	  could	  only	  be	  performed	  in	  a	  small	  number	  of	  
embryos	  due	  to	  the	  fact	  that	  this	  genotype	  was	  embryonic	  lethal	  in	  most	  embryos	  by	  E10.	  The	  
time	  point	  of	  lethality	  and	  the	  loss	  of	  arterial	  markers	  suggested	  that	  arterial/venous	  defects	  
were	  the	  cause	  of	  death.	  As	  such,	  it	  would	  be	  difficult	  to	  determine	  the	  contribution	  of	  Notch	  
to	  lymphatic	  specification	  without	  first	  taking	  into	  account	  the	  effects	  on	  the	  blood	  vasculature.	  
Furthermore,	  RBP-­‐Jk/CSL	  functions	  as	  a	  transcriptional	  repressor	  in	  the	  absence	  of	  activated	  
Notch[25,	  26].	  Thus,	  deletion	  of	  RBP-­‐Jk/CSL	  not	  only	  prevents	  Notch	  signaling,	  but	  also	  interferes	  
with	  the	  intrinsic	  transcriptional	  repressor	  functions	  of	  RBP-­‐Jk/CSL	  independent	  of	  Notch.	  It	  is	  
for	  these	  reasons	  that	  our	  group	  used	  tamoxifen	  inducible	  drivers	  and	  specifically	  targeted	  
Notch1	  or	  DN-­‐MAML,	  neither	  of	  which	  alters	  RBP-­‐Jk/CSL’s	  repressor	  functions.	  	  
Although	  the	  specific	  contribution	  of	  Notch4	  in	  these	  processes	  was	  not	  analyzed	  in	  vivo,	  
our	  transcript	  analysis	  in	  HDLECs	  suggests	  that	  Notch4	  may	  also	  play	  a	  role	  in	  suppressing	  Prox1	  
and	  podoplanin	  in	  vivo.	  Furthermore,	  work	  from	  our	  group	  determined	  that	  Jag1	  expression	  
overlapped	  with	  Notch1	  expression	  in	  LEC	  progenitor	  cells	  within	  the	  cardinal	  vein.	  It	  would	  be	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interesting	  to	  overexpress	  or	  knock-­‐down	  of	  Jag1	  or	  Dll4	  in	  HDLECs	  to	  determine	  which	  of	  these	  
two	  ligands	  function	  to	  suppress	  PROX1	  transcripts.	  If	  Jag1	  overexpression	  could	  suppress	  
PROX1	  in	  HDLECs,	  it	  would	  suggest	  that	  Jag1	  functions	  in	  venous	  endothelium	  to	  suppress	  
Prox1.	  This	  would	  also	  validate	  our	  observations	  that	  Jag1	  expression	  is	  missing	  in	  multiple	  
lymphatic	  vascular	  beds	  (Chapters	  3	  and	  4).	  	  
We	  have	  demonstrated	  a	  role	  for	  Notch	  in	  transcriptionally	  inducing	  expression	  of	  FN-­‐
EIIIA,	  Connexin37,	  and	  Integrinα9	  during	  valve	  formation	  in	  lymphatic	  collecting	  ducts.	  We	  
report	  that	  activation	  of	  Notch1	  or	  Notch4	  in	  HDLECs	  induces	  FN-­‐EIIIA+,	  CX37,	  and	  ITGA9	  
transcripts.	  Overexpression	  of	  Notch	  effectors	  HEY1	  or	  HEY2	  either	  represses	  or	  does	  not	  affect	  
these	  genes.	  These	  results	  agree	  with	  in	  vivo	  observations	  made	  by	  our	  group,	  in	  which	  loss	  of	  
Notch1	  in	  LECs	  (Prox1CreERT2;N1fl/fl)	  at	  E15.5	  resulted	  in	  a	  reduced	  number	  of	  lymphatic	  valves,	  
as	  well	  as	  reduced	  expression	  of	  FN-­‐EIIIA	  and	  Integrinα9(Murtomaki	  et	  al.,	  submitted).	  Any	  
valves	  that	  managed	  to	  form	  were	  poorly	  organized	  and	  displayed	  reduced	  expression	  of	  FN-­‐
EIIIA	  and	  Integrinα9	  (Murtomaki	  et	  al.,	  submitted).	  Loss	  of	  all	  NICD/CSL	  signaling	  in	  LECs	  
(Prox1CreERT2;DNMAMLfl/+)	  resulted	  in	  a	  more	  severe	  phenotype	  than	  loss	  of	  Notch1	  alone	  
(Murtomaki	  et	  al.,	  submitted).	  	  Taken	  together,	  these	  results	  suggest	  a	  role	  for	  Notch	  as	  a	  
positive	  regulator	  of	  lymphatic	  valve	  formation.	  
Our	  work	  suggests	  that	  Notch	  activation	  is	  critical	  in	  suppressing	  PROX1	  transcripts	  
during	  early	  lymphatic	  specification.	  This	  would	  appear	  to	  conflict	  with	  the	  co-­‐expression	  of	  
high	  levels	  of	  Prox1	  and	  Notch1	  in	  lymphatic	  valve	  sites.	  One	  possibility	  is	  that	  Notch	  regulates	  
Prox1	  differently	  in	  larger	  lymphatic	  vessels	  compared	  to	  smaller	  lymphatic	  vessels.	  To	  support	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this	  hypothesis,	  Prox1	  expression	  could	  be	  quantified	  upon	  activation	  or	  inhibition	  of	  Notch	  in	  
capillary	  LECs	  compared	  to	  collecting	  duct	  LECs.	  Another	  possibility	  is	  that	  while	  Notch	  tightly	  
regulates	  Prox1	  during	  early	  lymphatic	  specification,	  it	  loses	  its	  ability	  to	  regulate	  Prox1	  after	  
this	  early	  time	  window.	  In	  fact	  our	  group	  has	  generated	  data	  to	  support	  this	  hypothesis,	  as	  
ectopic	  activation	  of	  Notch1	  in	  LECs	  does	  not	  appear	  to	  repress	  Prox1	  expression	  after	  E13.5[79].	  	  
In	  lymphatic	  collecting	  ducts	  as	  well,	  the	  specific	  contribution	  of	  Notch4	  was	  not	  
analyzed	  in	  vivo.	  However,	  transcript	  analysis	  in	  HDLECs,	  as	  well	  as	  the	  increased	  severity	  of	  the	  
phenotype	  in	  Prox1CreERT2;DNMAMLfl/+	  embryos	  compared	  to	  Prox1CreERT2;N1fl/fl	  embryos,	  
suggest	  that	  Notch4	  or	  another	  Notch	  family	  member	  may	  also	  play	  a	  role	  in	  inducing	  valve	  
markers	  in	  vivo.	  Furthermore,	  expression	  of	  Notch	  ligands	  has	  not	  been	  determined	  in	  
lymphatic	  collecting	  ducts.	  Based	  on	  our	  expression	  analysis	  of	  Notch	  ligands	  in	  other	  lymphatic	  
vascular	  beds,	  however,	  we	  would	  expect	  that	  Dll4	  is	  the	  ligand	  responsible	  for	  activating	  Notch	  
in	  lymphatic	  collecting	  ducts.	  	  
	   Here	  we	  show	  that	  Notch	  functions	  as	  a	  regulator	  of	  lymphatic	  endothelial	  cell	  fates	  in	  a	  
context-­‐dependent	  manner.	  During	  early	  lymphatic	  development,	  Notch	  acts	  as	  a	  negative	  
regulator	  of	  lymphatic	  endothelial	  cell	  fate	  by	  suppressing	  PROX1	  and	  PDPN	  transcripts.	  Later	  
on,	  during	  lymphatic	  valve	  formation,	  Notch	  acts	  as	  a	  positive	  regulator	  of	  lymphatic	  valve	  
endothelial	  cell	  fate	  by	  inducing	  FN-­‐EIIIA+,	  CX37,	  and	  ITGA9	  transcripts.	  Taken	  together,	  our	  






















Figure 1. Notch transcriptionally represses genes critical for lymphatic vascular specification and 
separation from venous vasculature. Quantitative RT-PCR with HDLEC cDNA. (A) qPCR validates that 
Notch1 lentiviral activation construct (N1IC) induces downstream effector HEY2, while Notch4 
lentiviral activation construct (N4/int3) induces downstream effectors HEY1 and HEY2. HEY1 and 
HEY2 lentiviral overexpression constructs result in increase of HEY1 and HEY2 transcripts, 
respectively. Overexpression of HEY2 significantly represses HEY1 transcripts. (B) Overexpression of 
Notch1 decoy lentiviral construct (N1ECDFc
1-36
) represses downstream effectors HEY1 and HEY2. (C) 
Activation of Notch1 or Notch4 represses PROX1 and PDPN, while overexpression of Notch effectors 
HEY1 and HEY2 only repress PROX1. 























































Figure 2. Notch activation results in overexpression of markers critical for lymphatic valve 
formation. Analysis of protein expression levels in HDLECs by Western blot (A-B) or flow cytometry 
(C). (A) Notch1 activation construct (N1IC) strongly induces expression of ECM protein fibronectin 
(FN), as well as splice variant FN-EIIIA. Notch4 activation construct (N4/int3) results in a modest 
increase of FN and FN-EIIIA. (B) Notch1 activation construct (N1IC) strongly induces expression of gap 
junction protein Cx37, while Notch4 activation construct (N4/int3) does not induce expression. (C) 
Notch1 activation construct (N1IC) strongly induces cell surface expression of FN-EIIIA adhesion 
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Figure 3. Notch transcriptionally induces genes critical for lymphatic valve formation. 
Quantitative RT-PCR with HDLEC cDNA. (A) Notch1 adenoviral activation construct (N1IC), and to a 
lesser extent Notch4 adenoviral activation construct (N4/int3), induce FNEIIIA+ and FNEIIIA- 
transcripts. HEY1 and HEY2 adenoviral overexpression constructs do not induce FNEIIIA+ and FNEIIIA- 
transcripts. (B) Activation of Notch1, and to a lesser extent Notch4, induce CX37 transcripts. HEY1 
and HEY2 adenoviral overexpression constructs do not induce CX37 transcripts. (C) Activation of 
Notch1, and to a lesser extent Notch4, induce ITGA9 transcripts. HEY1 and HEY2 adenoviral 
overexpression constructs do not induce ITGA9 transcripts. 





























































































Notch	  signaling	  suppresses	  sprouting	  lymphangiogenesis	  by	  restricting	  sprout	  formation	  
Notch	  functions	  to	  restrict	  sprouting	  angiogenesis	  of	  blood	  vessels,	  and	  here	  we	  report	  
that	  this	  function	  is	  conserved	  during	  sprouting	  lymphangiogenesis.	  We	  demonstrate	  that	  
Notch	  activation,	  likely	  via	  Dll4,	  suppresses	  sprouting	  lymphangiogenesis.	  Previous	  studies	  
found	  conflicting	  roles	  for	  Notch	  in	  sprouting	  lymphangiogenesis.	  Pharmacological	  inhibition	  of	  
Notch	  signaling	  using	  a	  Dll4	  decoy	  was	  shown	  to	  enhance	  developmental	  sprouting	  
lymphangiogenesis	  during	  murine	  development[73],	  while	  neutralizing	  antibodies	  against	  Dll4	  or	  
Notch1	  were	  shown	  to	  suppress	  developmental	  sprouting	  lymphangiogenesis[74].	  It	  should	  be	  
noted	  that	  these	  approaches	  were	  limited	  in	  that	  they	  depended	  on	  pharmacological	  agents,	  
whose	  activities	  are	  not	  always	  easily	  interpreted.	  In	  addition,	  these	  studies	  did	  not	  conclusively	  
establish	  whether	  the	  effects	  on	  lymphangiogenesis	  were	  cell-­‐autonomous	  or	  secondary	  effects.	  	  
We	  found	  that	  inhibition	  of	  Notch	  signaling	  in	  the	  lymphatic	  endothelium	  during	  
developmental	  sprouting	  lymphangiogenesis	  (Prox1CreERT2;DNMAMLfl/+)	  increased	  dermal	  
lymphatic	  vessel	  density.	  Thus,	  precise	  genetic	  manipulation	  of	  the	  Notch	  pathway	  in	  lymphatic	  
endothelium	  allowed	  us	  to	  definitively	  demonstrate	  that	  Notch	  must	  be	  activated	  within	  the	  
lymphatic	  endothelium	  to	  restrict	  sprouting	  lymphangiogenesis.	  We	  built	  upon	  this	  finding	  and	  
demonstrated	  that	  Dll4	  is	  highly	  expressed	  by	  lymphatic	  tip	  cells	  during	  developmental	  
sprouting	  lymphangiogenesis	  of	  the	  murine	  embryonic	  dermis.	  In	  contrast,	  Jag1	  expression	  was	  
not	  detected	  in	  the	  dermal	  lymphatic	  vascular	  bed.	  The	  high	  expression	  of	  Dll4	  in	  lymphatic	  tip	  
cells	  suggested	  that	  these	  cells	  have	  a	  specialized	  identity	  and	  function.	  Notch	  signaling	  in	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cultured	  HDLECs	  was	  induced	  by	  Dll4	  but	  neither	  induced	  nor	  suppressed	  by	  Jag1,	  further	  
highlighting	  the	  importance	  of	  Dll4/Notch	  signaling	  in	  the	  lymphatic	  endothelium.	  	  
The	  murine	  embryonic	  dermis	  allowed	  us	  to	  follow	  the	  function	  of	  Notch	  in	  newly	  
sprouting	  lymphatic	  vessels	  at	  the	  lymphatic	  front,	  and	  in	  recently	  established	  lymphatic	  vessels	  
at	  the	  lymphatic	  plexus,	  within	  the	  same	  tissue.	  At	  the	  lymphatic	  front,	  Notch	  inhibition	  was	  
concurrent	  with	  increased	  sprouts	  and	  branch	  points,	  while	  at	  the	  lymphatic	  plexus,	  Notch	  
inhibition	  caused	  no	  change	  in	  branch	  points.	  However,	  Notch	  inhibition	  caused	  an	  increase	  in	  
lymphatic	  vessel	  diameter.	  	  
We	  propose	  several	  mechanisms,	  which	  are	  not	  mutually	  exclusive,	  to	  explain	  how	  
Notch	  signaling	  suppresses	  sprouting	  lymphangiogenesis.	  First,	  we	  found	  that	  Notch	  activation	  
suppresses	  HDLEC	  proliferation,	  migration,	  and	  network	  formation.	  As	  each	  of	  these	  processes	  
contribute	  to	  sprouting	  lymphangiogenesis,	  we	  propose	  that	  Notch	  inhibition	  may	  increase	  
proliferation,	  migration,	  and	  network	  formation	  of	  LECs,	  resulting	  in	  hyperplasia	  at	  the	  
lymphatic	  plexus	  and	  contributing	  to	  hypersprouting	  at	  the	  lymphatic	  front.	  Second,	  Notch	  and	  
VEGF	  receptors	  display	  complex	  cross-­‐regulation	  (Chapter	  3,	  Figure	  14),	  and	  we	  postulate	  that	  
this	  may	  be	  critical	  for	  controlling	  sprouting	  lymphangiogenesis.	  We	  identified	  a	  feedback	  loop	  
between	  VEGFR-­‐3/VEGFR-­‐2	  and	  Notch.	  Notch	  signaling	  was	  activated	  when	  HDLECs	  were	  
treated	  with	  VEGF	  or	  VEGF-­‐C.	  In	  turn,	  Notch	  activation	  suppressed	  VEGFR-­‐2	  transcripts	  through	  
HEY1/HEY2	  in	  HDLECs[79].	  In	  the	  lymphatics,	  VEGFR-­‐2	  signaling	  does	  not	  regulate	  sprout	  
formation	  but	  causes	  lymphatic	  hyperplasia[85].	  Our	  finding	  that	  Notch	  suppresses	  VEGFR-­‐2	  in	  
HDLECs	  suggests	  that	  increased	  VEGFR-­‐2	  levels	  upon	  Notch	  inhibition	  may	  contribute	  to	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hyperplasia	  at	  the	  lymphatic	  plexus.	  Notch	  has	  been	  reported	  to	  induce[70,	  71],	  suppress[61,	  67-­‐69],	  
or	  not	  affect[73,	  74]	  VEGFR-­‐3	  expression.	  Our	  work	  revealed	  that	  VEGFR-­‐3	  transcripts	  are	  
regulated	  by	  Notch	  and	  HEYs	  in	  a	  dynamic	  manner,	  resulting	  in	  oscillating	  transcript	  levels[79]	  in	  
a	  manner	  consistent	  with	  a	  negative	  regulatory	  feedback	  loop.	  During	  sprouting	  angiogenesis,	  
blood	  endothelial	  cells	  (BECs)	  shuffle	  between	  the	  tip	  and	  stalk	  cell	  identities	  by	  dynamic	  
regulation	  of	  VEGFR-­‐2	  and	  VEGFR-­‐1	  expression[40],	  and	  we	  suggest	  that	  the	  ability	  of	  Notch	  to	  
dynamically	  regulate	  VEGFR-­‐3	  may	  be	  important	  in	  determining	  tip	  and	  stalk	  cell	  identities	  in	  
sprouting	  lymphangiogenesis.	  We	  postulate	  that	  when	  Notch	  signaling	  is	  inhibited	  in	  LECs,	  
VEGFR-­‐3	  expression	  is	  deregulated,	  which	  contributes	  to	  hypersprouting	  at	  the	  lymphatic	  front.	  
Given	  the	  dynamic	  expression	  patterns	  of	  VEGF	  receptors,	  live	  imaging	  and	  time	  course	  analysis	  
will	  be	  necessary	  in	  the	  future	  to	  understand	  Notch/VEGF	  receptor	  signaling	  during	  sprouting	  
lymphangiogenesis.	  
Our	  studies	  shed	  new	  light	  on	  the	  relative	  roles	  of	  Dll4	  and	  Jag1	  in	  sprouting	  
lymphangiogenesis.	  Dll4	  was	  highly	  expressed	  by	  lymphatic	  tip	  cells	  during	  pathological	  
sprouting	  lymphangiogenesis	  in	  the	  sutured	  murine	  cornea.	  Jag1	  expression	  was	  not	  detected	  
in	  this	  lymphatic	  vascular	  bed.	  Pharmacological	  inhibition	  of	  pan-­‐ligand	  Notch	  signaling	  
(N1ECDFc1-­‐24)	  or	  Dll	  inhibition	  (N1ECDFc1-­‐13)	  resulted	  in	  increased	  corneal	  area	  occupied	  by	  
lymphatic	  vasculature.	  Increased	  lymphatic	  vascular	  coverage	  after	  N1ECDFc1-­‐24	  treatment	  was	  
concomitant	  with	  lymphatic	  hypersprouting,	  but	  increased	  lymphatic	  vascular	  coverage	  after	  
N1ECDFc1-­‐13	  treatment	  was	  not	  accompanied	  by	  hypersprouting.	  Jag	  inhibition	  (N1ECDFc10-­‐24)	  
did	  not	  affect	  lymphatic	  vascular	  coverage	  or	  sprouting.	  Given	  that	  Dll4	  was	  strongly	  expressed	  
in	  lymphatic	  tip	  cells	  and	  Jag1	  was	  not	  detected	  in	  the	  lymphatic	  vessels	  in	  this	  setting,	  we	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postulate	  that	  N1ECDFc1-­‐24	  enhances	  lymphatic	  vascular	  coverage	  and	  sprouting	  
lymphangiogenesis	  by	  targeting	  Dll4/Notch	  signaling.	  N1ECDFc1-­‐24	  has	  been	  shown	  to	  elicit	  
more	  dramatic	  phenotypes	  than	  N1ECDFc1-­‐13	  or	  N1ECDFc10-­‐24	  alone[83].	  We	  postulate	  that	  
relatively	  weak	  inhibition	  of	  Dll4/Notch	  signaling	  is	  sufficient	  to	  enhance	  lymphatic	  coverage,	  
but	  stronger	  inhibition	  of	  Dll4/Notch	  signaling	  may	  be	  necessary	  to	  enhance	  lymphatic	  
sprouting.	  This	  may	  explain	  why	  N1ECDFc1-­‐13	  was	  able	  to	  enhance	  lymphatic	  vascular	  coverage	  
but	  unable	  to	  induce	  lymphatic	  hypersprouting.	  	  
Tumor	  lymphatic	  vessels	  are	  poorly	  understood	  and	  likely	  differ	  in	  fundamental	  ways	  
from	  physiological	  lymphatics	  and	  even	  from	  other	  pathological	  lymphatics	  (i.e.,	  corneal	  suture-­‐
induced	  lymphatics).	  For	  one,	  lymphatics	  often	  grow	  in	  a	  peritumoral	  manner,	  failing	  to	  
penetrate	  deeply	  into	  tumors,	  whereas	  most	  normal	  tissues	  are	  infused	  with	  lymphatic	  
capillaries.	  We	  found	  that	  pathological	  lymphatic	  capillaries	  recruited	  by	  orthotopically	  
implanted	  D3H2LN	  human	  breast	  tumors	  express	  both	  Dll4	  and	  Jag1,	  showing	  a	  key	  difference	  
in	  Notch	  ligand	  expression	  in	  the	  D3H2LN	  lymphatic	  vascular	  bed,	  as	  compared	  to	  non-­‐tumor	  
lymphatics.	  We	  suggest	  several	  possibilities	  that	  may	  explain	  why	  Jag1	  is	  expressed	  in	  231	  
tumor	  lymphatics:	  1)	  Notch	  expression	  by	  231	  tumor	  cells	  may	  induce	  Jag1	  expression	  in	  tumor	  
lymphatics;	  2)	  231	  tumors	  may	  secrete	  factors	  that	  induce	  Jag1	  expression	  in	  lymphatics;	  3)	  231	  
tumor	  lymphatics	  may	  be	  mis-­‐specified	  and	  thus	  possess	  characteristics	  of	  blood	  vessels,	  
including	  Jag1	  expression.	  
Notch	  inhibitors,	  including	  Notch1	  decoys	  (N1ECDFc),	  have	  been	  used	  with	  great	  success	  
in	  suppressing	  angiogenesis,	  lymphangiogenesis,	  and	  metastasis	  in	  multiple	  tumor	  models[83,	  90-­‐
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94,	  127].	  Of	  particular	  interest	  to	  us	  were	  preliminary	  studies	  conducted	  by	  our	  group	  that	  
showed	  that	  Notch	  inhibition	  suppresses	  tumor	  lymphangiogenesis	  (Yasuhiro	  Funahashi	  and	  
Xing	  Wang,	  unpublished	  data).	  However,	  we	  found	  that	  pharmacological	  inhibition	  of	  Notch	  
signaling	  with	  N1ECDFc1-­‐13	  (Dll	  inhibitor)	  or	  N1ECDFc10-­‐24	  (Jag	  inhibitor)	  had	  no	  effect	  on	  
pathological	  sprouting	  lymphangiogenesis	  in	  the	  D3H2LN	  orthotopic	  model	  of	  human	  breast	  
cancer.	  We	  suggest	  several	  possibilities	  to	  explain	  why	  adenoviral	  delivery	  of	  Notch1	  decoy	  
treatment	  did	  not	  affect	  D3H2LN	  tumor	  progression:	  1)	  The	  mammary	  fat	  pad	  
microenvironment	  may	  provide	  advantages	  to	  tumors	  that	  allow	  them	  to	  overcome	  Notch	  
inhibition;	  2)	  Orthotopic	  implantation	  in	  general	  may	  provide	  advantages	  over	  subcutaneous	  
implantation	  that	  allows	  tumors	  to	  overcome	  Notch	  inhibition;	  3)	  Adenoviral	  delivery	  of	  Notch1	  
decoys	  may	  not	  achieve	  the	  necessary	  serum	  levels	  to	  affect	  tumor	  lymphangiogenesis;	  4)	  
Notch1	  decoy	  treatment	  may	  need	  to	  be	  used	  as	  combination	  therapy	  with	  another	  
lymphangiogenic	  inhibitor;	  5)	  D3H2LN	  tumors	  may	  be	  refractory	  to	  Notch	  inhibition.	  
	  
Notch	  determines	  cell	  fate	  during	  lymphatic	  development	  
Notch	  is	  known	  to	  regulate	  cell	  fates	  in	  multiple	  contexts	  and	  tissues[24-­‐26].	  In	  blood	  
vascular	  development	  alone,	  Notch	  regulates	  at	  least	  two	  cell	  fate	  decisions.	  Notch	  signaling	  
induces	  arterial	  fate	  over	  venous	  fate,	  and	  stalk	  cell	  fate	  over	  tip	  cell	  fate[29].	  Lymphatic	  vascular	  
formation	  requires	  cell	  fate	  decisions	  during	  early	  specification	  and	  separation	  from	  the	  venous	  
vasculature,	  as	  well	  as	  during	  lymphatic	  valve	  formation.	  Initiation	  of	  lymphatic	  development	  
requires	  cell-­‐fate	  determination,	  as	  the	  first	  lymphatic	  endothelial	  cells	  (LECs)	  are	  specified	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within	  the	  cardinal	  vein	  by	  inducing	  Prox1[9-­‐12].	  They	  then	  further	  differentiate	  and	  separate	  
from	  the	  cardinal	  vein	  by	  inducing	  podoplanin	  expression[9-­‐12].	  Work	  from	  our	  group	  showed	  
that	  within	  the	  cardinal	  vein,	  Notch1	  and	  Jag1	  were	  expressed	  in	  the	  cells	  that	  did	  not	  go	  on	  to	  
induce	  Prox1	  and	  podoplanin	  expression[79].	  Work	  from	  our	  group	  showed	  that	  activation	  of	  
Notch1	  in	  LEC	  progenitors	  (Prox1CreERT2;N1IC)	  led	  to	  reduced	  expression	  of	  Prox1	  and	  
podoplanin,	  and	  reduced	  lymphatic	  differentiation	  and	  separation	  from	  the	  venous	  
vasculature[79].	  This	  suggested	  a	  suppressive	  role	  for	  Notch	  during	  lymphatic	  specification	  and	  
separation.	  We	  report	  that	  Notch	  activation	  in	  HDLECs	  suppresses	  PROX1	  and	  PDPN	  
transcripts[79].	  Thus,	  Notch	  functions	  as	  a	  negative	  regulator	  of	  lymphatic	  specification	  and	  
separation	  through	  transcriptional	  repression	  of	  PROX1	  and	  PDPN.	  
Lymphatic	  valve	  formation	  also	  requires	  cell-­‐fate	  determination,	  as	  a	  subset	  of	  LECs	  
within	  the	  collecting	  ducts	  must	  become	  committed	  to	  the	  valve	  LEC	  fate.	  Work	  from	  our	  group	  
showed	  that	  Notch1	  is	  expressed	  throughout	  lymphatic	  collecting	  ducts	  and	  becomes	  
upregulated	  at	  sites	  of	  valve	  formation	  at	  E17.5	  (Murtomaki	  et	  al.,	  submitted).	  Loss	  of	  Notch1	  in	  
lymphatic	  collecting	  ducts	  (Prox1CreERT2;N1fl/fl)	  led	  to	  reduced	  lymphatic	  valve	  formation,	  
concurrent	  with	  reduced	  expression	  of	  FN-­‐EIIIA	  and	  Integrinα9	  (Murtomaki	  et	  al.,	  submitted).	  
This	  suggested	  an	  inductive	  role	  for	  Notch	  in	  lymphatic	  valve	  formation.	  We	  report	  that	  Notch	  
activation	  in	  HDLECs	  induces	  transcripts	  for	  FN-­‐EIIIA,	  ITGA9,	  and	  CX37,	  another	  important	  
regulator	  of	  lymphatic	  valve	  formation	  (Murtomaki	  et	  al.,	  submitted).	  Thus,	  we	  conclude	  that	  
Notch	  functions	  as	  a	  positive	  regulator	  of	  lymphatic	  valve	  formation	  through	  transcriptional	  
induction	  of	  FN-­‐EIIIA,	  ITGA9,	  and	  CX37.	  
146
	  
Notch	  signaling	  in	  lymphatic	  vasculature	  is	  context-­‐dependent	  
The	  studies	  described	  here	  establish	  that	  Notch	  functions	  as	  a	  regulator	  of	  cell-­‐fate	  
decisions	  in	  lymphatic	  vasculature,	  and	  that	  this	  function	  is	  conserved	  in	  several	  steps	  of	  
lymphatic	  vascular	  formation.	  Notch	  functions	  during	  the	  early	  stages	  of	  lymphatic	  specification	  
from	  the	  venous	  vasculature,	  in	  sprouting	  lymphangiogenesis	  during	  development	  and	  disease,	  
and	  during	  lymphatic	  valve	  formation.	  Expression	  of	  Notch	  family	  proteins	  and	  function	  of	  
Notch	  signaling,	  even	  within	  the	  lymphatic	  vasculature,	  is	  highly	  context-­‐dependent.	  For	  
example,	  Jag1	  is	  not	  expressed	  in	  developing	  lymphatic	  vessels	  of	  the	  embryonic	  dermis	  and	  
pathological	  lymphatic	  vessels	  of	  the	  wounded	  cornea,	  but	  is	  expressed	  in	  pathological	  tumor	  
lymphatic	  vessels.	  Notch	  can	  both	  directly	  induce	  or	  indirectly	  repress	  VEGFR-­‐3	  levels	  in	  HDLECs,	  
a	  distinction	  that	  may	  be	  critical	  for	  context-­‐dependent	  functions	  of	  Notch.	  Notch	  inhibition	  has	  
been	  shown	  to	  induce	  sprouting	  lymphangiogenesis	  in	  the	  embryonic	  dermis	  and	  wounded	  
cornea,	  while	  it	  suppresses	  sprouting	  lymphangiogenesis	  in	  certain	  tumor	  models.	  Notch	  
suppresses	  Prox1	  in	  the	  cardinal	  vein	  during	  lymphatic	  specification	  but	  does	  not	  suppress	  
Prox1	  in	  valve	  LECs	  during	  lymphatic	  valve	  formation.	  Although	  Notch	  functions	  differently	  in	  
different	  contexts,	  it	  is	  undeniably	  important	  in	  the	  lymphatic	  vasculature.	  Identifying	  these	  








Here	  we	  show	  that	  Notch	  signaling	  functions	  to	  regulate	  sprouting	  lymphangiogenesis.	  
Dll4	  was	  highly	  expressed	  in	  capillary	  lymphatic	  tip	  cells	  during	  sprouting	  lymphangiogenesis,	  
and	  inhibition	  of	  Notch	  signaling	  resulted	  in	  lymphatic	  hypersprouting.	  We	  demonstrate	  a	  
feedback	  loop	  between	  Notch	  and	  VEGF	  signaling,	  which	  we	  postulate	  is	  important	  in	  
regulating	  sprouting	  lymphangiogenesis.	  Our	  results	  validate	  the	  tip/stalk	  model	  in	  sprouting	  
lymphangiogenesis.	  We	  also	  identify	  Notch	  as	  a	  transcriptional	  inhibitor	  of	  lymphatic	  
specification/separation	  and	  transcriptional	  inducer	  of	  lymphatic	  valve	  formation.	  Our	  work	  
identifies	  novel	  roles	  for	  Notch	  signaling	  as	  a	  cell	  fate	  determinant	  in	  tip/stalk,	  venous	  to	  
lymphatic,	  and	  duct	  to	  valve	  LEC	  cell	  fate	  decisions	  in	  lymphatic	  vasculature.	  Given	  the	  
importance	  of	  the	  lymphatic	  vascular	  system	  in	  physiological	  and	  pathological	  settings,	  our	  
work	  suggests	  that	  the	  Notch	  signaling	  pathway	  may	  a	  productive	  therapeutic	  target	  in	  treating	  
























Figure 1. Model. Notch regulates lymphatic endothelial cell fate decisions and sprouting lymphangio-

















- Notch restricts Prox1-dependent 
lymphatic specification and Pdpn-
dependent lymphatic separation from 
cardinal vein
- Notch restricts lymphatic tip cell 
specification during dermal sprouting 
lymphangiogenesis, which may depend 
on its ability to suppress VEGFR-2 and 
biphasically regulate VEGFR-3
- Notch induces FnEIIIA, Cx37, and 
Itga9-dependent valve formation in 
lymphatic collecting ducts
- In immunocompromised mice, Notch 
inhibition with Notch1 decoys does not 
alter MDA-MB-231-D3H2LN tumor 
lymphangiogenesis or axillary lymph 
node metastasis
- In C57BL/6 mice, Notch restricts 
lymphatic tip cell 
specification during corneal suture-
induced sprouting lymphangiogenesis, 
which may depend on its ability to 
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Introduction	  
In	  mice,	   lymphatic	  vascular	  development	  initiates	  around	  embryonic	  day	  9.75	  (E9.75)	  with	  
the	  expression	  of	  Prox1	  in	  a	  subset	  of	  the	  endothelial	  cells	  (ECs)	  of	  the	  cardinal	  vein	  (CV)	  (Oliver	  
et	   al.	   1993;	   Oliver	   and	   Harvey	   2002).	   Prox1,	   a	   homeobox	   transcription	   factor,	   functions	   as	  
master	  regulator	  of	  lymphatic	  endothelial	  cell	  (LEC)	  specification	  and	  maintains	  LEC	  fate	  (Wigle	  
et	   al.	   2002).	   In	   vitro	   studies	   suggest	   Prox1	   functions	   in	   LEC	   progenitors	   to	   promote	  
differentiation	  and	  upregulate	  LEC	  specific	  genes,	  such	  as	  SLC,	  neuropilin-­‐2	  (Nrp2),	  podoplanin,	  
and	   a9	   integrin	   and	   downregulate	   blood	   endothelial	   cells	   (BEC)	   genes,	   CD34,	   neuropilin-­‐1	  
(Nrp1),	   and	   endoglin	   (Petrova	   et	   al.	   2002;	   Hong	   and	   Detmar	   2003).	   	   Prox1	   deletion	   in	  mice	  
results	   in	   a	   loss	  of	   LEC	  progenitor	   cells	   in	   veins	  and	  blocked	   lymphatic	   vascular	  development	  
(Wigle	   and	   Oliver	   1999;	   Wigle	   et	   al.	   2002;	   Johnson	   et	   al.	   2008).	   In	   contrast,	   ectopic	   Prox1	  
expression	  in	  the	  blood	  endothelium	  results	  in	  enlarged	  lymphatic	  sacs	  (LS)	  and	  edema	  (Kim	  et	  
al.	   2010).	   Loss	   of	   Prox1	   after	   completion	   of	   lymphatic	   development	   leads	   to	   a	   loss	   of	   LEC	  
specific	   proteins	   and	  misexpression	   of	   BEC	  markers,	   demonstrating	   that	   Prox1	   is	   required	   to	  
maintain	  LEC	  identity	  (Johnson	  et	  al.	  2008).	  	  
At	  E9.75,	  expression	  of	  Prox1	  in	  the	  cardinal	  vein	  requires	  Coup-­‐TFII	  and	  Sox18	  transcription	  
factors	  (Srinivasan	  et	  al.	  2007;	  Francois	  et	  al.	  2008;	  Lin	  et	  al.	  2010).	  After	  E13.5,	  maintenance	  of	  
Prox1	  expression	  no	  longer	  requires	  either	  Coup-­‐TFII	  or	  Sox18;	  thus	  the	  maintenance	  of	  Prox1	  
transcription	   occur	   by	   different	   mechanisms	   (Srinivasan	   et	   al.	   2007;	   Srinivasan	   et	   al.	   2010).	  
Coup-­‐TFII	   further	   cooperates	   with	   Prox1	   to	   drive	   the	   expression	   of	   lymphatic	   endothelial	  
specific	  genes,	  such	  as	  Nrp2	  and	  VEGFR-­‐3	  (Lee	  et	  al.	  2009;	  Lin	  et	  al.	  2010).	  Recently,	  it	  has	  been	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shown	  that	  Prox1	  and	  Coup-­‐TFII	  function	  together	  to	  regulate	  lymphovenous	  valve	  formation	  in	  
mice	  (Srinivasan	  and	  Oliver	  2011).	  	  
Migration	  of	  Prox1-­‐positive	   LEC	  progenitors	   from	   the	   veins	   and	   formation	  of	   LSs	   requires	  
the	  activity	  of	  Vascular	  Endothelial	  Growth	  Factor	  C	  (VEGF-­‐C)	  (Karkkainen	  et	  al.	  2004).	  VEGF-­‐C	  
through	   its	   receptor,	   VEGFR-­‐3,	   induces	   LEC	   proliferation,	   survival	   and	   migration	   in	   culture	  
(Makinen	   et	   al.	   2001).	   VEGFR-­‐3	   is	   a	   tyrosine	   kinase	   receptor	   that,	   in	   complex	   with	   the	   co-­‐
receptor	  Nrp2,	  binds	  VEGF-­‐C	  (Favier	  et	  al.	  2006;	  Kärpänen	  T	  2006;	  Xu	  et	  al.	  2010).	  
Notch	   signaling	  modulates	   cell-­‐fate	   decisions	   via	   direct	   cell-­‐cell	   contact	   (Andersson	   et	   al.	  
2011).	   The	  Notch	   pathway	   comprises	   a	   family	   of	   four	   transmembrane	   receptors	   (Notch	   1-­‐4)	  
and	   five	   membrane-­‐bound	   ligands	   (Delta-­‐like1,	   3,	   4,	   Jagged1	   and	   2).	   Receptor–ligand	  
interactions	   release	   the	   intracellular	   domain	   via	   proteolysis	   that	   translocates	   to	   the	   nucleus,	  
where	  it	  binds	  to	  CBF1/Su(H)/LAG1	  (CSL)	  (Borggrefe	  and	  Liefeke	  2012).	  The	  intracellular	  Notch	  
peptide	  recruits	  a	  transcriptional	  activating	  complex	  to	  CSL	  converting	  it	  from	  a	  repressor	  to	  an	  
activator	   of	   transcription,	   inducing	   multiple	   downstream	   targets	   such	   as	   the	   transcriptional	  
repressors,	  HES	  and	  Hey.	  
In	   the	   blood	   vasculature,	   Notch	   signaling	   regulates	   arterial/venous	   specification	   and	  
sprouting	   angiogenesis.	   In	   the	   arterial	   endothelium,	   high	   Dll4/Notch1	   signaling	   maintains	  
arterial	  identity	  and	  inhibits	  venous	  EC	  differentiation	  (Gridley	  2010).	  In	  sprouting	  angiogenesis,	  
Dll4	   in	   tip	   cells	   signal	   to	  Notch1	   in	  adjacent	   stalk	   cells	   to	   restrict	   the	  number	  of	   tip	   cells	   and	  
vascular	  density	  (Jakobsson	  et	  al.	  2009;	  Tung	  et	  al.	  2012).	  Dll4/Notch1	  signaling	  also	  has	  a	  role	  
in	  lymphatic	  vascular	  development.	  In	  zebrafish,	  Dll4	  functions	  in	  thoracic	  duct	  morphogenesis	  
(Geudens	   et	   al.	   2010).	   Dll4	   expressed	   on	   the	   intersomitic	   arteries	   guides	   secondary	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lymphangiogenic	   sprouting	   from	   the	   posterior	   CV.	   In	   mice,	   Dll4/Notch1	   signaling	   has	   been	  
shown	   to	   function	   in	   sprouting	   lymphangiogenesis,	   by	   acting	   to	   control	   lymphatic	   tip	   cell	  
differentiation	  (Niessen	  et	  al.	  2011;	  Zheng	  et	  al.	  2011).	  Consistent	  with	  this	  finding,	  Notch1	  and	  
Notch4	  are	  expressed	   in	  dermal	   lymphatic	   endothelium,	  when	   the	  embryonic	   lymphatics	   are	  
actively	  remodeling	  (Shawber	  et	  al.	  2007).	  	  
We	   demonstrate	   a	   novel	   role	   for	   Notch	   in	   lymphatic	   vascular	   development;	   that	   of	  
regulating	   the	   choice	   between	   venous	   and	   lymphatic	   endothelial	   identity	   during	   murine	  
development.	   Using	   the	  Prox1CreERT2	   inducible	   driver	   (Srinivasan	   et	   al.	   2007),	   Notch	   activity	  
was	  manipulated	  in	  Prox1+	  LEC	  progenitor	  cells	  in	  veins.	  Conditional	  loss	  of	  Notch1	  or	  inhibition	  
of	  Notch/CSL	  transcriptional	  activation	  resulted	  in	  precocious	  and	  excessive	  LEC	  differentiation	  
that	   correlated	   with	  misexpression	   of	   Prox1	   in	   the	   veins	   and	   dilation	   of	   lymphatics.	   Ectopic	  
Notch1	  activation	  in	  Prox1+	  ECs	  resulted	  in	  misspecified	  LECs	  leading	  to	  severe	  edema,	  blood-­‐
filled	  lymphatics	  and	  incorporation	  of	  BECs	  into	  the	  peripheral	  lymphatics.	  	  
	  
Materials	  and	  Methods	  
	  
Constructs/Cell	  Culture	  
Early	  passage	  HdMVECs	   (Lonza)	  were	   infected	  with	  25	  pfu/cell	   adenoviruses	  encoding	  
the	  intracellular	  domain	  of	  human	  Notch1	  (N1IC),	  or	  LacZ,	  as	  previously	  described	  (Shawber	  et	  
al.	   2007).	   HdLECs	   were	   isolated	   from	   human	   foreskins	   (Exemption	   AAAB-­‐1700)	   using	   CD31	  
conjugated	  Dynabeads	  (Invitrogen).	  Passage	  1	  cells	  were	  FACS	  sorted	  for	  podoplanin	  (Angiobio),	  
then	   negatively	   sorted	   by	   FACS	   for	   CD34	   (Pharmingen).	   HdLEC	   were	   maintained	   in	   EGM-­‐
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2MV	  BulletKit	   (Lonza)	  with	   10	   ng/ml	   VEGF-­‐C	   (RnD).	   HdLEC	   lines	  were	   generated	   by	   lentiviral	  
infection	   using	   pCCL.pkg.wpre	   vector	   encoding	   N1IC,	   Hey1,	   Hey2	   or	   GFP	   (Tung	   et	   al.	   2009).	  
Transgene	  expression	  was	  confirmed	  by	  quantitative	  (q)	  RT-­‐PCR	  and	  Westerns.	  	  
For	   activation	   of	   endogenous	   Notch	   signaling,	   HDLEC	   grown	   to	   confluency	   on	  
fibronectin-­‐coated	  dishes	  were	  treated	  overnight	  with	  200nM	  Compound	  E,	  a	  gamma	  secretase	  
inhibitor	  (GSI).	  The	  next	  day,	  GSI	  was	  removed	  and	  cells	  treated	  with	  10mM	  EDTA/PBS	  at	  37oC	  
for	  up	   to	  15	  minutes.	  Media	  was	   then	   replaced	  with	  EGM-­‐2	  MV	  containing	  10	  ng/ml	  VEGF-­‐C	  
(RnD	  systems).	  	  
	  
RT-­‐PCR/Western	  Analyses	  
RNA	   (RNeasy	  Mini	   Kit;	  Qiagen)	   and	  protein	  was	   isolated	   24	   hours	   after	   adenoviral	   infections	  
and	  48	  hours	  after	  lentiviral	  infection	  (Shawber	  et	  al.	  2007).	  RT-­‐PCR	  was	  performed	  (Funahashi	  
et	   al.	   2010),	   and	  Westerns	   performed	  with	   antibodies	   against	   Prox1	   (Millipore),	   or	   a-­‐tubulin	  
(Sigma).	  cDNAs	  were	  synthesized	  and	  qPCR	  performed	  with	  Sybr	  Green	  PCR	  Master	  Mix	  (ABI)	  
and	  7300	  Real-­‐Time	  PCR	  System	  (ABI).	  PCR	  amplicons	  for	  genes	  cloned	  into	  pDrive	  (Stratagene)	  
served	   as	   reference	   standards.	   b-­‐actin	   qRT-­‐PCR	   was	   used	   to	   normalize	   samples.	   Primers	  
described	  in	  Table	  S1.	  
	  
Mice	  	  
Notch1+/-­‐	  (Krebs	  et	  al.	  2000),	  Prox1CreERT2	  (Srinivasan	  et	  al.	  2007),	  Prox1GFPcre	  (Srinivasan	  et	  al.	  
2010;	  Srinivasan	  and	  Oliver	  2011),	  NI1C	   (Buonamici	  et	  al.	  2009),	  Notch1fl/fl	   (Yang	  et	  al.	  2004),	  
and	   DNMAML	   (Tu	   et	   al.	   2005)	   mice	   are	   described.	   Notch1fl/fl	   and	   ROSA:LacZfl/fl	  mice	   were	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purchased	   (Jax	   Labs).	   Tamoxifen	   (5mg/40g	   or	   7mg/40g)	   dissolved	   in	   corn	   oil	   was	   injected	  
intraperitoneally	   at	   E9.75,	   E10.5,	   E13.5	   and	   E14.5	   for	   N1IC	   and	  Notch1fl/fl	   studies.	   5mg/40g	  
tamoxifen	  was	  administered	  orally	  at	  E9.75	  for	  DNMAML	  studies.	  2-­‐7	  litters	  were	  evaluated	  for	  
each	  time-­‐point	  and	  described	  in	  Table	  S2.	  	  
	  
Immunohistochemistry	  
Immunohistochemistry	   on	   5	   mm	   fixed-­‐frozen/paraffin-­‐embedded	   and	   30	   mm	   fixed-­‐frozen	  
sections	   was	   performed	   (Shawber	   et	   al.	   2007).	   Wholemounts	   were	   performed	   as	   described	  
(Lohela	   et	   al.	   2008).	   Antibodies	   listed	   in	   Table	   S3.	   MOM	   kit	   (Vector)	   was	   used	   with	   mouse	  
monoclonal	  antibodies.	  Secondary	  antibodies	  were	  from	  Invitrogen	  (Alexa	  fluor	  488,	  Alexa	  fluor	  
594)	   and	  Vector	   Labs	   (Biotinylated-­‐anti-­‐goat,	  biotinylated	  anti-­‐hamster).	   Colorimetric	   staining	  
was	   hematoxylin	   counterstained.	   Nuclei	   visualized	   with	   DAPI	   in	   immunofluorescent	   staining.	  
Images	  captured	  using	  a	  Nikon	  SMZ-­‐U	  Zoom	  1:10	  microscope	  and	  Nikon	  4500	  digital	  camera,	  or	  
Nikon	  ECLIPSE	  E800	  microscope,	  Nikon	  DXM	  1200	  digital	  camera,	  and	  Image	  ProPlus	  software.	  




ImageJ	  software	  (NIH)	  was	  used	  for	  quantitative	  analyses	  of	  images.	  Prox1+	  cells	  within	  
the	   CV	   or	   LS	   were	   normalized	   by	   vessel/sac	   circumference	   and	   emerging	   from	   CV	   by	   area	  
analyzed.	   LYVE1	   vessels	   were	   normalized	   by	   area	   analyzed	   to	   determine	   lymphatic	   vessel	  
density.	  Significance	  between	  two	  groups	  determined	  by	  T-­‐Test.	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  Results	  
Notch1	   activation	   suppresses	   lymphatic	   endothelial	   gene	   expression	   in	   microvascular	  
endothelial	  cells.	  
To	   determine	   if	   Notch	   regulates	   LEC	   specific	   gene	   expression,	   a	   constitutively	   active	  
Notch1	   protein	   (N1IC)	   was	   ectopically	   expressed	   in	   human	   neonatal	   dermal	   microvascular	  
endothelial	   cells	   (HdMVEC)	   by	   adenoviral	   infection	   and	   human	   dermal	   lymphatic	   endothelial	  
cells	   (HdLEC)	   by	   lentiviral	   infection.	  HdMVEC	   consist	   of	   both	   BECs	   and	   LECs,	   and	   a	   subset	   of	  
HdMVEC	  express	  LEC	  genes,	  Prox1,	  LYVE1	  and	  podoplanin.	  Notch1	  activation	  suppressed	  Prox1,	  
podoplanin	  and	  LYVE1	  transcripts	  in	  both	  HdMVEC	  and	  HdLEC,	  and	  Prox1	  protein	  in	  HdMVECs	  
(Figs.	   1A,B).	   Notch	   activation	   did	   not	   affect	   the	   expression	   of	   Sox18	   in	   HdLEC	   (Fig.	   S1A).	   In	  
HdLEC,	   ectopic	   expression	   of	   the	   Notch	   effectors,	   Hey1	   or	   Hey2,	   reduced	   expression	   of	   LEC	  
genes	   Prox1,	   LYVE1,	   and	   podoplanin	   (Fig.	   1B).	   Hey2	   suppression	   of	   Prox1	   and	   LYVE1	   was	  
stronger	   relative	   to	   Hey1.	   Notch1-­‐	   and	   Hey2-­‐mediated	   downregulation	   of	   Prox1	   and	  
podoplanin	  in	  cultured	  LECs	  is	  consistent	  with	  previous	  observations	  (Kang	  et	  al.	  2010).	  	  
Notch	   regulates	   the	   expression	   of	   Vascular	   Endothelial	   Growth	   Factor	   Receptors	  
(VEGFR)	   in	   BECs.	   Notch	   downregulates	   VEGFR-­‐2	   (Taylor	   et	   al.	   2002;	   Shawber	   et	   al.	   2007;	  
Funahashi	  et	  al.	  2010).	  Notch	  either	  induces	  or	  suppresses	  VEGFR-­‐3,	  depending	  on	  the	  cellular	  
context	   in	  vivo	   (Shawber	  et	  al.	  2007;	  Tammela	  et	  al.	  2008).	  The	  effect	  of	  activating	  Notch1	  or	  
ectopic	  Hey1	  or	  Hey2	  on	  VEGFR-­‐2/3	  was	  evaluated	   in	  HdLEC.	  N1IC,	  Hey1	  or	  Hey2	  suppressed	  
VEGFR-­‐2	   transcript	   levels	   (Fig.	   1C,D).	   N1IC	   induced	   VEGFR-­‐3,	   while	   ectopic	   Hey1	   or	   Hey2	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suppressed	   VEGFR-­‐3	   (Fig.	   1C,D),	   suggesting	   that	   Notch	   dynamically	   regulated	   VEGFR-­‐3	  
expression.	  
We	   previously	   established	   that	   Notch	   directly	   induces	   VEGFR-­‐3	   via	   Notch/CSL	  
transactivation	  of	  the	  VEGFR-­‐3	  promoter	  (Shawber	  et	  al.	  2007).	  We	  hypothesize	  that	  VEGFR-­‐3	  
may	  be	   downregulated,	   secondary	   to	  Notch/CSL	   induction,	   by	   the	   action	   of	  Hey	   proteins,	   as	  
part	   of	   a	   negative	   feedback	   loop.	   	   	   To	   evaluate	   this	   possibility,	  we	   determined	   the	   effect	   of	  
activating	  endogenous	  Notch	  on	   the	   timing	  of	  VEGFR-­‐3	  and	  Hey1/2	   induction.	  HdLEC	  express	  
Notch1-­‐4,	  Jagged1	  and	  Dll4	  (Fig.	  S1B).	  Confluent	  HdLEC	  were	  grown	  overnight	  with	  the	  gamma	  
secretase	  inhibitor	  (GSI),	  Compound	  E,	  to	  suppress	  Notch	  signaling.	  	  The	  following	  day	  GSI	  was	  
removed,	   endogenous	   Notch	   activated	   by	   EDTA,	   and	   RNA	   collected	   at	   different	   time-­‐points	  
post-­‐Notch	   activation.	   	   Significant	   induction	   of	   VEGFR-­‐3	   was	   observed	   after	   5	   minutes	   and	  
reached	  maximum	  expression	  at	  10	  minutes	  (Fig.	  1E).	   	  At	  20	  minutes,	  VEGFR-­‐3	   induction	  was	  
significantly	  downregulated,	  which	   followed	   low	   level	  Hey1/2	   induction	  observed	  at	  5	  and	  10	  
minutes.	  After	  Hey1/2	  levels	  went	  back	  to	  baseline	  at	  20	  minutes,	  VEGFR-­‐3	  was	  significantly	  up	  
at	   30	  minutes.	   	   Strong	   induction	  of	  Hey1/2	  observed	  at	   60	  minutes	   correlated	  with	  VEGFR-­‐3	  
downregulation.	  	  These	  data	  suggest	  that	  VEGFR-­‐3	  is	  an	  immediate	  response	  gene	  downstream	  
of	  Notch	  activation	  and	  downregulated	  by	  the	  Notch	  effectors,	  Hey1	  and	  Hey2.	  
	  
Notch1	   expression	   and	   activity	   in	   the	   cardinal	   vein	   during	   venous/lymphatic	   endothelial	  
specification.	  	  
LEC	  differentiation	   is	   a	   dynamic	   process	   that	   initiates	   around	   E9.75	  with	   the	   onset	   of	  
Prox1	   expression	   and	   progresses	   anterior	   to	   posterior	   along	   the	   cardinal	   veins	   (Oliver	   et	   al.	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1993;	  François	  et	  al.	  2011).	  As	  Notch1	  suppressed	  Prox1	   in	  vitro	   (Figs.	  1A,B),	  we	  hypothesized	  
that	  Notch	  acts	  in	  the	  venous	  endothelium	  to	  restrict	  the	  differentiation	  of	  Prox1+	  progenitor	  
cells.	  	  Expression	  of	  Notch	  proteins	  (Notch	  1-­‐4)	  and	  Notch	  ligands	  Dll4	  and	  Jagged1,	  relative	  to	  
endothelial	   Prox1	   was	   determined	   in	   murine	   E9.75	   and	   E10.5	   wild-­‐type	   and	   Notch	   reporter	  
(TNR)	   embryos.	   The	   transgenic	   TNR	   mouse	   line	   expresses	   GFP	   in	   response	   to	   Notch	   signal	  
activation	   (Duncan	   et	   al.	   2005).	  We	   found	   that	   the	   venous	   endothelium	   primarily	   expressed	  
Notch1	  and	  Jagged1	  during	  this	  developmental	  period	  (Figs.	  1F-­‐H,	  S1C-­‐E).	  	  
Analysis	  of	  E9.75	  transverse	  sections	  anterior	  to	  the	  common	  atrial	  chamber	  identified	  a	  
region	   of	   the	   CV	   where	   Notch1	   expression	   was	   opposite	   of	   polarized	   Prox1	   (Fig.	   1F).	   This	  
pattern	  differed	   from	  the	  aorta,	  where	  high	  Notch1	  expression	  was	  observed	  throughout	   the	  
aortic	   endothelium	   (Fig.	   1F),	   suggesting	  distinct	   expression	  patterns	   in	   arterial	   versus	   venous	  
vessels.	  The	  Notch	  ligands,	  Dll4	  and	  Jagged1	  were	  both	  expressed	  in	  the	  aortic	  endothelium	  at	  
E9.75	  (Fig.	  S1C).	  Notch	  activity	  (GFP)	  was	  detected	  in	  a	  subset	  of	  Notch1-­‐expressing	  CV	  ECs	  (Fig.	  
1F),	  when	  weak	  punctate	  Jagged1	  expression	  was	  first	  observed	  in	  the	  E9.75	  CV	  (Fig.	  S1C).	  	  Thus,	  
Jagged1	  may	  function	  as	  the	  ligand	  for	  Notch1	  in	  venous	  endothelium.	  
Analysis	   of	   thick	   sagittal	   sections	   of	   E10.5	   embryos	   demonstrated	   that	   Notch1	  
expression	   was	   discontinuous	   in	   the	   CV	   and	   jugular	   vein	   (JV)	   with	   punctate	   weak	   Notch1	  
expression	   observed	   dorsally	   (Fig.	   1G).	   	   In	   serial	   sections,	   Prox1+	   progenitors	   resided	   in	   the	  
dorsal	   JV	  where	  Notch1	  was	  sometimes	  co-­‐expressed	  with	  Prox1	   (Fig.	  1G).	  Dorsally	  migrating	  
Prox1+	   progenitors	   were	   negative	   for	   Notch.	   In	   thick	   E10.5	   transverse	   sections,	   Notch1	   and	  
Prox1	  had	  both	  distinct	  and	  overlapping	  expression	  in	  the	  posterior	  cardinal	  vein	  (PCV;	  Fig.	  1H).	  	  
At	   this	   posterior	   position	   of	   the	   PCV,	   Prox1+	   progenitors	   were	   evenly	   distributed,	   not	   yet	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polarized	  to	  one	  side.	  Three	  distinct	  expression	  patterns	  were	  observed	  for	  Prox1	  and	  Notch1;	  
PCV	  cells	   that	  expressed	  high	  Prox1	  and	   low	  Notch1,	  cells	   that	  expressed	   low	  Prox1	  and	  high	  
Notch1	  and	  cells	   that	  co-­‐expressed	  both	  proteins	   (Fig.	  1H).	  At	  E10.5,	   Jagged1	  expression	  was	  
polarized	  medially	  in	  the	  anterior	  CV	  (Fig.	  S1D);	  this	  region	  displayed	  punctate	  Notch	  activation	  
(GFP)	  (Fig.	  1I,	  S2A).	  	  
The	  level	  of	  Notch	  signaling	  in	  the	  CV	  was	  much	  lower	  than	  that	  observed	  in	  the	  aortic	  
endothelium	  and	  vascular	  smooth	  muscle	  cells	  at	  E10.5	  and	  E11.5	  (Fig.	  S2A,C)	  which	  correlated	  
with	   the	   level	   of	   Notch1	   expression	   (Fig.	   S2B).	   Notch1	   expression	   was	   evaluated	   in	   the	  
mesenteric	   vasculature	   that	   consists	   of	   arterial,	   venous	   and	   lymphatic	   vessels	   (Fig.	   S2D).	   	   At	  
E16.5	  and	  E17.5,	  Notch1	  expression	  was	  strongest	  in	  the	  artery,	  weaker	  in	  veins	  and	  weakest	  in	  
lymphatics	   (Fig.	  S2D,E).	   	  This	  pattern	  was	  quantified,	  and	  Notch1	  expression	   in	   the	  veins	  was	  
51%	  and	  43%	  of	  that	  in	  the	  arteries	  at	  E16.5	  and	  E17.5,	  respectively	  (Fig.	  S2E).	  In	  the	  lymphatic	  
vessels,	  Notch1	  was	  expressed	  22%	  at	  E16.5	  and	  13%	  at	  E17.5	  relative	  to	  the	  artery	  (Fig.	  S2E).	  
These	   expression	   studies	   suggest	   that	   Notch1	   expression	   and	   activity	   is	   found	   in	   arterial,	  
venous	   and	   lymphatic	   endothelium,	   but	   differs	   depending	   on	   the	   vessel	   type	   and	  
developmental	  stage.	  
	  
Loss	  of	  Notch	  signaling	  in	  Prox1-­‐positive	  endothelial	  cells	  caused	  ectopic	  lymphatic	  endothelial	  
cell	  specification	  and	  enlarged	  lymph	  sacs	  
To	  determine	  the	  effect	  of	  deleting	  Notch	  in	  the	  Prox1+	  LEC	  progenitors	  residing	  in	  veins,	  
we	  used	  the	  inducible	  Prox1-­‐CreERT2	  driver	  (Johnson	  et	  al.	  2008).	  The	  Prox1-­‐CreERT2	  line	  drives	  
recombination	   in	   Prox1+	   ECs	   in	   response	   to	   tamoxifen	   without	   disrupting	   the	   endogenous	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Prox1	   gene.	   Prox1CreERT2	   drivers	   were	   crossed	   with	   mice	   carrying	   a	   floxed	   allele	   of	  Notch1	  
(N1fl/fl)	  (Yang	  et	  al.	  2004),	  or	  a	  dominant	  negative	  isoform	  of	  Mastermind-­‐like	  (DNMAML)	  (Tu	  et	  
al.	   2005).	   	   DNMAML	   forms	   an	   inactive	   transcriptional	   complex	   with	   Notch	   on	   CSL	   without	  
disrupting	   CSL	   repressor	   activity.	  Prox1CreERT2;N1fl/+	  males	  were	   crossed	  with	  N1fl/+	   females.	  
Prox1CreERT2	   females	   were	   crossed	   with	   homozygous	   DNMAML	   males.	   	   Tamoxifen	   was	  
administered	  at	  E9.75,	   a	   time	  when	  Prox1	  expression	   initiates	  and	  Notch1	  and	  Prox1	  are	   co-­‐
expressed	   in	   the	   venous	   endothelium	   (Figs.	   1F-­‐H).	   E14.5	   Prox1CreERT2;N1fl/fl	   (Fig.	   2A)	   and	  
Prox1CreERT2;DNMAML	   embryos	   (data	   not	   shown)	   displayed	   mild	   edema	   and	   small	   foci	   of	  
blood	   filled	   dermal	   lymphatics.	   Prox1CreERT2;N1fl/+,	   Prox1CreERT2,	   and	  N1fl/+	   control	   embryos	  
were	  indistinguishable	  from	  wild-­‐type	  littermates	  (data	  not	  shown).	  	  
Immunohistochemistry	   on	   E14.5	  wild-­‐type	   and	  Prox1CreERT2;N1fl/fl	   transverse	   sections	  
was	  performed	  using	  antibodies	  against	  BEC	  (CD31/endomucin)	  and	  LEC	  (Prox1/LYVE1)	  specific	  
proteins.	   Compared	   to	   wild-­‐type	   littermates,	   Prox1CreERT2;N1fl/fl	   embryos	   had	   enlarged	   LSs	  
surrounding	  the	  CV	  at	  the	  level	  of	  the	  aortic	  arch	  (Fig.	  2B),	  and	  descending	  thoracic	  aorta	  (Fig.	  
2C),	   and	   dermal	   lymphatic	   vessels	   (Fig.	   2D).	   Prox1CreERT2;N1fl/fl	   LS	   luminal	   area	  was	   5.7-­‐fold	  
greater	  than	  wild-­‐type	  littermates	  and	  4.7-­‐fold	  greater	  than	  Prox1CreERT2	  littermates	  (Fig.	  2G).	  
The	   increase	   in	   LS	   size	   in	   Prox1CreERT2;N1fl/fl	  embryos	   correlated	   with	  a	   2.5-­‐fold	   increase	   in	  
Prox1+	  LEC	  emerging	  from	  veins	  relative	  to	  control	  embryos	  (Fig.	  2E,G),	  indicative	  increased	  LEC	  
differentiation.	  	  Similarly,	  Prox1CreERT2;DNMAML	  lymphatic	  vessels	  were	  enlarged	  4.2-­‐fold	  and	  
lymphatic	  vessel	  density	   increased	  2.3-­‐fold	   relative	   to	  DNMAML	   controls	   (Figure	  2F,H).	  These	  
data	   suggest	   that	   the	   increase	   in	   Prox1+	   progenitors	   emerging	   from	   veins	   in	  Notch	   deficient	  
embryos	  contributed	  to	  lymphatic	  sac	  enlargement.	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As	  VEGF-­‐C	  signaling	  is	  necessary	  for	  LEC	  progenitors	  to	  migrate	  from	  the	  CV	  (Favier	  et	  al.	  
2006;	   Kärpänen	   T	   2006),	   expression	   of	   the	   VEGF-­‐C	   receptors,	   VEGFR-­‐2	   and	   VEGFR-­‐3	   was	  
evaluated.	   	   Conditional	   deletion	   of	  Notch1	   in	   the	   Prox1+	   ECs	   resulted	   in	   increased	   VEGFR-­‐2	  
expression	  in	  the	  venous	  endothelium,	  but	  not	  the	  lymphatic	  (Fig.	  S3A)	  and	  is	  consistent	  with	  a	  
loss	   of	   Notch-­‐mediated	   suppression	   of	   VEGFR-­‐2	   (Taylor	   et	   al.	   2002;	   Shawber	   et	   al.	   2007).	  
VEGFR-­‐3	  expression	  was	  relatively	  unaffected.	   	  The	   increase	   in	  migrating	  Prox1+	  cells	  may	  be	  
due	  to	  changes	  in	  LEC	  VEGFR-­‐2	  or	  VEGFR-­‐3	  expression.	  	  
	  
Loss	  of	  Notch	  in	  Prox1+	  EC	  progenitors	  resulted	  LECs	  in	  veins	  
As	  expected,	  Prox1	  expression	  was	  restricted	  to	  the	  lymphatic	  endothelium	  at	  E14.5	  and	  
rarely	   observed	   in	   the	   CV	   of	   control	   embryos	   (Fig.	   2E,	   3A).	   Prox1CreERT2;N1fl/fl	   	  tissues	  had	   a	  
significant	  3.75-­‐	  and	  5.32-­‐fold	  increase	  in	  the	  number	  of	  Prox1+	  cells	  in	  the	  CV	  relative	  to	  wild-­‐
type	   and	   Prox1CreERT2	   embryos,	   respectively	   (Fig.	   3B).	   Prox1	   expression	   was	   observed	  
throughout	  the	  CV	  of	  Prox1CreERT2;N1fl/fl	  tissues	  at	  E14.5.	  This	  phenotype	  was	  also	  observed	  in	  
Prox1CreERT2;DNMAML	  embryos	  that	  had	  a	  1.89-­‐fold	  increase	  in	  Prox1+	  cells	  in	  the	  CV	  (Fig.	  3B).	  
Similar	   to	   the	   conditional	   Notch	   loss-­‐of-­‐function	   mice,	   Prox1+	   ECs	   residing	   in	   the	   CV	   was	  
increased	  1.58-­‐fold	  in	  N1+/-­‐	  heterozygotes	  at	  E10,	  relative	  to	  wild-­‐type	  littermates	  (Figs.	  S4A,B).	  
These	   results	   suggest	   that	  Notch1	   activity	   is	   necessary	   to	   assure	   that	   Prox1	   is	   suppressed	   in	  
venous	  endothelium.	  
The	   presence	   of	   Prox1+	   ECs	   in	   the	   CV	   of	   Notch	   mutant	   embryos	   suggested	   a	  
specification	  defect	  in	  the	  CV	  endothelium.	  To	  explore	  this,	  we	  determined	  if	  the	  CV	  expressed	  
LYVE1	  and	  podoplanin,	  proteins	  normally	  restricted	  to	  the	  lymphatic	  endothelium	  at	  E14.5	  (Fig.	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3A,C,D).	   In	  Prox1CreERT2;N1fl/fl	   embryos,	   LYVE1	   and	   podoplanin	  were	  misexpressed	   in	   the	   CV	  
endothelium	   (Figs.	   3A,C,D).	   Staining	   for	   podoplanin	   revealed	   that	   the	   lymphatic	   vessels	  
surrounding	  the	  CV	  of	  Prox1CreERT2;N1fl/fl	  embryos	  were	  sometimes	  merged	  with	  the	  CV	  (Fig.	  
3A,C),	   indicative	   of	   a	   failure	   to	   segregate	   lymphatic	   and	   venous	   vessels.	   LYVE1	   was	   also	  
misexpressed	  in	  the	  CV	  of	  E10.0	  N1+/-­‐	  embryos	  relative	  to	  their	  wild-­‐type	  littermates	  (Fig.	  S4C).	  
These	  data	  indicate	  that	  reduced	  Notch1	  activity	  resulted	  in	  an	  increase	  of	  venous	  Prox1+	  ECs	  
coincident	  with	  the	  expression	  of	  several	  key	  lymphatic	  proteins	  within	  veins,	  well	  beyond	  the	  
time	  when	  LECs	  should	  have	  segregated	  from	  venous	  endothelium.	  	  
We	  next	  examined	  whether	  Notch1	   loss	  could	  rescue	  the	  embryonic	   lethality	  of	  Prox1	  
haploinsufficiency,	  as	  might	  be	  predicted	  if	  Notch1	  downregulates	  Prox1.	  In	  a	  mixed	  C57Bl	  and	  
NMRI	  background,	  Prox1GFPCre/+	  mice,	   in	  which	  one	  allele	  of	   Prox1	   is	   disrupted	  with	   a	  GFPCre	  
cassette	   (Srinivasan	   et	   al.	   2010;	   Srinivasan	   and	   Oliver	   2011),	   are	   not	   viable	   (Table	   1).	  
Prox1GFPCre/+	  mice	  were	  crossed	  with	  N1fl/+	  mice	  to	  generate	  Prox1GFPCre/+;N1fl/+	  mice	  where	  one	  
copy	  of	  Notch1	   is	   lost	  in	  Prox1+	  ECs.	  Prox1GFPCre/+;N1fl/+	  were	  viable	  and	  observed	  at	  predicted	  
frequency.	   	  Endomucin	  and	  Prox1	  staining	  of	  E10.5	  Prox1GFPCre/+;N1fl/+,	  Prox1GFPCre/+,	   	  and	  N1fl/+	  
embryos	  was	  carried	  out	  to	  determine	  if	   improved	  viability	  correlated	  with	  rescued	  lymphatic	  
endothelial	  specification.	  Prox1+	  LECs	  were	  reduced	  1.9-­‐fold	  in	  the	  CV	  and	  3.35-­‐fold	  emerging	  
out	  of	  the	  CV	  in	  Prox1GFPCre/+	  tissues	  relative	  to	  N1fl/+	  (Fig.	  3E).	  	  	  Prox1+	  LEC	  numbers	  were	  not	  
significantly	  different	   in	   the	  CV	  of	  Prox1GFPCre/+;N1fl/+	   tissues	   relative	   to	  N1fl/+	   tissues.	   	   	  Prox1+	  
LECs	  emerging	   from	  the	  CV	  were	  significantly	   increased	  2.41-­‐fold	   in	  Prox1GFPCre/+;N1fl/+	   tissues	  
compared	   to	   Prox1GFPCre/+	   tissues.	   	   	   Thus,	   losing	   one	   copy	   of	   Notch1	   in	   the	   LEC	   progenitors	  
rescued	  the	  LEC	  specification	  defect	  within	  the	  CV	  and	  viability	  of	  Prox1	  heterozygous	  mice.	  	  
174
	  Notch1	  activation	  in	  Prox1+	  endothelial	  cells	  resulted	  in	  edema,	  blood-­‐filled	  lymphatics	  	  
To	  conditionally	  activate	  Notch1	  within	  Prox1+	  ECs,	  the	  Prox1CreERT2	  driver	  was	  crossed	  
with	   mice	   carrying	   a	   Cre-­‐responsive,	   constitutively	   activated	   Notch1	   (N1IC)	   transgene	  
downstream	   (N1IC)	   (Buonamici	   et	   al.	   2009).	   Tamoxifen	   was	   administered	   at	   E9.75	   or	   E10.5.	  
Prox1CreERT2;N1IC	  embryos	  died	  prior	   to	   E15.5.	   	  When	  analyzed	   at	   E14.5,	  Prox1CreERT2;N1IC	  
embryos	   displayed	   severe	   edema,	   and	   an	   extensive	   network	   of	   blood-­‐filled	   superficial	  
lymphatics	   (Figs.	   4A,	   S5A).	   After	   fixation,	   a	   blood-­‐filled	   jugular	   LS	   was	   observed	   in	  
Prox1CreERT2;N1IC	  embryos	  (Fig.	  4A).	  When	  tamoxifen	  was	  administered	  at	  E10.5	  and	  embryos	  
isolated	  at	  E13.5,	  Prox1CreERT2;N1IC	  embryos	  displayed	  mild	  edema	  and	  appeared	  to	  undergo	  
normal	   blood	   vascular	   development	   (Fig.	   S5A).	   Thus,	   the	   severe	   lymphatic	   defects	   arose	  
between	   E13.5	   and	   E14.5	   when	   flow	   begins	   in	   the	   embryonic	   lymphatics.	   Staining	   with	   an	  
antibody	   against	   the	   intracellular	   domain	   of	   Notch1	   confirmed	   that	   the	   N1IC	   transgene	  was	  
expressed	   in	   the	   lymphatic	   endothelium	   of	   Prox1CreERT2;N1IC	   tissues	   (Fig.	   S5B).	   	   	   The	  
Prox1CreERT2	   driver	   was	   crossed	   with	   a	   mouse	   carrying	   a	   conditional	   LacZ	   transgene	  
downstream	  of	  the	  ROSA26	  promoter	  to	  generate	  Prox1CreERT2;LacZfl/fl	  mice	  that	  were	  crossed	  
with	   N1IC	   mice.	   Prox1CreERT2;LacZfl/+;N1IC	   	   embryos	   displayed	   severe	   lymphatic	   vascular	  
defects	   at	   E14.5.	   Staining	   for	   b-­‐gal	   and	   LYVE1	   confirmed	   recombination	   occurred	   in	   ECs	  
incorporated	   into	   the	   LSs	   and	   nearby	   lymphatic	   vessels	   in	   control	   Prox1CreERT2;LacZfl/+,	   and	  
Prox1CreERT2;LacZfl/+;N1IC	  tissues	  (Fig.	  S5C).	  	  Thus,	  Notch1	  activation	  in	  Prox1+	  ECs	  led	  to	  severe	  
edema	  and	  embryonic	  lethality,	  likely	  related	  to	  venous/lymphatic	  defects.	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We	  hypothesized	  that	  the	  Prox1CreERT2;N1IC	  phenotype	  was	  due	  to	  aberrant	  lymphatic	  
endothelial	   specification.	   	   The	   lymphatic	   vascular	   phenotype	  was	   determined	   by	   staining	   for	  
Prox1,	  podoplanin,	  and	  LYVE1.	  	  In	  wild-­‐type	  tissues,	  Prox1	  expression	  was	  absent	  from	  the	  CV	  
endothelium	  and	  restricted	  to	  the	  LSs	  and	  peripheral	  lymphatic	  vasculature	  at	  E13.5	  and	  E14.5	  
(Fig.	   4B,C).	   In	   E14.5	   Prox1CreERT2;N1IC	   embryos,	   expression	   of	   Prox1	   and	   podoplanin	   was	  
strongly	   reduced	   in	   the	   presumptive	   LSs	   (Fig.	   4B).	   	   The	   presumptive	   LSs	   of	   E14.5	  
Prox1CreERT2;N1IC	   consisted	   of	   numerous	   small	   disorganized	   blood-­‐filled	   channels	   (Fig.	   4B,	  
S5D).	   These	   abnormal	   lymphatic	   channels	   had	   spotty	  Prox1	   and	  weak	  podoplanin	   expression	  
(Fig.	   S5D).	   Unlike	   the	  Notch	   loss-­‐of-­‐function	  models,	   the	   presumptive	   LSs	   clearly	   segregated	  
from	  the	  CV	  in	  Prox1CreERT2;N1IC	  embryos.	  A	  less	  severe	  lymphatic	  phenotype	  was	  observed	  in	  
E13.5	  Prox1CreERT2;N1IC	  embryos	  and	  correlated	  with	  a	  3.72-­‐fold	  decrease	  in	  Prox1+	  ECs	  in	  the	  
lymphatic	  endothelium	  where	  LYVE1	  expression	  was	  also	  reduced	  (Fig.	  4C,D).	  The	  reduction	  in	  
Prox1+	   ECs	   was	   associated	   with	   a	   significant	   3.8-­‐fold	   and	   2.31-­‐fold	   decrease	   in	   Prox1+	   EC	  
density	  in	  Prox1CreERT2;N1IC	  tissues	  relative	  to	  control	  tissues	  at	  E13.5	  and	  E14.5,	  respectively	  
(Fig.	  4E).	  To	  determine	  if	  this	  phenotype	  was	  due	  to	  an	  early	  migration	  defect,	  the	  number	  of	  
Prox1+	   progenitor	   cells	   within	   and	   emerging	   from	   the	   CV	   was	   determined	   in	   E10.5	  
Prox1CreERT2;N1IC	  and	  control	  embryos	  in	  which	  tamoxifen	  was	  administered	  at	  E9.75.	  Prox1+	  
progenitors	   numbers	   did	   not	   significantly	   differ	   between	   the	   two	   groups	   (Fig.	   S6).	   Thus,	  
activation	  of	  Notch1	  in	  the	  Prox1+	  progenitor	  cells	  suppressed	  lymphatic	  specification,	  opposite	  
to	  that	  observed	  when	  Notch	  signaling	  was	  inhibited	  in	  the	  lymphatic	  progenitor	  ECs.	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Notch1	   inhibition	   of	   Prox1	   was	   restricted	   to	   the	   initiation	   and	   early	   maintenance	   phase	   of	  
lymphatic	  vascular	  development	  	  
The	  transcription	  factors,	  Sox18	  and	  Coup-­‐TFII	  cooperate	  to	  regulate	  Prox1	  expression	  in	  
the	  lymphatic	  progenitor	  ECs	  between	  E9.75	  and	  E13.5	  in	  mice	  (Francois	  et	  al.	  2008;	  Lee	  et	  al.	  
2009;	   Srinivasan	   et	   al.	   2010).	   	   In	   the	   blood	   vasculature	   Coup-­‐TFII	   and	   Notch	   function	  
reciprocally	   to	   inhibit	   the	   other’s	   expression	   and	   maintain	   venous	   and	   arterial	   EC	   identity,	  
respectively	  (You	  et	  al.	  2005;	  Diez	  et	  al.	  2007),	  suggesting	  that	  Notch	  downregulates	  Coup-­‐TFII.	  
In	   fact,	  Notch	  via	  Hey1	  and	  Hey2	  directly	  suppresses	  Coup-­‐TFII	  expression	   in	  cultured	  HdLECs	  
(Kang	  et	  al.	  2010).	  	  
As	  Notch1	  did	  not	  suppress	  Sox18	  in	  HdLECs	  (Fig.	  S1B),	  we	  analyzed	  Notch	  regulation	  of	  
Coup-­‐TFII	   during	   lymphatic	   endothelial	   specification.	   On	   the	   side	   of	   the	   CV	   where	   Prox1+	  
progenitors	   resided,	   Notch	   activity	   and	   Coup-­‐TFII	   expression	   did	   not	   overlap,	   but	   were	  
observed	  in	  neighboring	  cells	  at	  E10.5	  (Fig.	  5A),	  consistent	  with	  Notch	  functioning	  to	  suppress	  
Coup-­‐TFII.	  To	  determine	  if	  activation	  of	  Notch1	  in	  Prox1+	  ECs	  influenced	  Coup-­‐TFII	  expression	  in	  
vivo,	   E12.5	   and	   E13.5	  wild-­‐type	   and	  Prox1CreERT2;N1IC	   tissues	  were	   stained	   for	   Coup-­‐TFII.	   In	  
the	  wild-­‐type	  CV,	  Coup-­‐TFII	  was	  expressed	  throughout	  the	  venous	  and	  lymphatic	  endothelium	  
(Fig.	   5B).	   In	   contrast,	   Coup-­‐TFII	   was	   strongly	   suppressed	   in	   the	   venous	   and	   LS	   ECs	   of	  
Prox1CreERT2;N1IC	  embryos.	  The	  loss	  of	  Coup-­‐TFII	  in	  the	  Prox1CreERT2;N1IC	  embryos	  preceded	  
Prox1	  downregulation	  (Fig.	  4C),	  suggesting	  the	  loss	  of	  Prox1	  may	  be	  secondary	  to	  that	  of	  Coup-­‐
TFII.	  	  
As	  Coup-­‐TFII	  is	  not	  required	  to	  maintain	  Prox1	  expression	  in	  LECs	  after	  E13.5	  (Srinivasan	  
et	  al.	  2010),	  tamoxifen	  was	  administered	  at	  E13.5	  and	  E14.5	  to	  Prox1CreERT2	  and	  N1IC	  crosses	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and	   embryos	   isolated	   at	   E16.5	   and	   E18.5.	   When	   tamoxifen	   was	   administered	   at	   E14.5,	  
Prox1CreERT2;N1IC	   embryos	   were	   indistinguishable	   from	   their	   wild-­‐type	   and	   heterozygote	  
littermates	   (Fig.	   5C).	   Expression	   of	   Prox1	   and	   podoplanin	   was	   unchanged	   in	   the	   lymphatic	  
endothelium	  of	  E16.5	  Prox1CreERT2;N1IC	  tissues	  compared	  to	  wild-­‐type	  tissues	  (Fig.	  5D).	  When	  
recombination	  was	  initiated	  at	  E13.5,	  approximately	  40%	  of	  E18.5	  Prox1CreERT2;N1IC	  embryos	  
displayed	   mild	   lymphatic	   defects	   (Fig.	   S7),	   that	   included	   small	   blood-­‐filled	   subcutaneous	  
lymphatics	   around	   the	   base	   of	   the	   head.	   	   Thus,	   a	   developmental	  window	   exists	   from	   E9.75-­‐
E13.5	  during	  which	  Notch1	  functions	  to	  suppress	  endothelial	  Prox1	  in	  veins,	  most	  likely	  via	  its	  
suppression	  of	  Coup-­‐TFII.	  
	  
Notch1	  activation	  suppressed	  VEGFR-­‐2	  and	  VEGFR-­‐3,	  but	  not	  Nrp2	  
Expression	  of	  multiple	  lymphatic	  specific	  proteins	  was	  reduced	  in	  the	  LEC	  progenitors	  in	  
Prox1CreERT2;N1IC	   embryos;	   however,	   misspecified	   LECs	   still	   segregated	   from	   veins	   and	  
coalesced	  at	   sites	  of	   LS	   formation.	   	   LEC	  migration	   from	  veins	   requires	  VEGF-­‐C/VEGFR-­‐3/Nrp2	  
signaling	   (Karkkainen	  et	  al.	  2004;	  Kärpänen	  T	  2006;	  Xu	  et	  al.	  2010).	  Expression	  of	   the	  VEGF-­‐C	  
receptor	  complexes,	  VEGFR-­‐2,	  VEGFR-­‐3	  and	  the	  VEGFR-­‐3	  co-­‐receptor,	  Nrp2,	  was	  evaluated.	  	  At	  
E14.5,	  VEGFR-­‐2	  was	  expressed	  in	  the	  CV	  and	  LS	  endothelium,	  and	  VEGFR-­‐3	  expressed	  in	  the	  LS	  
of	  control	  tissues	  (Fig.	  6A,B;	  S8A).	   	   In	  contrast,	  VEGFR-­‐2	  and	  VEGFR-­‐3	  expression	  was	  strongly	  
reduced	   in	   E14.5	   Prox1CreERT2;N1IC	   CV	   and	   LS.	   At	   E13.5,	   reduced	   VEGFR-­‐2	   expression	   was	  
observed	   in	  LYVE1+	   lymphatic	  vessels	  of	  Prox1CreERT2;N1IC	  tissues;	  while	  VEGFR-­‐3	  expression	  
was	  absent	  in	  the	  Prox1CreERT2;N1IC	  lymphatic	  vessels	  (Fig.	  S8B,C).	  	  A	  reduction	  in	  VEGFR-­‐3	  was	  
observed	   in	   limb	   bud	   peripheral	   lymphatics	   of	   gain-­‐of-­‐function	   tissues	   (Fig.	   S9A).	   Nrp2	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expression	   within	   the	   LS	   endothelium	   was	   unaffected	   in	   Prox1CreERT2;N1IC	   presumptive	  
lymphatics	   (Fig.	   6C),	   even	   though	   Prox1	   and	   podoplanin	   expression	   was	   reduced	   (Fig	   6D).	  
VEGFR-­‐2	   and	   VEGFR-­‐3	  were	   both	   strongly	   downregulated	   by	   Notch	   activation	   in	   Prox1+	   LEC	  
progenitors,	  while	  Nrp2	  expression	  was	  maintained.	  	  
	  
Notch1	  activation	  in	  Prox1+	  endothelial	  cells	  resulted	  in	  abnormal	  thoracic	  duct	  and	  peripheral	  
lymphatic	  morphogenesis.	  
We	   examined	   the	   morphology	   of	   the	   thoracic	   duct	   and	   the	   peripheral	   lymphatics	   in	  
embryos	  with	  ectopic	  Notch1	  activation.	  Staining	  for	  LYVE1	  or	  podoplanin	  revealed	  a	  defect	  in	  
thoracic	  duct	  morphogenesis	  at	  the	  level	  of	  the	  descending	  thoracic	  aorta	  at	  E14.5.	  Instead	  of	  a	  
well-­‐defined	   thoracic	   duct	   observed	   in	   wild-­‐type	   embryos,	   the	   thoracic	   duct	   of	  
Prox1CreERT2;N1IC	   embryos	   consisted	   of	   numerous	   small	   vessels	   (Fig.	   7A).	   This	   phenotype	  
correlated	  with	  discontinuous	  expression	  of	  podoplanin.	  The	  dermal	  lymphatics	  were	  also	  more	  
numerous	   in	   the	  Prox1CreERT2;N1IC	  tissues	  with	  discontinuous	  LYVE1	  expression	  and	  reduced	  
podoplanin	   levels	   (Fig.	   7B).	   As	   podoplanin	   is	   necessary	   to	  maintain	   the	   segregation	   between	  
BEC	  and	  LECs,	  we	  evaluated	  the	  expression	  of	  the	  blood	  endothelial	  markers,	  CD34	  and	  Nrp1,	  in	  
the	   peripheral	   lymphatics.	   CD34+	   and	   Nrp1+	   ECs	   were	   found	   in	   the	   enlarged	   peripheral	  
lymphatic	  vessels	  of	  Prox1CreERT2;N1IC	   embryos,	  a	  phenotype	  not	   seen	   in	  control	   tissue	   (Fig.	  
7C).	  LYVE1+	  ECs	  were	  not	  observed	  in	  the	  peripheral	  blood	  vasculature	  indicating	  defects	  were	  
restricted	  to	  the	  lymphatic	  vasculature.	  The	  ectopic	  appearance	  of	  Nrp1	  and	  CD34	  in	  peripheral	  
lymphatics	  seen	  upon	  Notch1	  activation	  could	  be	  interpreted	  as	  a	  defect	  in	  separation	  of	  blood	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and	   LECs	   during	   development,	   which	   might	   lead	   to	   the	   abnormal	   blood-­‐filled	   lymphatic	  
vasculature.	  	  
	  
Presumptive	  LS	  of	  Prox1CreERT2;N1IC	  embryos	  did	  not	  express	  blood	  endothelial	  cell	  markers.	  
Prox1	  downregulates	  the	  expression	  BEC	  genes	  (Petrova	  et	  al.	  2002;	  Hong	  and	  Detmar	  
2003;	  Johnson	  et	  al.	  2008).	  We	  determined	  the	  expression	  of	  the	  BEC	  markers,	  Nrp1	  and	  CD34,	  
both	   repressed	   by	   Prox1	   (Wigle	   et	   al.	   2002;	   Johnson	   et	   al.	   2008).	   In	   E13.5	   and	   E14.5	  
Prox1CreERT2;N1IC	  tissues,	  Nrp1	  and	  CD34	  expression	  was	  identical	  to	  the	  controls	  (Fig.	  S10A,B).	  
Neither	  Nrp1,	  nor	  CD34	  was	  missexpressed	   in	   the	   LS	  endothelium	  demonstrating	   that	   the	   LS	  
endothelium	  of	  Prox1CreERT2;N1IC	  embryos	  did	  not	  result	  misexpress	  BEC	  specific	  proteins.	  
	  
Notch1	  activation	  in	  Prox1+	  endothelium	  did	  not	  induce	  arterial	  endothelial	  cell	  proteins.	  
Global	   or	   endothelial	   loss	   of	  Notch	   signaling	   results	   in	   venous	   gene	   expression	   in	   the	  
arterial	  endothelium,	  while	  ectopic	  Notch	  activation	  leads	  to	  misexpression	  of	  arterial	  genes	  in	  
the	  venous	  endothelium	  (Gridley	  2010).	  CV	  expression	  of	  arterial	  endothelial	  specific	  proteins,	  
CD34	  and	  ephrinB2,	  and	  vascular	  smooth	  muscle	  cell	  recruitment	  was	  determined	  in	  the	  gain-­‐
of-­‐function	  model.	   	   CD34	   expression	  was	   unaltered	   in	   Prox1CreERT2;N1IC	   tissues	   (Fig.	   S10B).	  
EphrinB2	  expression	  was	  restricted	  to	  the	  aortic	  endothelium,	  and	  SMA	  was	  expressed	   in	  the	  
aortic	  vascular	  smooth	  muscle	  cells	  of	  Prox1CreERT2;N1IC	  and	  wild-­‐type	  embryos	  (Fig.	  S11A,B).	  
Weak	   punctate	   expression	   of	   ephrinB2	   observed	   in	   the	   wild-­‐type	   LS	   was	   not	   seen	   in	  
Prox1CreERT2;N1IC	   LSs	   (Fig.	   S11A).	   Thus,	   midgestational	   Notch	   activation	   in	   the	   venous	  
endothelium	   did	   not	   promote	   arterial	   endothelial	   differentiation,	   suggesting	   that	   there	   is	   a	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We	  report	  a	  novel	  role	  for	  Jagged1/Notch1	  signaling	  in	  the	  venous	  endothelium	  during	  
lymphatic	   endothelial	   specification,	   whereby	   Notch	   suppresses	   lymphatic	   endothelial	  
differentiation	  to	  maintain	  venous	  cell	  identity.	  We	  demonstrated	  that	  Notch1	  inhibited	  Prox1	  
expression	  within	  the	  CV,	  most	  likely	  via	  suppression	  of	  Coup-­‐TFII.	  Loss	  of	  Notch	  signaling,	  via	  
either	  loss	  of	  Notch1	  or	  expression	  of	  DNMAML,	  in	  the	  LEC	  progenitors	  resulted	  in	  Prox1+	  ECs	  
in	   the	   CV	   and	   disrupted	   lymphatic	   and	   CV	   separation.	   Loss	   of	   Notch	   signaling	   led	   to	   over-­‐
commitment	  of	   LEC	  progenitors	   resulting	   in	  enlarged	   lymphatic	   sacs	  and	  vessels.	   Loss	  of	  one	  
allele	  of	  Notch1	  also	  rescued	  embryonic	  lethality	  due	  to	  Prox1	  haploinsuffiency	  and	  resulted	  in	  
a	   significant	   increase	   in	   Prox1+	   EC	   progenitor	   cells	   at	   E10.5.	   	   In	   contrast,	   ectopic	   Notch1	  
signaling	  suppressed	  endothelial	  expression	  of	  Prox1	  resulting	  in	  perturbed	  LEC	  differentiation.	  
These	  misspecified	  LECs	  failed	  to	  express	  LEC	  specific	  proteins,	  podoplanin,	  LYVE1	  and	  VEGFR-­‐3,	  
but	  still	  emerge	  from	  veins	  and	  form	  disorganized	  lymphatic	  sac-­‐like	  structures.	  In	  these	  gain-­‐
of-­‐function	   embryos,	   BECs	   were	   found	   incorporated	   into	   the	   endothelium	   of	   blood-­‐filled	  
peripheral	   lymphatics	  suggesting	  a	  failure	   in	  either	  the	  segregation	  of	  blood	  and	  LEC	  types	  or	  
maintenance	  of	  LEC	  fate.	  Taken	  together,	  our	  results	  demonstrate	  an	  essential	  role	  for	  Notch1	  
in	  limiting	  the	  number	  of	  LECs	  that	  differentiate	  from	  the	  embryonic	  veins.	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Our	   studies	   suggest	   that	   Notch	   has	   a	   distinct	   role	   in	   veins	   relative	   to	   arterial	  
endothelium.	   Unlike	   the	   aorta	   where	   Notch1,	   Dll4	   and	   Jagged1	   are	   strongly	   and	   uniformly	  
expressed,	  Notch1	  and	  Jagged1	  expression	  was	  weak	  and	  discontinuous	  in	  the	  E9.75	  and	  E10.5	  
veins	  when	  Prox1+	  LEC	  progenitors	  arise.	  Consistent	  with	  the	  low	  levels	  of	  ligand	  and	  receptor	  
expression,	  Notch	  activity	  was	  weaker	  in	  the	  CV	  as	  compared	  to	  the	  aorta.	  	  In	  leukemogenesis	  
and	  T-­‐cell	   development,	  different	   levels	  of	  Notch	   signaling	   transactivate	  distinct	   target	   genes	  
(Liu	  et	  al.	  2010).	  	  Thus,	  the	  low	  levels	  of	  Notch	  signaling	  in	  the	  venous	  endothelium	  may	  induce	  
unique	  target	  genes	  from	  those	  in	  arteries.	  In	  fact,	  activation	  of	  Notch	  in	  the	  Prox1+	  progenitors	  
did	  not	   lead	   to	   the	  expression	  of	   arterial	   specific	  proteins	   in	   the	  CV.	   	   The	  ability	  of	  Notch	   to	  
drive	   arterial	   specification	   may	   be	   limited	   to	   a	   specific	   developmental	   time	   window.	  
Alternatively,	   Prox1+	   progenitors	   may	   be	   sufficiently	   committed	   to	   the	   lymphatic	   fate	   to	  
override	  Notch-­‐driven	  arterialization.	  	  
	   The	   genetic	   studies	   presented	   demonstrate	   that	   Notch1	   functions	   in	   the	   venous	  
endothelium	  to	  suppress	  lymphatic	  endothelial	  differentiation.	  Reduction	  of	  Notch	  signaling	  in	  
Prox1+	   venous	   cells	   resulted	   in	   precocious	   Prox1	   expression	   in	   the	   CV.	   	   The	   extent	   of	   Prox1	  
missexpression	  in	  the	  CV	  of	  Notch	  loss-­‐of-­‐function	  embryos	  was	  much	  more	  extensive	  than	  that	  
observed	   for	   either	   podoplanin	   or	   LYVE1.	   Therefore,	   Prox1	   expression	   in	   the	   venous	  
endothelium	   was	   not	   sufficient	   to	   drive	   LEC	   differentiation,	   and	   an	   additional	   factor	   with	  
polarized	  expression	  may	  cooperate	  with	  Prox1	  in	  LEC	  specification.	  One	  such	  potential	  factor,	  
Sox18	  is	  necessary	  for	  Prox1	  expression	  and	  LEC	  specification	  (Francois	  et	  al.	  2008).	  We	  found	  
that	   Notch	   activation	   did	   not	   alter	   Sox18	   in	   cultured	   HdLECs,	   though	   the	   effect	   of	   altering	  
Notch1	  signaling	  on	  Sox18	  expression	  in	  vivo	  remains	  to	  be	  determined.	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   The	   ability	   of	   Notch1	   to	   suppress	   endothelial	   Prox1	   was	   limited	   to	   E9.75-­‐E13.5.	   This	  
developmental	   window	   overlaps	   with	   the	   requirement	   of	   Coup-­‐TFII	   for	   Prox1	   expression	  
(Srinivasan	  et	  al.	  2010),	  suggesting	  Notch1	  inhibited	  Prox1	  via	  Coup-­‐TFII	  repression.	  In	  HdLECs,	  
Notch	  via	  its	  induction	  Hey1	  and	  Hey2,	  inhibited	  Coup-­‐TFII	  reporters	  (Kang	  et	  al.	  2010).	  	  In	  the	  
E10.5	   CV,	   Notch	   activity	   and	   Coup-­‐TFII	   expression	   was	   in	   neighboring	   cells	   consistent	   with	  
Notch	   inhibiting	   Coup-­‐TFII	   via	   lateral	   inhibition.	   	   In	   fact,	   ectopic	   Notch	   activation	   in	   Prox1+	  
progenitors	   strongly	   suppressed	   Coup-­‐TFII	   expression	   in	   both	   the	   venous	   and	   lymphatic	  
endothelium.	   Loss	   of	   Coup-­‐TFII	   was	   observed	   at	   E12.5,	   two	   days	   before	   strong	   Prox1	  
downregulation	   observed	   at	   E14.5.	   	   Taken	   together,	   the	   data	   suggests	   that	   Jagged1/Notch1	  
signaling	  in	  a	  subset	  of	  venous	  ECs	  downregulates	  Coup-­‐TFII	  to	  suppress	  LEC	  differentiation	  and,	  
by	   default,	   maintain	   venous	   identity.	   In	   cells	   with	   little	   to	   no	   Notch	   signaling,	   Coup-­‐TFII	   is	  
upregulated	  to	  drive	  Prox1	  in	  LEC	  progenitors	  and	  repress	  Notch1	  signaling.	  Thus,	  we	  propose	  
that	   Notch1	   regulates	   venous/lymphatic	   specification	   via	   suppression	   of	   the	   Coup-­‐TFII/Prox1	  
signaling	  axis.	  	  Whether	  Notch	  signaling	  more	  directly	  represses	  Prox1,	  possibly	  at	  the	  level	  of	  
transcription,	  remains	  unknown.	  	  
	   Loss	  and	  activation	  of	  Notch1	  signaling	  both	  led	  to	  a	  failure	  to	  separate	  the	  blood	  and	  
lymphatic	   vasculature,	   but	   by	   distinct	  mechanisms.	   In	  Prox1CreERT2;N1fl/fl	  embryos,	   lymphatic	  
vessels	   sometimes	   failed	   to	   separate	   from	   the	   CV,	   most	   likely	   due	   the	   persistence	   of	   LECs	  
within	  the	  CV.	  In	  contrast,	  BECs	  were	  incorporated	  in	  the	  affected	  peripheral	  lymphatic	  vessels	  
of	   Prox1CreERT2;N1IC	   embryos.	   This	   gain-­‐of-­‐function	   phenotype	  may	   arise	   from	   the	   reduced	  
podoplanin	   expression,	   as	   podoplanin	   is	   necessary	   to	  maintain	   the	   segregation	   of	   blood	   and	  
lymphatic	  vessels	  (Bertozzi	  	  et	  al.	  2010).	  In	  support	  of	  this	  hypothesis,	  Notch1	  signaling	  via	  the	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induction	  of	  Hey1	  and	  Hey2	  suppressed	  podoplanin	  in	  cultured	  HdLECs	  (Fig.	  1;	  Kang	  et	  al.	  2010).	  
In	  murine	  dermal	  lymphatics,	  Notch1	  and	  podoplanin	  have	  non-­‐overlapping	  expression	  (Kang	  et	  
al.	  2010).	  The	  reduction	  of	  podoplanin	  in	  Prox1CreERT2;N1IC	  embryos	  was	  most	  likely	  due	  to	  a	  
loss	  of	  Prox1,	  as	  podoplanin	  is	  induced	  by	  Prox1	  (Johnson	  et	  al.	  2008;	  Kim	  et	  al.	  2010).	  In	  fact,	  
we	  found	  that	  the	  loss	  of	  podoplanin	  expression	  was	  coincident	  with	  the	  loss	  of	  Prox1.	  
	   Loss	  of	  Notch	  signaling	  resulted	  in	  an	  increase	  in	  the	  number	  of	  LECs	  that	  emerged	  from	  
the	   CV	   that	   correlated	   with	   lymphatic	   vessel	   enlargement	   and	   increased	   lymphatic	   density.	  
Unexpectedly,	  misspecified	  LECs	   in	  the	  Prox1CreERT2;N1IC	   	  embryos	  still	   separated	  from	  veins	  
and	   formed	   disorganized	   lymph	   sac-­‐like	   structures,	   although	   Notch1	   activation	   suppressed	  
VEGFR-­‐3	   in	   this	   model.	   This	   downregulation	   of	   VEGFR-­‐3	   may	   occur	   via	   Notch	   induction	   of	  
Hey1/2.	  Alternatively,	  it	  may	  be	  secondary	  to	  Notch	  suppression	  of	  the	  CoupTFII/Prox1	  axis,	  as	  
VEGFR-­‐3	  is	  a	  transcriptional	  target	  of	  both	  Coup-­‐TFII	  and	  Prox1	  (Lin	  et	  al.	  2010;	  Srinivasan	  and	  
Oliver	  2011).	  	  VEGFR-­‐3	  and	  its	  co-­‐receptor	  Nrp2	  have	  been	  shown	  to	  be	  necessary	  to	  promote	  
LEC	   migration	   towards	   VEGF-­‐C	   (Karkkainen	   et	   al.	   2004;	   Xu	   et	   al.	   2010).	   It	   is	   unknown	   if	  
alternative	   signaling	   pathways	   can	   promote	   lymphatic	   endothelial	   migration	   independent	   of	  
VEGFR-­‐3.	   The	   expression	   of	   VEGFR-­‐3	   co-­‐receptor,	   Nrp2,	  was	   unaffected	   in	   the	   LS	   and	   vessel	  
endothelium	   of	   the	   gain-­‐of-­‐function	   embryos.	   Nrp2	   can	   form	   complexes	  with	   plexin	   to	   bind	  
semaphorin3F	  in	  cultured	  LECs	  (Coma	  et	  al.	  2011).	  Thus,	  Nrp2	  may	  provide	  signals	  for	  migration	  
away	  from	  the	  CV	  via	  different	  ligands,	  despite	  the	  reduced	  VEGFR-­‐3	  levels.	  Alternatively,	  our	  in	  
vitro	   studies	   suggest	   that	   Notch	   transiently	   induces	   VEGFR-­‐3	   in	   HdLECs,	   and	   this	   may	   be	  
sufficient	  for	  the	  misspecified	  LECs	  to	  migrate	  away	  from	  veins.	  In	  fact,	  the	  number	  of	  Prox1+	  
progenitors	   emerging	   from	   the	   CV	   did	   not	   differ	   between	   control	   and	   Prox1CreERT2;N1IC	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embryos	   	   at	   E10.5.	   The	   level	   of	  VEGFR-­‐3	  necessary	   for	   LEC	  migration	  may	  also	  be	  below	   the	  
level	   of	   antibody	   detection	   and	   still	   functional	   in	   our	   model.	   	   Finally,	   a	   population	   of	  
Nrp2high/LYVE1low	  LECs	  has	  been	  identified	  to	  migrate	  directly	  off	  the	  CV,	  but	  do	  not	  incorporate	  
into	  lymph	  sacs	  and	  instead	  go	  on	  to	  form	  peripheral	  lymphatic	  vessels	  (François	  et	  al.	  2011).	  	  In	  
the	  Notch	  gain	  of	  function	  model,	  the	  lymphatic	  channels	  that	  arise	  at	  lymph	  sac	  sites	  may	  arise	  
from	   the	   migratory	   Nrp2high/LYVE1low	   LECs.	   Thus,	   the	   disorganized	   lymph	   sac-­‐like	   structures	  
consist	  of	  numerous	  misspecified	   lymphatic	  vessels	   in	  Prox1CreERT2;N1IC	   	  embryos.	   	  Whether	  
this	  Nrp2high/LYVE1low	  population	  also	  expresses	  VEGFR-­‐3	  is	  unknown.	  	  
Our	  study	  of	  venous/lymphatic	  differentiation	  in	  mammals	  uncovered	  a	  unique	  role	  for	  
Notch	   in	   limiting	   lymphatic	   endothelial	   differentiation	   in	   veins.	   Recent	   studies	   in	   zebrafish	  
suggest	  that	  blood	  endothelial	  Dll4	  signals	  to	  the	  adjacent	   lymphatic	  endothelium	  to	  regulate	  
lymphatic	  sprouting	  angiogenesis	  and	  formation	  of	  the	  thoracic	  duct	  (Geudens	  et	  al.	  2010).	  Our	  
studies	  do	  not	  exclude	  the	  possibility,	  that	  Notch	  has	  a	  role	  in	  lymphatic	  sprouting	  or	  functions	  
in	   guiding	   lymphatic	   growth	   along	   arterial	   vasculature.	   We	   observed	   that	   Notch	   signal	  
activation	   no	   longer	   suppressed	   Prox1	   after	   E14.5,	   and	   thus	   this	   would	   allow	   for	   Notch	   to	  
function	  in	  the	  Prox1+	  lymphatic	  endothelium	  later	  in	  development.	  Using	  inhibitors	  of	  Notch1	  
or	  Dll4,	   it	  was	  recently	  shown	  Notch	  regulates	  postnatal	  and	  pathological	   lymphatic	  sprouting	  
angiogenesis	   (Niessen	   et	   al.	   2011),	   and	   Notch	   has	   a	   role	   in	   restricting	   in	   lymphatic	   tip	   cells	  
(Zheng	   et	   al.	   2011).	   Consistent	   with	   these	   findings,	   Notch1	   and	   Notch4	   are	   expressed	   in	  
postnatal	   dermal	   lymphatic	   vessels	   and	   tumor	   lymphatic	   vasculature	   (Shawber	   et	   al.	   2007).	  
Thus,	  Notch	  may	  have	  a	  distinct	  role	  in	  the	  postnatal	  lymphatic	  endothelium.	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We	  concluded	  that	  the	  venous	  to	  lymphatic	  differentiation	  event	  represents	  a	  unique	  a	  
Notch-­‐regulated	  cell	  fate	  decision.	  Once	  the	  fate	  of	  lymphatic	  endothelium	  has	  been	  achieved,	  
the	  differentiated	  lymphatic	  endothelium	  may	  once	  again	  call	  upon	  a	  Notch	  fate	  mechanism	  to	  
further	  specialize	  or	  shape	  the	  lymphatic	  vasculature.	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Figure	  1.	  Notch1	  regulation	  of	  LEC	  specific	  genes	   in	  vitro,	  and	  Notch1	  expression/activity	   in	  
E9.75/E10.5	   veins.	   	  A)	  Prox1,	  LYVE1	  and	  b-­‐actin	  RT-­‐PCR	  and	  Prox1	  and	  a-­‐tubulin	  Westerns	  of	  
LacZ	  and	  N1IC	  expressing	  HMVECs.	  B-­‐D)	  Prox1,	  LYVE1,	  podoplanin,	  VEGFR-­‐2	  and	  VEGFR-­‐3	  qRT-­‐
PCR	  of	  N1IC,	  Hey1,	  Hey2	  and	  GFP	  expressing	  HdLECs.	  E)	  VEGFR-­‐3,	  Hey1	  and	  Hey2	  qRT-­‐PCR	  on	  
RNA	  isolated	  at	  different	  times	  post	  EDTA-­‐induced	  Notch	  activation.	  Data	  represented	  as	  mean	  
+/-­‐	   s.e.m.	   *p	   <	   0.05,	   **p	   <	   0.05,	   ***p<0.005.	   F)	   Endomucin	   (BEC	   marker),	   Prox1	   (yellow	  
arrowheads),	  and	  Notch1	  staining	  of	  serial	  E9.75	  transverse	  sections	  (20X	  mag.).	  Endomucin	  or	  
Notch1	   (N1)/GFP	   staining	   of	   E9.75	   TNR	   transverse	   sections	   to	   determine	   Notch	   activation	  
(white	   arrowheads;	   50X	   mag.)	   G)	   Endomucin/Notch1,	   endomucin	   (endo)/Prox1	   or	  
Notch1/Prox1	  staining	  of	  serial	  E10.5	  sagittal	  thick	  sections.	  Boxed	  areas	  enlarged	  on	  right	  (20X	  
mag.).	   H)	   Notch1/Prox1	   staining	   of	   E10.5	   sagittal	   thick	   sections.	  White	   arrowheads	   highlight	  
Prox-­‐/N1+	  ECs,	  yellow	  arrowheads	  Prox+/N1-­‐	  ECs,	  blue	  arrowheads,	  Prox1+/N1+	  within	  the	  CV	  
(20X	   mag.).	   I)	   Endomucin/GFP	   staining	   of	   E10.5	   TNR	   transverse	   section.	   White	   arrowhead	  
highlight	  ECs	  with	  Notch	  activity.	   aorta	   (ao),	  brachial	   arch	   (ba),	   cardinal	   vein	   (cv),	  descending	  
aorta	  (dao),	  dorsal	  (d),	  jugular	  vein	  (jv),	  posterior	  cardinal	  vein	  (pcv),	  ventral	  (v).	  	  
	  
Figure	  2.	  E9.75	  conditional	  loss	  of	  Notch	  in	  Prox1+	  ECs	  increased	  LEC	  differentiation	  at	  E14.5.	  
A)	   Prox1CreERT2;N1fl/fl	   (CreERT2;N1fl/fl)	   embryos	   displayed	   mild	   edema	   and	   occasional	   blood	  
filled	  dermal	  lymphatics	  (black	  arrowheads).	  Boxed	  areas	  enlarged	  below.	  B)	  LYVE1	  staining	  of	  
transverse	   sections	   at	   the	   level	   of	   the	   aortic	   arch	   (20X	   mag.).	   C)	   CD31/LYVE1	   staining	   of	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transverse	   sections	   through	   the	   descending	   thoracic	   aorta	   (20X	   mag.).	   D)	   LYVE1	   staining	   of	  
dermal	  cross-­‐sections	  (50X	  mag.)	  E)	  CD31/Prox1	  staining	  of	  transverse	  sections	  at	  the	   level	  of	  
the	  aortic	  (20X	  mag.).	  White	  boxes	  enlarged	  below	  highlight	  Prox1+	  ECs	  surrounding	  the	  aorta.	  
Yellow	  boxes	  enlarged	  below	  highlight	  Prox1+	  ECs	  residing	  in	  (white	  arrowheads)	  and	  emerging	  
from	  CV.	  G)	  Quantitation	  of	  Prox1+	  EC	  density	  surrounding	  the	  CV	  (out),	  and	  LS	  luminal	  area	  in	  
Prox1CreERT2;N1fl/fl	   and	   control	   tissues	   normalized	   by	   area.	   F)	   Endomucin/LYVE1	   staining	   of	  
E14.5	   DNMAML	  and	   Prox1CreERT2;DNMAML	   (CreERT2;DNMAML)	   transverse	   sections	   through	  
the	   level	  of	   the	  brachial	  arch	   (upper)	  and	  aortic	  arch	   (lower;10X	  mag.).	  H)	  Quantitation	  of	   LS	  
luminal	   area	   and	   lymphatic	   vessel	   density	   in	   Prox1CreERT2;DNMAML	   and	   DNMAML	   tissues	  
normalized	  by	  area.	  G,H)	  Data	   represented	  as	  mean	  +/-­‐	  s.e.m.	  *p<	  0.05,	  ***p<	  0.0005.	  aorta	  
(ao),	  cardinal	  vein	  (cv),	  internal	  jugular	  vein	  (ijv),	  lymph	  sac	  (ls),	  subclavian	  vein	  (scv).	  	  
	  
Figure	  3.	  	  Loss	  of	  Notch	  signaling	  in	  Prox1+	  ECs	  resulted	  in	  lymphatic	  specification	  within	  the	  
CV	  at	  E14.5,	  and	  rescued	  the	  Prox1	  heterozygous	  phenotype	  at	  E10.5.	   	  A)	  Prox1/podoplanin	  
staining	   of	   transverse	   sections	   at	   the	   level	   of	   the	   aortic	   arch	   (20X	  mag.).	   B)	   Quantitation	   of	  
Prox1+	  EC	  density	  in	  the	  CV.	  C)	  CD31/podoplanin	  staining	  of	  transverse	  sections	  at	  the	  level	  of	  
the	   aortic	   arch.	   B,C)	   Podoplanin	   expression	   (yellow	   arrowheads)	   and	   non-­‐expression	   (white	  
arrowheads)	  was	  observed	  in	  the	  CV	  Prox1CreERT2;N1fl/fl	  and	  wild-­‐type	  tissues,	  respectively.	  D)	  
CD31/LYVE1	   staining	  of	   transverse	   sections	   at	   the	   level	   of	   the	  aortic	   arch.	   	   LYVE1	  expression	  
(yellow	   arrowheads)	   and	   non-­‐expression	   (white	   arrowheads)	  was	   observed	   in	   the	   CV.	   A,C,D)	  
20X	   mag.	   Boxed	   areas	   are	   enlarged	   below.	   E)	   Quantitation	   of	   Prox1+	   EC	   density	   in	   and	  
emerging	   from	   CV	   of	   N1fl/+,	   Prox1GFPCre/+,	   and	   Prox1GFPCre/+;N1fl/+.	   B,E)	   Prox1+	   EC	   in	   CV	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normalized	  by	  CV	  circumference.	  	  Data	  represented	  as	  mean	  +/-­‐	  s.e.m.	  *p<	  0.05,	  **p<	  0.005.,	  
***p<	  0.0005.	  	  aorta	  (ao),	  cardinal	  vein	  (cv).	  	  
	  
Figure	  4.	  Notch1	  activation	  in	  Prox1+	  LEC	  progenitors	  resulted	  in	  severe	  edema,	  blood-­‐filled	  
lymphatics	   and	   loss	   of	   Prox1.	   A)	   E14.5	  Prox1CreERT2;N1IC	   embryos	   displayed	   severe	   edema	  
(red	   arrowheads),	   blood-­‐filled	   superficial	   lymphatics	   and	   jugular	   LS	   (blue	   arrowhead).	   B)	  
Podoplanin/Prox1	  staining	  of	  transverse	  sections	  at	  the	  level	  of	  the	  aortic	  arch.	  Asterisks	  mark	  
lymph	  sac-­‐like	  structures	  (20X	  mag).	  C)	  Endomucin/Prox1	  (20X	  mag)	  or	  Prox1/LYVE1	  (50X	  mag.)	  
staining	  of	  transverse	  sections	  at	  the	   level	  of	   the	  aortic	  arch.	  Boxed	  areas	  enlarged	  below.	  D)	  
Quantitation	  of	  Prox1+	  ECs	  in	  lymphatic	  sacs	  	  normalized	  by	  LS	  circumference.	  	  E)	  Quantitation	  
of	  Prox1+	  EC	  density	  at	  E13.5	  and	  E14.5	  normalized	  by	  area.	  D,E)	  Data	  represented	  as	  mean	  +/-­‐	  
s.e.m.	  .	  *p<	  0.05,	  ***p<	  0.0005.	  aorta	  (ao),	  cardinal	  vein	  (cv),	  lymph	  sac	  (ls)	  
	  
Figure	   5.	   Notch	   activation	   downregulated	   venous	   and	   lymphatic	   endothelial	   Coup-­‐TFII.	   	  A)	  
GFP/Coup-­‐TFII	   or	   Prox1	   staining	   of	   E10.5	   TNR	   transverse	   sections	   at	   the	   level	   of	   the	   heart	  
stained.	   Boxed	   area	   enlarged	   below	   and	   re-­‐adjusted	   to	   highlight	   expression	   pattern.	   White	  
arrowheads	  highlight	   Coup-­‐TFII+/GFP-­‐	   ECs,	   yellow	  arrowheads	  Coup-­‐TFII-­‐/GFP+	  ECs,	   and	  blue	  
arrowheads	   Coup-­‐TFII+/GFP+	   ECs	   (20X	  mag.)	   B)	   Coup-­‐TFII/LYVE1	   staining	   of	   E12.5	   transverse	  
sections	  at	  the	   level	  of	   jugular	  vein/LS	  and	  E13.5	  transverse	  sections	  at	  the	   level	  of	  the	  aortic	  
arch	  (20X	  mag.).	  E12.5	  control-­‐wild-­‐type,	  E13.5	  control-­‐Prox1CreERT2.	  C)	  E16.5	  and	  E18.5	  wild-­‐
type	   and	   Prox1CreERT2;N1IC	   (CreERT2;N1IC)	   embryos.	   D)	   Prox1/podoplanin	   or	   CD31/Prox1	  
staining	  of	  E16.5	  of	  peripheral	  lymphatic	  vessels	  (50X	  mag.)	  	  Tamoxifen	  was	  administered	  E10.5	  
197
(B)	  and	  E14.5	  (C,D).	  Boxed	  areas	  enlarged	  below.	  aorta	  (ao),	  cardinal	  vein	  (cv),	  jugular	  vein	  (jv),	  
jugular	  lymph	  sac	  (jls),	  lymph	  sac	  (ls).	  	  
	  
Figure.	   6.	   Notch	   activation	   downregulated	   VEGFR-­‐2	   and	   VEGFR-­‐3.	   	   A)	   LYVE1/VEGFR-­‐2,	   B)	  
LYVE1/VEGFR-­‐3	  staining	  of	  E14.5	  transverse	  sections.	  Asterisks	  mark	  lymph	  sac-­‐like	  structures.	  
C)	   Nrp2/endomucin,	   D)	   Prox1/podoplanin	   staining	   of	   E13.5	   transverse	   serial	   section.	   Boxed	  
areas	  are	  enlarged	  below.	  	  White	  arrowhead	  highlight	  Prox1/podoplanin	  coincident	  expression.	  
A-­‐D)	  Images	  at	  the	  level	  of	  the	  aortic	  arch	  (20X	  mag.).	  	  aorta	  (ao),	  cardinal	  vein	  (cv),	  lymph	  sac	  
(ls).	  
	  
Figure.	  7.	  Thoracic	  duct	  morphogenesis	  and	  BEC/LEC	  segregation	  defects	  in	  Prox1CreERT2;N1IC	  
embryos.	   A)	   LYVE1	   or	   podoplanin	   staining	   of	   E14.5	   transverse	   sections	   at	   the	   level	   of	   the	  
descending	  aorta	  (left)	  and	  esophagus	  (right).	  B)	  LYVE1	  or	  podoplanin	  staining	  of	  dermal	  cross-­‐
sections.	   Black	   arrowheads	   highlight	   discontinuous	   LYVE1	   in	   effected	   dermal	   lymphatics.	   C)	  
Nrp1/LYVE1	  or	  CD34/LYVE1	  staining	  of	  peripheral	  lymphatics.	  Yellow	  arrowheads	  marked	  Nrp1	  
and	  CD34	  BECs	   incorporated	   into	   LYVE1+	  vessels.	  A-­‐C)	  Boxed	  areas	  are	  enlarged	  below.	   (20X	  
mag.)	   aorta	   (ao),	   cardinal	   vein	   (cv),	   esophagus	   (es),	   hemiazygos	   vein	   (hv),	   lymph	   sac	   (ls),	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The	   lymphatic	   system	  consists	  of	  capillaries	   that	  uptake	   interstitial	   fluid	  and	  collecting	  
ducts	   that	   transport	   the	   fluid	   back	   into	   the	   bloodstream.	   The	   intraluminal	   valves	   of	   the	  
lymphatic	   collecting	   ducts	   ensure	   unidirectional	   flow	   of	   fluid.	   Mature	   lymphatic	   valves	   are	  
made	  up	  of	  leaflets	  consisting	  of	  an	  extracellular	  matrix	  (ECM)	  core	  surrounded	  by	  specialized	  
lymphatic	  endothelial	  cells	  (LECs).	  In	  mice,	  lymphatic	  valve	  formation	  begins	  at	  embryonic	  day	  
(E)	  15.5.	  LECs	  expressing	  high	  levels	  of	  transcription	  factors,	  Prox1	  (Prox1high)	  and	  Foxc2,	  begin	  
clustering	  at	  putative	  valve	  sites,	  becoming	  clearly	  distinguishable	  from	  ductal	  LECs	  expressing	  
lower	  Prox1	  (Prox1low).	  At	  the	  same	  time,	  the	  first	  valve-­‐specific	  ECM	  component,	  laminin	  a5	  is	  
detected	  in	  the	  clustered	  LECs	  (Sabine	  et	  al.	  2012).	  The	  gap	  junction	  protein	  Connexin	  37	  (Cx37)	  
is	  induced	  in	  clustered	  LECs	  and	  is	  required	  for	  valve	  morphogenesis	  (Kanady	  et	  al.	  2011,	  Sabine	  
et	   al.	   2012).	   A	   more	   organized	   ring-­‐like	   structure	   forms	   and	   constricts	   the	   collecting	   duct,	  
followed	  by	  invagination	  of	  valve	  forming	  LECs	  into	  the	  duct	  lumen.	  During	  these	  stages,	  a	  valve	  
leaflet	  ECM	  core	  consisting	  of	  laminin	  α5,	  collagen	  IV	  and	  fibronectin-­‐EIIIA	  is	  formed,	  enabling	  
leaflet	  elongation	  and	  maturation.	  Integrin	  α9	  expression	  is	  increased	  in	  valve	  LECs	  protruding	  
into	   the	   lumen	   allowing	   them	   to	   attach	   to	   the	   ECM	   core	   and	   form	   mature	   valve	   leaflets	  
(Bazigou	  et	  al.	  2009,	  Sabine	  et	  al.	  2012).	  
The	   molecular	   mechanism	   of	   valve	   initiation	   and	   maturation	   are	   beginning	   to	   be	  
understood.	  Lymphatic	  genes	  Prox1,	  Foxc2,	  integrin	  a9,	  fibronectin	  splice	  variant	  containing	  the	  
EIIIA	  domain	  (FN-­‐EIIIA)	  and	  Connexin37	  are	  all	  highly	  expressed	  in	  lymphatic	  valves	  (Bazigou	  et	  
al.	  2009,	  Kanady	  et	  al.	  2011,	  Norrmen	  et	  al.	  2009,	  Petrova	  et	  al.	  2004).	  Integrin	  a9	  interaction	  
with	  its	  ligand	  FN-­‐EIIIA	  is	  necessary	  for	  proper	  valve	  leaflet	  ECM	  core	  assembly	  and	  subsequent	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leaflet	  elongation	  while	  Connexin37	   is	   thought	   to	   facilitate	   the	   coordination	  of	   valve-­‐forming	  
LECs	  into	  a	  more	  organized	  valve	  structure	  (Bazigou	  et	  al.	  2009,	  Sabine	  et	  al.	  2012).	  It	  is	  unclear	  
how	   a	   select	   group	   of	   LECs	   in	   these	   lymphatic	   vessels	   is	   induced	   to	   form	   a	   valve	   while	   the	  
surrounding	  duct	  LECs	  do	  not	  adopt	  the	  valve	  fate.	  	  
Notch	   signaling	   requires	   direct	   cell-­‐cell	   contact	   between	  Notch	   ligand	   expressing	   cells	  
and	  receptor	  presenting	  cells	  (Andersson	  et	  al.	  2011).	  Upon	  ligand	  binding	  proteolytic	  cleavage	  
releases	  the	  Notch	  intracellular	  domain	  allowing	  it	  to	  translocate	  to	  the	  nucleus	  where	  it	  forms	  
a	  transcriptional	  activation	  complex	  with	  CSL,	  Mastermind-­‐like	  and	  coactivators	  (Borggrefe	  and	  
Liefeke	   2012).	   The	   Notch	   signaling	   pathway	   regulates	   lymphatic	   sprouting	   events,	   both	   in	  
physiological	   and	   pathological	   settings	   (Niessen	   et	   al.	   2011,	   Zheng	   et	   al.	   2011).	   Notch	   has	  
recently	  been	  shown	  to	   function	   in	  embryonic	  venous	  endothelium	  to	   restrict	   the	  number	  of	  
venous	   ECs	   that	   go	   on	   to	   adopt	   the	   lymphatic	   fate	   (Murtomaki	   et	   al.	   2013).	   As	   the	   Notch	  
pathway	   mediates	   bi-­‐potential	   cell	   fate	   decisions	   in	   multiple	   biological	   settings,	   we	  
hypothesized	   that	   Notch	   may	   regulate	   lymphatic	   valve	   fate	   decisions.	   Consistent	   with	   this	  
hypothesis,	  Notch1	  expression	   and	  Notch	  activation	  was	  observed	   in	   the	   valve	   forming	   LECs.	  	  
To	  assess	  Notch	  function	  in	  lymphatic	  valve	  morphogenesis	  we	  used	  the	  Prox1CreERT2	  inducible	  
driver	   (Srinivasan	   et	   al.	   2007)	   to	   delete	   Notch1	   or	   inhibit	   Notch	   signaling	   by	   expressing	   a	  
dominant	  negative	  Mastermind-­‐like	  transgene	  (Tu	  et	  al.	  2005)	  in	  the	  lymphatic	  endothelium	  at	  
the	   initiation	   of	   valve	   formation.	   Lymphatic	   endothelial-­‐specific	   loss	   of	   Notch1	   or	   of	   Notch	  
signaling	   resulted	   in	  abnormal	  Prox1high-­‐	  Prox1low	  expression	  pattern,	   reduced	   integrin	  a9	  and	  
FN-­‐EIIIA	  expression	  in	  valve	  LECs,	  and	  abnormal	  valve	  morphology.	  In	  human	  dermal	  lymphatic	  
endothelial	   cells	   (HdLECs),	   ectopic	   activation	   of	   Notch1	   or	   Notch4	   resulted	   in	   significant	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induction	  of	  integrin	  a9,	  FN-­‐EIIIA,	  and	  Cx37	  expression.	  Thus,	  we	  report	  a	  novel	  role	  for	  Notch	  in	  
lymphatic	  valve	  formation	  through	   its	  regulation	  of	  the	  Prox1	  expression	  pattern	  and	   integrin	  
a9	  and	  FN-­‐EIIIA	  expression.	  
	  
	  
Materials	  and	  Methods	  
Mouse	  lines	  
Prox1CreERT2	  (Srinivasan	  et	  al.	  2007),	  Notch1fl/fl	  (Yang	  et	  al.	  2004)	  and	  DNMAML	  (Tu	  et	  al.	  2005)	  
mice	   were	   described.	   Notch1fl/fl,	   ROSA:LacZfl/fl	   and	   TNR	   mice	   from	   Jax	   Labs.	   Tamoxifen	  
(20mg/ml)	  in	  corn	  oil	  was	  administered	  via	  oral	  gavage	  or	  intraperitoneal	  injection	  (10mg/40g)	  
to	  pregnant	  females	  at	  E15.5.	  2-­‐6	  litters	  were	  analyzed	  for	  each	  time-­‐point.	  3-­‐6	  embryos	  were	  
analyzed	  for	  each	  genotype.	  
	  
Immunohistochemistry	  
Mesenteries	  collected	  at	  E16.5,	  E17.5	  and	  E18.5	  were	  stained	  as	  described	  (Lohela	  et	  al.	  2008).	  
Samples	  were	  fixed	  in	  4%	  paraformaldehyde,	  washed,	  blocked	  in	  5%	  donkey	  serum,	  0.2%	  BSA,	  
0.5%	   Triton-­‐X100,	   PBS	   and	   incubated	   overnight	   with	   primary	   antibodies.	   The	   following	   day	  
mesenteries	  were	  washed	  and	  incubated	  with	  secondary	  antibodies	  diluted	  in	  0.2%	  BSA,	  0.3%	  
Triton-­‐X100,	  PBS.	  Samples	  were	  washed	  and	  mounted	  with	  Vectashield	  with	  DAPI	  (Vector	  Labs).	  
MOM	  kit	   (Vector	   Labs)	  was	   used	  with	  mouse	  monoclonal	   antibodies.	   Primary	   antibodies	   are	  
listed	  in	  Table	  S1.	  Secondary	  Alexa	  Fluor	  antibodies	  from	  Invitrogen.	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Constructs	  and	  Cell	  Culture	  
HdLECs	   were	   isolated	   from	   human	   neonatal	   foreskins	   (Exemption	   AAAB-­‐1700)	   as	   described	  
(Murtomaki	  et	  al.	  2013)	  and	  maintained	  in	  EGM-­‐2MV	  BulletKit	  (Lonza)	  with	  VEGF-­‐C	  (10	  ng/ml,	  
RnD	   Systems).	   HdLECs	   were	   infected	   with	   adenovirus	   expressing	   the	   intracellular	   domain	   of	  
Notch1	   (N1IC)	   and	  Notch4	   (N4/int-­‐3),	   HEY1,	   HEY2,	   Prox1,	   LacZ	   or	   GFP	   (Shawber	   et	   al.	   2007,	  
Tung	  et	  al.	  2009)	  with	  expression	  verified	  by	  qRT-­‐PCR	  and/or	  Western	  analyses.	  
	  
RT-­‐PCR	  and	  Western	  analyses	  
RNA	   was	   isolated	   48h	   after	   adenoviral	   infections	   using	   RNeasy	   Mini	   Kit	   (Qiagen)	   and	   cDNA	  
synthesized	  with	   Verso	   cDNA	   synthesis	   kit	   (Fisher	   Scientific).	   qPCR	  was	   performed	  with	   Sybr	  
Green	  Master	  Mix	   (ABI)	   or	   Absolute	   Blue	   qPCR	   SYBR	  Green	  ROX	  Mix	   (Fisher	   Scientific)	   using	  
7300	  Real-­‐Time	  PCR	  System	  (ABI).	  Gene	  specific	  PCR	  products	  were	  generated	  and	  cloned	  into	  
pDrive	   (Stratagene)	   for	   reference	   standards.	   b-­‐actin	  was	  used	   to	  normalize	  qRT-­‐PCRs.	   Primer	  
sequences	  listed	  in	  Table	  S2.	  Protein	  was	  isolated	  48h	  after	  adenoviral	  infections	  in	  TENT	  lysis	  




48h	   after	   adenoviral	   infection	   HdLECs	   were	   harvested,	   incubated	   with	   anti-­‐integrin	   a9b1	  
antibody	   (abcam),	   washed,	   labeled	  with	   anti-­‐rabbit-­‐APC	   (Jackson	   Immunoresearch)	   and	   flow	  
cytometry	  performed.	  10,000	  cells	  per	  group	  were	  counted	  using	  FACSCalibur	  and	  CellQuestPro	  
acquisition	  software	  (BD	  Biosciences).	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  Statistical	  Analysis	  and	  Imaging	  
Quantification	   of	   Prox1+	   area	   was	   done	   with	   ImageJ	   software,	   normalizing	   to	   duct	   length.	  
Statistical	   significance	  was	  determined	  using	  2-­‐tailed	  Student’s	  T-­‐test,	  with	  P-­‐value	  of	  0.05	  or	  
less	   statistically	   significant.	   Data	   presented	   is	   representative	   of	   three	   or	   more	   independent	  
experiments.	   Images	  were	   acquired	  using	   either	   laser	   scanning	   confocal	   Zeiss	   LSM	  510	  Meta	  
microscope	  and	  LSM	  software,	  or	  Nikon	  A1	  confocal	  microscope	  and	  NIS	  Elements	  software.	  
	  
Results	  and	  Discussion	  
Notch1	  expression	  and	  Notch	  activity	  becomes	  enriched	  in	  lymphatic	  valves	  	  
Notch1	   expression	   was	   analyzed	   in	   lymphatic	   ducts	   and	   valves	   of	   the	   embryonic	  
mesenteries	  during	  development.	  At	  E16.5,	  Notch1	  was	  uniformly	  expressed	  in	  the	  mesenteric	  
collecting	   lymphatic	  ductal	  endothelium	  (Fig.	  1A).	  At	  E17.5,	  Notch1	  expression	  was	  highest	  at	  
putative	  valve	  sites,	   identified	  as	  clusters	  of	   lymphatic	  endothelial	  cells	   (LECs)	  expressing	  high	  
levels	  of	  Prox1	  (Prox1high;	  Fig.	  1A).	  By	  E18.5,	  Notch1	  expression	  was	  enriched	  in	  valve	  forming	  
LECs	   and	   weak	   Notch1	   expression	   was	   seen	   in	   the	   lymphatic	   collecting	   ducts	   (Fig.	   1A,	   S1).	  
Notch1	  expression	  was	  seen	  in	  adjacent	  blood	  vessels	  and	  capillaries	  at	  all	  time-­‐points.	  	  
We	   assessed	   Notch	   signaling	   in	   developing	   mesenteric	   lymphatic	   vessels	   and	   valves	  
using	   the	   transgenic	   Notch	   reporter	  mouse	   (TNR),	   which	   expresses	   GFP	   in	   response	   to	   CSL-­‐
dependent	   Notch	   signaling.	   TNR	  mesenteries	   were	   stained	   for	   GFP	   and	   a	   lymphatic	  marker,	  
VEGFR-­‐3	  or	  integrin	  a9	  (a9).	  At	  E17.5,	  Notch	  signal	  activation	  was	  seen	  in	  clusters	  of	  cells	  at	  the	  
209
putative	  valve	  sites	  (Fig.	  1B).	  LECs	  in	  the	  developing	  collecting	  ducts	  and	  blood	  vessels	  adjacent	  
to	   the	   ducts	   also	   expressed	   GFP	   (data	   not	   shown).	   At	   E18.5,	   GFP	   expression	   was	   mainly	  
detected	  in	  the	  a9+	  LECs	  of	  the	  lymphatic	  valves	  (Fig.	  1B).	  The	  initial	  expression	  of	  Notch1	  and	  
Notch	   reporter	   protein	   in	   the	   mesenteric	   collecting	   ducts	   and	   subsequent	   restriction	   of	  
expression	  to	  the	  lymphatic	  valves	  suggested	  Notch1	  functions	  in	  lymphatic	  valve	  development.	  	  
	  
Notch1	  is	  required	  for	  lymphatic	  collecting	  duct	  valve	  morphogenesis	  
	   We	  examined	   the	  effect	  of	   lymphatic	  endothelial	   specific	   loss	  of	  Notch1	   on	   lymphatic	  
valve	   development.	   A	   Prox1CreERT2	   driver	   was	   crossed	   with	   mice	   carrying	   a	   floxed	   allele	   of	  
Notch1	  (N1fl/fl)	  to	  generate	  Prox1CreERT2;N1fl/fl	  (LOF)	  embryos.	  Recombination	  was	  induced	  with	  
tamoxifen	   at	   E15.5,	   when	   murine	   valve	   morphogenesis	   begins,	   and	   embryonic	   mesenteries	  
analyzed	  at	  E18.5	  (Fig.	  S2A-­‐C).	  Prox1CreERT2;N1fl/fl	  embryos	  were	  indistinguishable	  from	  	  control	  
littermates	   (data	  not	   shown).	  Control	  mesenteric	   valve	   forming	  LECs	  expressed	  high	   levels	  of	  
Prox1	   (Prox1high),	   while	   the	   duct	   LECs	   expressed	   lower	   levels	   of	   Prox1	   (Prox1low)	   (Fig.	   2A).	  	  
Prox1high	   valve	   LECs	   had	   reoriented	   themselves	   perpendicularly	   to	   the	   duct	   walls	   in	   control	  
mesenteries	  (Fig.	  2B).	  The	  Prox1high	  LECs	  of	  the	  Prox1CreERT2;N1fl/fl	  mesenteric	  lymphatic	  ducts	  
failed	  to	  reoriented	  perpendicularly	  to	  the	  ductal	  LECs	  (Fig.	  2B).	  	  LOF	  mesenteric	  lymphatics	  had	  
fewer	   valves	   and	   those	   that	   were	   observed	   were	   poorly	   organized.	   Prox1	   expression	   in	  
mesenteries	   of	   LOF	   embryos	   was	   more	   uniform	   in	   LECs	   along	   the	   duct	   with	   an	   overall	  
significant	  increase	  in	  Prox1high	  LECs	  over	  the	  length	  of	  a	  duct	  (Fig.	  2C).	  Clusters	  of	  valve	  forming	  
LECs	   were	   reduced	   in	   the	   dermal	   lymphatics	   of	   LOF	   embryos	   (Fig.	   S3).	   The	   increase	   in	   the	  
number	  of	  Prox1high	  LECs	  suggests	  that	  Notch1	  functions	  to	  restrict	  the	  number	  of	  LECs	  that	  go	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on	   to	  become	  Prox1high.	   Even	  when	  Prox1high	  LECs	   in	   LOF	  mice	   come	   together	   their	   failure	   to	  
reorient	   may	   perturb	   subsequent	   steps	   of	   valve	   formation,	   a	   phenotype	   similar	   to	   that	  
described	  for	  Connexin37	  mouse	  mutants	  (Kanady	  et	  al.	  2011,	  Sabine	  et	  al.	  2012).	  
	  
Integrin	   a9	   and	   Fibronectin	   EIIIA	   expression	   are	   dependent	   on	  Notch	   in	   the	  mesenteric	   valve	  
LECs	  	  
	   Formation	  of	  the	  lymphatic	  valve	  leaflets	  requires	  the	  expression	  of	  integrin	  a9	  and	  its	  
ligand	   fibronectin	  EIIIIA	   (FNEIIIA).	   	  The	  expression	  of	   these	  proteins	  was	  evaluated	   in	   the	  dis-­‐
organized	  lymphatic	  valves	  in	  Prox1CreERT2;N1fl/fl	  	  and	  compared	  to	  control	  embryos.	  	  At	  E18.5,	  
expression	  of	   integrin	  a9	  and	  FNEIIIA	  and	  high	   levels	  of	  Prox1	   (Prox1high)	  was	  observed	   in	   the	  
maturing	  mesenteric	  valves	  of	  control	  embryos	  (Fig.	  2D).	  In	  the	  poorly	  organized	  LOF	  valves	  in	  
which	   Prox1high	   LECs	   had	   migrated	   into	   the	   lumen,	   integrin	   α9,	   and	   FNEIIIA	   expression	   was	  
reduced,	  demonstrating	  that	  Notch1	  regulates	  integrin	  α9,	  and	  FNEIIIA	  expression	  in	  valve	  LECs.	  	  
	   We	  speculated	  that	  additional	  Notch	  proteins	  compensate	  for	  the	  loss	  of	  Notch1,	  partly	  
based	  upon	  incomplete	  loss	  of	  integrin	  a9	  and	  FNEIIIA	  expression	  observed	  in	  the	  LOF	  embryos.	  	  
We	   addressed	   this	   hypothesis	   using	   a	   transgenic	  mouse	   line	   to	   express	   a	   dominant-­‐negative	  
Master-­‐mind	   like-­‐GFP	   fusion	   protein	   (DNMAML)	   (Tu	   et	   al.	   2005)	   in	   Prox1-­‐expressing	   LECs.	  	  
DNMAML	   forms	   an	   inactive	   complex	   with	   Notch	   bound	   to	   CSL	   and	   thus	   inhibits	   canonical	  
Notch/CSL	  signaling.	  DNMAMLfl/fl	  mice	  were	  crossed	  with	   the	  Prox1CreERT2	  driver	  to	  generate	  
Prox1CreERT2;DNMAMLfl/+	   embryos.	   	   Recombination	   was	   induced	   at	   E15.5	   and	   mesenteries	  
collected	  at	  E18.5.	  GFP	  expression	  was	  detected	   in	  Prox1CreERT2;DNMAMLfl/+	  (Fig.	   S4A-­‐C),	  but	  
not	   control	   (DNMAMLfl/+)	   mesenteries	   (data	   not	   shown).	   Prox1CreERT2;DNMAMLfl/+	  embryos	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had	   a	   valve	   morphogenesis	   phenotype	   that	   was	   more	   severe	   (Fig.	   2D,	   3A)	   than	   the	  
Prox1CreERT2;N1fl/fl	  embryos	  (Fig.	  2D,).	  Many	  of	  the	  Prox1CreERT2;DNMAMLfl/+	  embryos	  had	  no	  
identifiable	   lymphatic	  valves.	  Where	  partial	  valves	  were	  present	   these	  structures	  usually	  only	  
expressed	  one	  of	   the	  two	  valve	  markers,	   integrin	  a9	  or	  FNEIIIA	   (Fig.	  3A).	   Integrin	  a9	  was	  also	  
expressed	  by	  smooth	  muscle	  cells	  around	  arteries	  in	  the	  mesentery	  and	  this	  was	  not	  affected	  in	  
Prox1CreERT2;N1fl/fl	  or	  Prox1CreERT2;DNMAMLfl/+	  mesenteries	  (Figs.	  2D,	  3A).	   Integrin	  a9	  and	  its	  
ligand	   FNEIIIA	   are	   indispensable	   for	   valve	   leaflet	   formation.	   As	   Integrin	   a9	   and	   FNEIIIA	  
expression	   is	   reduced	   in	   LOF	   mesenteries	   with	   defective	   valves,	   we	   propose	   that	   Notch	  
functions	  in	  valve	  morphogenesis	  by	  inducing	  expression	  of	  these	  proteins.	  
	  
Notch	   induces	   integrin	   a9,	   fibronectin	   EIIIA	   and	   Connexin37	   in	   human	   dermal	   lymphatic	  
endothelial	  cells	  in	  vitro.	  
Notch	   functions	   by	   eliciting	   transcriptional	   responses	   and	   our	   data	   implicate	   Notch1,	   and	  
possibly	  Notch4,	   in	  promotion	  of	   lymphatic	  valve	  formation.	  We	  sought	  to	  determine	   if	  these	  
Notch	  proteins	  could	  regulate	  the	  expression	  of	  lymphatic	  valve	  proteins	  in	  LECs	  by	  expressing	  
constitutively	   active	   Notch1	   intracellular	   domain	   (N1IC)	   or	   a	   form	   of	   constitutively	   active	  
Notch4,	  N4/int-­‐3	   (Shawber	  et	  al.	  2007,	  Tung	  et	  al.	  2009).	  Activated	  Notch1	  and	  Notch4	  were	  
expressed	   in	   human	   dermal	   lymphatic	   endothelial	   cells	   (HdLECs)	   by	   adenoviral	   infection	   and	  
LEC	   transcript	   and	   protein	   levels	   evaluated.	   N1IC	   was	   a	   more	   potent	   inducer	   of	   Notch	  
downstream	   effectors	   Hey1	   and	   Hey2	   than	   N4/int-­‐3	   (Fig.	   S5).	   N1IC	   and	   N4/int-­‐3	   induced	  
integrin	   a9	   transcripts	   (Fig.	   4A),	   while	   only	   N1IC	   resulted	   in	   increased	   integrin	   a9	   surface	  
expression	  (Fig.	  4A).	  The	  absence	  of	  increased	  integrin	  a9	  surface	  in	  N4/int-­‐3	  expressing	  HdLECs	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may	  be	  due	  to	  its	  reduced	  activity	  relative	  to	  N1IC	  (Fig.	  S5).	  	  The	  transcriptional	  repressors	  Hey1	  
and	  Hey2	  did	  not	  affect	  integrin	  α9	  levels	  suggesting	  the	  α9	  gene	  is	  a	  direct	  target	  of	  Notch	  or	  is	  
regulated	  by	  other	  Notch	  induced	  proteins.	  
Mammalian	  fibronectin	  consists	  of	  various	  isoforms,	  created	  through	  alternative	  splicing	  
(Muro	   et	   al.	   2003).	   Fibronectin	   EIIIA	   splice	   variant	   is	   expressed	   in	   the	   developing	   lymphatic	  
valve	  ECM	  core	  (Bazigou	  et	  al.	  2009).	  We	  evaluated	  fibronectin	  transcript	  and	  protein	  levels	  for	  
fibronectin	   with	   (FN-­‐EIIIA+)	   or	   without	   (FN-­‐EIIIA-­‐)	   the	   EIIIA	   domain.	   Expression	   of	   N1IC	   or	  
N4/int-­‐3	   increased	   both	   FN-­‐EIIIA+	   and	   FN-­‐EIIIA-­‐	   transcripts	   (Fig.	   4B).	   Western	   blot	   analyses	  
showed	  increased	  total	  fibronectin	  levels	  and	  FN-­‐EIIIA+	  in	  both	  N1IC	  and	  N4/int-­‐3	  samples.	  The	  
antibody	  used	  to	  detect	  total	  fibronectin	  recognizes	  both	  FN-­‐EIIIA+	  and	  FN-­‐EIIIA-­‐	  proteins,	  thus	  
the	   increase	   in	   total	   fibronectin	   levels	   may	   be	   due	   to	   increased	   FN-­‐EIIIA+	   levels	   or	   a	  
combination	  of	  increased	  FN-­‐EIIIA+	  and	  FN-­‐EIIIA-­‐	  levels.	  	  
Gap	  junction	  protein	  Connexin37	  (Cx37)	  is	  specifically	  expressed	  in	  developing	  lymphatic	  
valves	   and	   required	   for	   valve	   formation	   in	  mice	   (Kanady	  et	   al.	   2011,	   Sabine	  et	   al.	   2012).	  We	  
evaluated	   Cx37	   transcript	   and	   protein	   levels	   following	  Notch	   signal	   activation	   in	   HdLECs	   and	  
observed	  strong	  induction	  of	  both	  Cx37	  transcripts	  and	  protein	  by	  either	  N1IC	  or	  N4/int-­‐3.	  As	  
Cx37	   is	   required	   for	   reorientation	  of	  Prox1high	   LECs	   in	  valve	  morphogenesis,	   the	   reorientation	  
phenotype	  in	  the	  LOF	  models	  may	  be	  due	  to	  a	  loss	  of	  Cx37	  expression.	  
We	   demonstrate	   that	   lymphatic	   specific	   loss	   of	   either	  Notch1	   or	   a	   block	   of	   canonical	  
Notch	   signaling	   using	   DNMAML	   disrupted	   lymphatic	   valve	   morphogenesis.	   Loss	   of	   Notch	  
altered	  proper	   levels	  of	  Prox1	  expression	  along	   the	  duct,	   caused	  abnormal	  valve	  morphology	  
and	   reduced	   integrin	   α9	   and	   FN-­‐EIIIA	   expression	   by	   valve	   forming	   LECs.	   Either	   Notch1	   or	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Notch4	   activated	   alleles	   induced	   integrin	   a9,	   FN-­‐EIIIA+	   and	   Cx37	   transcript	   and	   protein	  
expression.	  We	   conclude	   that	  Notch	   functions	   to	   induce	   the	  expression	  of	   both	   FN-­‐EIIIA	   and	  
integrin	   α9	   in	   valve	   LECs.	   Notch	   induced	   their	   expression	   in	   vitro	   and	   their	   expression	   was	  
reduced	  when	  Notch	  signaling	  was	  disrupted	  in	  vivo.	  We	  propose	  that	  Notch	  signaling	  functions	  
in	   multiple	   steps	   of	   valve	   formation.	   Notch	   regulates	   Prox1high/low	   ratios,	   reorientation	   of	  
Prox1high	  valve-­‐forming	  LEC	  and	  induction	  FN-­‐EIIIA	  and	  integrin	  α9	  in	  valve	  LECs.	  We	  conclude	  
that	  Notch	  signaling	  is	  essential	  for	  LECs	  to	  properly	  adopt	  the	  valve	  LEC	  fate.	  




































































































































































































































α9 FNEIIIA Prox1 E18.5 























































































Sample % in M1 % in M2 
LacZ  93.2  6.8 
N1IC  83.6  16.4 
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Figure	  Legends	  
Figure	  1.	  Notch1	  expression	  pattern	  and	  Notch	  signaling	  activity	  in	  embryonic	  lymphatic	  ducts	  
and	   valves.	   	   A)	   E16.5,	   E17.5	   and	   E18.5	   wild-­‐type	  mesenteries	   were	   stained	   for	   Notch1	   and	  
Prox1.	  Boxed	  areas	  enlarged	  on	  right.	  Lymphatic	  ducts	  marked	  with	  white	  dotted	  lines.	  White	  
arrows	  indicate	  lymphatic	  valves.	  Yellow	  asterisks	  mark	  blood	  capillaries.	  Scale	  bars	  100	  µm.	  B)	  
TNR	  mesenteries	  were	  stained	  for	  GFP	  to	  detect	  Notch	  activity	  and	  VEGFR-­‐3	  (E17.5)	  or	  integrin	  
a9	   (E18.5).	   Lymphatic	   ducts	  marked	  with	  white	   dotted	   lines.	   Artery	   (A),	   lymphatic	   collecting	  
duct	  (L)	  and	  vein	  (V).	  Scale	  bars	  50	  µm.	  
	  
Figure	   2.	   Lymphatic	   endothelial	   specific	   loss	   of	   Notch1	   resulted	   in	   defective	   valve	  
morphogenesis	   and	   decreased	   valve	   LEC	   integrin	   a9	   and	   FN-­‐EIIIA	   expression.	   Notch1	   was	  
deleted	   in	   LECs	   at	   E15.5	   by	   tamoxifen	   administration	   and	   embryonic	  mesenteries	   isolated	   at	  
E18.5.	  A)	  Control	  (N1fl/+)	  and	  CreERT2;N1fl/fl	  (Prox1CreERT2;N1fl/fl)	  mesenteries	  stained	  for	  Prox1.	  
Arrows	   point	   at	   Prox1high	   valves,	   and	   bracket	   denotes	   expansion	   of	   Prox1high	   cells	  within	   the	  
duct	  walls	  in	  Prox1CreERT2;N1fl/fl	  mesenteries.	  Lymphatic	  collecting	  duct	  (L).	  Scale	  bars	  100	  µm.	  
B)	   Control	   (N1fl/+)	   and	   CreERT2;N1fl/fl	   (Prox1CreERT2;N1fl/fl)	   mesenteries	   stained	   for	   Prox1	   and	  
DAPI.	   White	   arrowheads	   indicate	   Prox1high	   valve	   forming	   LECs	   in	   control	   valve,	   reoriented	  
perpendicularly	  to	  duct	  wall.	  Yellow	  arrowheads	  indicate	  Prox1high	  LECs	  that	  are	  poorly	  oriented	  
in	  LOF	  valve.	  Scale	  bars	  50	  µm.	  C)	  Quantification	  of	  Prox1high	  area	  normalized	  by	  duct	   length.	  
Note	   increased	   Prox1high	   area,	   seen	   as	  more	   uniform	   expression	   along	   LOF	   ducts.	   Error	   bars	  
indicate	   s.d.	   *p<0.05.	   D)	   Control	   (N1fl/fl)	   and	   CreERT2;N1fl/fl	   (Prox1CreERT2;N1fl/fl)	   mesenteries	  
stained	  for	  Prox1,	  integrin	  α9	  and	  FN-­‐EIIIA.	  Note	  abnormal	  location	  and	  morphology	  of	  valves	  in	  
220
LOF	  embryos.	   Lymphatic	  collecting	  ducts	  marked	  by	  white	  dotted	   line.	  White	  arrows	   indicate	  
valves	  magnified	   in	   upper	   left	   corner.	   Asterisk	  marks	   a	   cluster	   of	   Prox1high	   cells	  magnified	   in	  
bottom	  right	  corner.	  Artery	  (A),	  lymphatic	  collecting	  duct	  (L)	  and	  vein	  (V).	  Scale	  bars	  100	  µm.	  
	  
Figure	   3.	   Lymphatic	   endothelial	   specific	   loss	   of	   Notch	   signaling	   resulted	   in	   defective	   valve	  
formation	   with	   decreased	   integrin	   a9	   and	   FN-­‐EIIIA	   expression.	   DNMAML	   expression	   was	  
induced	   in	   LECs	   at	   E15.5	   by	   tamoxifen	   and	   embryonic	   mesenteries	   isolated	   at	   E18.5.	   A)	  
DNMAMLfl/+	   (Control)	   and	   Prox1CreERT2;DNMAMLfl/+	   (CreERT2;DNMAMLfl/+)	   mesenteries	  
stained	  for	  Prox1,	  integrin	  α9	  and	  FN-­‐EIIIA.	  Middle	  row	  shows	  LOF	  mutant	  with	  mild	  phenotype,	  
showing	   reduced	   integrin	   α9	   and	   FN-­‐EIIIA	   expression.	   Bottom	   row	   shows	   severely	  
affected	  ,mesentery	  with	  uniform	  Prox1	  expression	  and	  complete	  loss	  of	  both	  integrin	  α9	  and	  
FN-­‐EIIIA.	   Lymphatic	   collecting	   ducts	   marked	   with	   white	   dotted	   lines.	   White	   arrows	   indicate	  
valves	  magnified	  in	  upper	  left	  corner.	  Artery	  (A),	  lymphatic	  collecting	  duct	  (L)	  and	  vein	  (V).	  Scale	  
bars	  100	  µm.	  
	  
Figure	  4.	  Ectopic	  activation	  of	  Notch1	  or	  Notch4	  induces	  integrin	  a9,	  FN-­‐EIIIA	  and	  Connexin37	  
expression	   in	   HdLECs.	   HdLECs	   were	   adenovirally	   infected	   with	   N1IC,	   N4/int-­‐3,	   HEY1,	   HEY2,	  
Prox1	  or	  LacZ	  coding	  viruses	  and	  RNA	  and	  protein	  were	  isolated	  48h	  after	  infection.	  A)	  qRT-­‐PCR	  
and	  FACs	  for	   integrin	  a9.	  B)	  qRT-­‐PCR	  of	  fibronectin	  transcripts	  containing	  EIIIA	  (FN-­‐EIIIA+)	  and	  
without	  EIIIA	  (FN-­‐EIIIA-­‐).	  Western	  analyses	  of	  FN-­‐EIIIA,	  total	  fibronectin	  or	  a-­‐tubulin.	  C)	  qRT-­‐PCR	  
and	  western	  analyses	  of	  Connexin37.	  A-­‐C)	  All	  values	  are	  means	  and	  error	  bars	  indicate	  s.d.	  	  *p	  ≤	  
0.05	  and	  **p	  ≤	  0.005.	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